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Preface and outline






Genetics is one of the most dynamcally evolving 
fields of science in the past decade. Huntington’s 
disease was the first disease for which a gene 
was mapped using DNA polymorphisms. 
This took place in 1983 and the following 
years yielded rapid advances in discovering 
genes for rare disorders. However, unlike 
rare Mendelian diseases, common diseases, 
such as coeliac disease, type 1 diabetes, 
inflammatory bowel disease or rheumatoid 
arthritis, are developed as a consequence of 
the interplay between multiple genes and one 
or more environmental triggers. But, with 
only a few exceptions, until a few years ago 
the gene mapping for these complex diseases 
had been rather disappointing. The HapMap 
release of a Catalogue of Common Human 
Genetic Variation in 20051 and the technical 
developments in large-scale genotyping 
platforms led to tremendous advances in gene 
mapping for complex diseases. The HapMap 
project provided the first haplotype map of 
the human genome and showed that most of 
the common single nucleotide polymorphisms 
(SNPs) are highly correlated and form block-
like structures of linkage disequilibrium (LD). 
This finding was of great importance as it 
allowed the testing of only a limited number 
of SNPs and then, based on their genotypes, 
the majority of untyped variation could be 
predicted. Over the past six years, genome-
wide association studies (GWAS; Figure 1) 
that assay hundreds of thousands of SNPs in 
thousands of affected and healthy individuals 
have convincingly identified hundreds of 
associations with dozens of traits and diseases2. 
Coeliac disease is a good example; it is a 
complex, immune disease and one of the 
most common food intolerance disorders 
(Figure 2). It affects around 1% of Western 
populations but its worldwide prevalence 
varies (Figure 3). It has a broad spectrum of 
manifestations3 and therefore remains largely 
under-diagnosed (Box 1). The best understood 
genetic components for coeliac disease are the 
HLA molecules. The first links between coeliac 
disease and HLA were reported over 30 years 
ago4, and were further characterized in 1989, 
pointing towards the involvement of particular 
HLA molecules, HLA-DQ2 and HLA-DQ85. 
Now, over 20 years later, we have contributed 
to the identification of an additional 39 non-
HLA genes that confer susceptibility to coeliac 
disease development and have advanced 
our knowledge about the disease biology.
This thesis had two principal aims: (i) to 
identify new coeliac disease loci to add to 
the eight loci known when my thesis work 
started, and (ii) to further interpret the coeliac 
disease associations by fine-mapping and 
cross-ethnic approaches. Part 1 describes 
how we identified novel coeliac disease genes 
using three complementary approaches: 
(1) by deep replication of the first GWAS for 
coeliac disease by following up some 500 
lower ranked GWAS SNPs, (2) by cross-disease 
replication, taking loci identified in rheumatoid 
arthritis and testing them for association 
in coeliac disease and vice versa, and (3) by 
performing a large GWAS across four different 
European populations. Part 2 describes our 
fine-mapping efforts to narrow down coeliac 
disease association signals to smaller genetic 
intervals, possibly harbouring one or more 
causal variants. For this, we performed dense, 
sequencing-based genotyping at all the non-
HLA loci and later cross-ethnic gene mapping 
and replication of the loci in a northern Indian 
population. Part 3 discusses our results in 
the context of coeliac disease and, more 
broadly, the impact of these studies for other 
complex disorders. We also outline some 
future research and clinical perspectives.
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Outline of the thesis
Part 1 | Deep Replication and Gene Discovery
In Chapter 2 I describe the association of two 
new risk loci for coeliac disease, TNFAIP3 and 
REL, which pointed towards the involvement of 
the nuclear factor kappa B (NF-κB) pathways. 
The two regions were identified via deep 
replication of coeliac disease GWAS results. 
We selected 458 SNPs that were moderately 
associated in our first coeliac disease GWAS, 
which was performed in 2007 on 778 UK cases 
and 1,422 matched controls, and genotyped 
these in an extended replication cohort 
comprising UK, Dutch, Irish and Italian samples.
In Chapter 3 I describe the genetic background 
shared between coeliac disease and rheumatoid 
arthritis. Coeliac disease has a strong 
autoimmune component and often co-occurs 
in patients or families with other immune-
related diseases, such as type 1 diabetes, 
inflammatory bowel disease or rheumatoid 
arthritis. There is a substantial overlap 
between the genomic regions associated to 
immune diseases, including coeliac disease 
and rheumatoid arthritis. We therefore tested 
if genes associated in one disease can be 
replicated in the other and vice versa.
In Chapter 4 I describe how we established 
association of 13 new loci via a second genome-
wide association study of 4,533 coeliac cases 
and 10,750 controls across four different 
European populations. We pointed out that over 
50% of risk alleles influence gene expression, 
indicating a potential pathogenic mechanism. 
I describe how our genetic findings translate 
to an impaired adaptive and innate immune 
system, the potential role of viral infection, 
and the role the thymus plays in coeliac disease 
pathogenesis.
Part 2 | Dissecting the Genetic Architecture at 
Coeliac Disease Loci
In Chapter 5 I review the genetic progress 
for coeliac disease, its shared background 
with other diseases and the gene pathways 
emerging from our GWAS findings.
In Chapter 6 I describe the use of dense, 
re-sequencing-based approaches to fine-map 
coeliac disease loci. I describe the results of 
genotyping approximately 200,000 markers 
present on the Immunochip in some 24,000 
samples from six countries. This study led to 
novel regions associated with coeliac disease, 
bringing the total number of non-HLA genes 
to 39. For one-third of these coeliac disease 
regions, we successfully narrowed down 
the association signal to a small genetic 
interval. The fine-mapped markers were often 
located in gene regulatory regions, either 3’ 
or 5’, suggesting the causative mechanism 
underlying the disease-alleles will alter gene 
expression.
In Chapter 7 I describe the replication of coeliac 
disease loci established in Europeans, in a 
northern Indian population. At the replicated 
loci, I outline the differences in long-range, 
inter-marker linkage disequilibrium structure 
between Europeans and northern Indians. I also 
point out how, at some loci, the association 
patterns are mis-localized between the two 
ethnic groups.
Part 3 | Results in the Context of Coeliac 
Disease and the Broader Perspective
In Chapter 8 I place the work described in this 
thesis in a broader perspective. I discuss the 
findings described in this thesis and the future 
research and clinical perspectives for coeliac 
disease and the field of complex genetics.
Chapter 1                                                                            Preface and outline of the thesis
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Box 1 | Characteristics of coeliac disease, its clinical manifestation and diagnosis
Figure 1 The concept of case-control genome-wide association studies. 
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Patients Healthy
Stage 1 | In the ﬁrst stage, large numbers of patients and healthy 
controls are recruited, often several hundreds or thousands. The cases 
and controls need to be ethnically matched to avoid spurious 
association results.
Stage 2 | Next, whole-genome DNA is isolated and hybridized on chips 
covering between 300,000 markers (single nucleotide polymorphisms, 
SNPs), to 2.5 million. SNP alleles are labelled with two ﬂuorescent 
dyes. The genotypes for each sample and each SNP on the GWAS 
platform are inferred from the ﬂuorescent signals.
Stage 3 | Allele frequencies for whole-genome markers are calculated 
and compared between the cases and controls. SNPs with signiﬁcantly 
(<5x10-8) diﬀerent frequencies are associated with disease. The results 
are often represented as a so-called “Manhattan plot”, in which the 
x-axis represents the chromosomes depicted in diﬀerent colours, and 
the y-axis shows the signiﬁcance of the association signal. To ensure 
meaningful associations are detected, several quality control steps, for 
samples and SNPs, are performed, e.g. excluding samples with a low 
call rate (<95%), a population stratiﬁcation analysis followed by 
removal of outlying samples, excluding SNPs with low genotype calls 
(<95%) or those deviating from Hardy-Weinberg equilibrium 
(p>0.0001).
Stage 4 | The principle of GWAS is based on the linkage disequilibrium 
(LD) existing between SNPs. The identiﬁed disease associations are 
therefore observed for the SNPs correlating with the real disease 
variant, rather than being disease-causing themselves. Hence, it is 
important to interpret the identiﬁed signals cautiously, as the 
associated loci may harbour many plausible disease genes and will 
need functional follow-up studies to prove causality.
from infancy to adulthood
classical: diarrhoea, abdominal distension, abdominal pain, anorexia, ﬂatulence, failure to thrive, 
muscle wasting, vomiting, weight loss
atypical: dermatitis herpetiformis, anaemia, arthritis, osteoporosis, neurological symptoms (e.g. 
cerebellar ataxia), chronic fatigue, epilepsy, short stature, hepatic steatosis
histological abnormalities of the small intestine based on a biopsy sample (villous atrophy, crypt 
hyperplasia), serological tests for elevated tissue transglutaminase (TGA) and endomysial 
antibodies (EMA), HLA genotyping







Untreated coeliac disease patients have a higher risk of developing other autoimmune diseases, 




Figure 2. Pathogenesis of coeliac disease
The main mediator of coeliac disease is gluten, a protein present in a wide range of dietary products. Gluten peptides pass 
through the epithelial barrier of the small intestine into the lamina propria, where they undergo enzymatic modification 
by tissue transglutaminase (1). This process is called deamidation and leads to an increased immunogenicity of gluten 
peptides. In the lamina propria, the gluten peptides are ‘recognized’ as foreign antigens and presented by particular HLA 
molecules on antigen-presenting cells (APCs) (1). This triggers a cascade of innate and adaptive immune responses and 
leads to the production of antibodies against gliadin - i.e. anti-endomysium and anti-tissue transglutaminase antibodies 
- as well as to the production of pro-inflammatory cytokines (2). This inflammatory response results in the destruction of 
the intestinal epithelium and mucosa, and to lymphocytic infiltration in the proximal part of the small bowel (3). This tissue 
remodelling eventually causes flattening of the intestinal mucosa, villous atrophy and crypt hyperplasia.
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Objective: Our previous coeliac disease genome-wide association study (GWAS) implicated risk 
variants in the human leucocyte antigen (HLA) region and eight novel risk regions. To identify 
more coeliac disease loci, we selected 458 single nucleotide polymorphisms (SNPs) that showed 
more modest association in the GWAS for genotyping and analysis in four independent cohorts.
Design: 458 SNPs were assayed in 1682 cases and 3258 controls from three populations (UK, 
Irish and Dutch). We combined the results with the original GWAS cohort (767 UK cases and 1422 
controls); six SNPs showed associaton with p<1x10-04 and where then genotyped in an independent 
Italian coeliac cohort (538 cases and 593 controls).
Results: We identified two novel coeliac disease risk regions: 6q23.3 (OLIG3-TNFAIP3) and 2p16.1 
(REL), both of which reached genome-wide significance in the combined analysis of all 2987 
cases and 5273 controls (rs2327832 p=1.3 x 10-08, and rs842647 p= 5.2 x 10-07) We investigated the 
expression of these genes in the RNA isolated from biopsies and from whole blood RNA. We 
did not observe any changes in gene expression, nor in the correlation of genotype with gene 
expression.
Conclusions: Both TNFAIP3 (A20, at the protein level) and REL are key mediators in the nuclear 
factor kappa B (NF-kB) inflammatory signalling pathway. For the first time, a role for primary 
heritable variation in this important biological pathway predisposing to coeliac disease has been 
identified. Currently, the HLA risk factors and the 10 established non-HLA risk factors explain ~40% 
of the heritability of coeliac disease.
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Coeliac disease is a common intestinal 
inflammatory disorder, characterised by 
intolerance to dietary gluten protein from 
wheat, and related proteins from barley and 
rye. It is the best understood human leucocyte 
antigen (HLA) associated disorder. Coeliac 
disease is rather special because it shares its 
pathogenesis with other autoimmune diseases 
(such as type 1 diabetes (T1D) and rheumatoid 
arthritis (RA)) and with intestinal inflammatory 
diseases (such as Crohn’s disease). Shared 
genetic risk factors for both coeliac disease and 
Crohn’s disease, as well as for coeliac disease 
and autoimmunity have been reported.1–4 To 
search for genetic risk factors, we recently 
performed a genome-wide association 
study (GWAS) in coeliac disease, followed 
by replication of the 1020 most strongly 
associated single nucleotide polymorphisms 
(SNPs) in case–control cohorts from three 
populations. These studies led to the discovery 
of eight new non-HLA loci.1, 5 The results led to 
three observations: 1 
* Only three of the confirmed loci were 
presented by SNPs located in the top-100 
associated signals in the GWAS, whereas 
three more associated SNPs ranked 
below the top-500, and one SNP ranked 
as low as 1004 in the initial GWAS2. 
* Seven of the eight new loci contained 
immune-related genes, four of which 
are cytokines or cytokine receptors 
(IL2/IL21, IL18RAP, IL12A, and the 
CCR1/CCR3 cluster locus).3
* Four of the new loci (IL2-IL21, IL18RAP, 
CCR3 and SH2B3) are shared by other 
autoimmune and inflammatory 
disorders. 1-3 ,5, 6 
These three observations prompted us to 
start a second replication study in which we 
followed up even lower ranking SNPs from 
our coeliac disease GWAS, and focused on the 
involvement of the immune pathways in the 
pathogenesis of coeliac disease (Fig 1). We 
therefore enriched our SNP set with SNPs that 
showed association to coeliac disease in our 
GWAS and that mapped to the immune-related 
genes (mostly interleukins and their receptors). 
In addition, we sought shared autoimmune and 
inflammatory genes by investigating an overlap 
between SNPs associated in our coeliac disease 
GWAS and to either T1D, RA or Crohn’s disease 
in the Wellcome Trust Case Control Consortium 
(WTCCC) GWAS data. 7
With such a study design we successfully 
identified two novel, genome-wide significant, 
coeliac disease loci: the intergenic region on 
6q23.3 located in the proximity of the TNFAIP3 
gene, and 2p16.1, mapping to the second 
intron of the REL gene. Both loci indicate an 
as yet unrecognised role for the nuclear factor 
kappa B (NF-kB) signalling pathway in the 
pathogenesis of coeliac disease.
MATERIALS AND METHODS
Subject DNA
DNA was extracted from whole blood, except 
for the 1958 cohort control samples, which 
were lymphoblastoid cell line DNA, and 374 
cases and 176 controls from the UK2 collection, 
which were Oragene saliva DNA. Whole-
genome amplified (WGA) blood DNA was 
used for 194 Irish cases and 18 Dutch cases. 
Genotype cluster theta values for WGA DNA 
were similar to blood DNA, for a small fraction 
of markers the intensity (R) was lower.
Detailed characteristics of UKGWAS, UK2, Irish, 
Dutch and Italian samples are provided in table 
1 and previously published studies.1 5, 8 Informed 
consent was obtained from all subjects.
SNP selection
Three groups of SNPs were selected for the 
genotyping:
• To follow up our GWAS SNPs were 
selected with p values between 
p>0.000275 and p<0.004 (indicated as 
SNP-group 1 in table 2 and supplementary 
data 1; also indicated as category 
‘‘WGAtop2000_noWTCCCassoc’’ in 
supplemen- tary data 1) (n = 300).
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• SNPs from immune-related genes 
associated in GWAS with p<0.05 
(indicated as SNP-group 2 in table 2 and 
supplementary data 1; also indicated as 
category ‘‘WGArepli_ ImmuneGenes’’ in 
supplementary data 1) (n = 55).
• SNPs within the top-3000 coeliac–GWAS 
ranking (p<0.009), which showed also 
association to either type 1 diabetes 
(T1D), rheumatoid arthritis (RA) or 
Crohn’s disease in the WTCCC study 
with p<0.05 (n=103). For calculation 
of association in the WTCCC cohort 
we used imputed genotypes (WTCCC 
data accessed on 21 November 2007). 
T1D, RA and Crohn’s cases were 
compared to the blood donor WTCCC 
control cohort (n=1500). The 1958 
birth cohort was excluded from the 
WTCCC analysis, as the majority of 
these samples overlapped with the 
coeliac disease GWAS control cohort. 
This SNP category is indicated as SNP-
group 3 in table 2 and supplementary 
Table 1 Subjects included in our replication study
data 1; also indicated as category 
‘WGAtop3000associatedWTCCC’’ in 
supplementary data 1). 
Golden Gate genotyping
Genotyping of all samples was performed 
following the manufacturer’s protocol. 
Genotyping data and clustering was 
performed in BeadStudio. Clustering clouds 
were manually investigated and adjusted 
if necessary. Four hundred and fifty-eight 
SNPs were included in the genotype analysis. 
Ten SNPs with <95% call rate, because of 
poor amplification or poor genotype cloud 
clustering, were excluded. For the top-6 
associated SNPs we investigated clustering in 
subgroups of blood, saliva and lymphoblastoid 
cell line DNAs. All groups showed similar 
patterns and comparable theta values. All 
plates included one duplicate sample to 
control for plate swaps. Six SNPs were out of 
Hardy–Weinberg equilibrium (p>0.001) and 
were excluded from further analysis. In total, 
1682 cases and 3258 controls from the three 









Coeliac-GWAS SNPs (p<0.009) 
also associated to one of the 
autoimmune disorders 
(p<0.05) in WTCCC
Figure 1 Scheme representing the single 
nucleotide polymorphisms (SNPs) selected 
for the second coeliac genomewide 
association study (GWAS) follow-up study. 



































Phase I - 
GWAS Replication cohort 1





populations (replication cohort 1; R1) were 
successfully genotyped for 442 SNPs.
Genotype concordance
A single control DNA sample was included in 
each 96-well plate. Genotype concordance for 
this sample was 99.9% for 45 replicates of 442 
SNPs.
Additional genotype quality control
Pairwise comparisons of identity-by-descent 
were made for all samples (UK2, Irish and 
Dutch) using PLINK v1.02. We detected the 
same proportion of first-degree relatives as 
described by Hunt et al and excluded one 
sample from each pair of first- degree relatives 
from the entire dataset in the current study.1 
All of the top association findings were in 
Hardy–Weinberg equilibrium in controls.
Taqman genotyping
Replication cohort 2 (Italian population) was 
genotyped using TaqMan probes and primers 
developed by Applied Biosystems, on an 
ABI 7900HT system (Applied Biosystems, 
Nieuwerkerk a/ d IJssel, the Netherlands). 
Genotyping was performed following the 
manufacturer’s specifications. DNA samples 
were processed in 384-well plates and each 
plate contained eight negative controls and 
16 genotyping controls (four duplicates of four 
different samples obtained from the Centre 
d’Etude du Polymorphisme Humain (CEPH), 
Paris, France).
Genotype statistical analysis
Cochran–Mantel–Haenszel allele count c2 
association tests were performed using 
PLINK9 with four clusters: UKGWAS (Infinium 
assay), UK2, IRISH and DUTCH (Golden Gate 
assay) collections. All p values are two-tailed. 
The Cochran–Mantel–Haenszel allele count 
c2 association test implicated in SPSS v 15 
was used for combined analysis of association 
of the coeliac disease cohort (including 
R2 (Italian) samples), and for analysis of 
the combined autoimmune cohort. Using 
Tarone’s statistic in SPSS v 15, we tested for 
heterogeneity of odds ratios between the 
different coeliac disease cohorts for the SNPs 
reported in table 2. The odds ratios differed 
significantly between cohorts (p=0.007) 
only for rs1160542. Haplotypes and linkage 
disequilibrium (LD) blocs were defined and 
analysed using Haploview v4.1.10
Intestinal biopsy expression analysis
The duodenal tissue biopsies from 12 healthy 
controls, 12 untreated coeliac individuals with 
Marsh III and 12 treated coeliac individuals with 
Chapter 2    Coeliac associated risk variants in  TNFAIP3 and REL implicate altered NF-kB signalling
Figure 2 Expression of candidate genes in small intestine tissue from 12 normal healthy controls (NC), 12 treated coeliac 
disease patients with a normal histology of the small intestine, Marsh 0 (M0) and 12 untreated coeliac disease patients 
with villous atrophy, Marsh III (MIII) (A–C). Correlation of the rs2327832 genotype with OLIG3 and TNFAIP3 (D,E) and 
rs842647 genotype with REL expression (F). Expression levels were determined from the whole blood PAXgene samples 
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Marsh 0 were collected in RNAlater (Applied 
Biosystems/Ambion, Austin, Texas, USA). 
RNA was extracted using TRIzol (Invitrogen, 
Carlsbad, California, USA) and glass beads, 
hybridised to HumanRef-8v2 arrays and 
analysed as previously described1
Quality control of whole blood PAXgene data
The whole blood PAXgene expression data 
from 110 unique coeliac individuals, who were 
also genotyped in the UKGWAS, was isolated, 
hybridized to the Illumina HumanRef-8v2 
arrays and analysed as previously described.11
RESULTS
In a combined analysis of 2449 cases and 4680 
controls (Replication cohort 1 (R1) + GWAS), 
eight SNPs were associated with p<1x10-04. 
The strongest association signal was 
observed for rs2327832 in the OLIG3-TNFAIP3 
locus (pCMH(GWAS+R1)=6.6x10-06) (see 
supplementary data 1 for the results of SNPs 
per population and combined results). Six SNPs 
with p<1x10-04 (combined GWAS+R1 cohort) 
were further genotyped in an independent 
cohort from Italy, comprising 538 cases and 
593 controls (Replication cohort 2, R2). We did 
not genotype rs842639 which was strongly 
correlated with rs842647 (r2>0.95), and 
rs4851274, which failed the Taqman design. 
Of these six SNPs, two SNPs were replicated 
with associations to the same allele (rs2327832 
p = 7.93 x 10-5, and rs842647 p = 0.015). rs1160542 
in the AFF3-LONRF2 locus, showed a trend of 
association to the opposite allele (p=0.048). 
Combining the results from our GWAS and 
the two replication cohorts revealed two 
SNPs (rs2327832 in the (OLIG3/TNFAIP3 locus 
and rs842647 in the REL locus) convincingly 
associated with coeliac disease with p = 1.3 x 10-08 
(odds ratio (OR) = 1.25; confidence interval (CI), 
1.15 to 1.34) and p = 5.2 x 10-07 (OR = 0.84; CI, 
0.78 to 0.90), respectively.
In addition, to search for independent 
association signals in coeliac disease we 
performed haplotype analysis with 85 coeliac-
GWAS genotyped SNPs encompassing the 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































bp137851837–138241110, NCBI build36) using 
the 767 coeliac cases and 1422 controls included 
in our GWAS study. However, none of the other 
single SNPs or haplotypes was more strongly 
associated than rs2327832 (data not shown).
To assess the functional role of the SNPs in 
two associated regions, we have investigated 
the available datasets of the genome-wide 
association studies of gene expression.12, 13 No 
significant effect of the rs2327832 SNP on the 
OLIG3 or TNFAIP3, nor of rs842647 on REL, was 
observed in these datasets. We also compared 
the RNA expression profiles of the OLIG3, 
TNFAIP3 and REL genes in small-intestine tissue 
from healthy controls and from treated and 
untreated coeliac patients. None of the genes 
showed significant differential expression 
between the three groups (Fig 2A–C).
We correlated cis gene expression in the 
whole blood samples from 110 patients with 
coeliac disease for the OLIG3/TNFAIP3 and 
rs2327832, as well as REL with rs842647 
genotypes. No significant effect of genotype 
on gene expression was observed (Fig 2D–F). 
We also investigated if any other SNP in the 
1 Mb window around each of the two associated 
SNPs affected gene expression. No cis effect 
was observed after correcting for multiple 
testing (supplementary data 2).
As one of our aims was to search for shared 
autoimmune genes, we also combined our 
results with those from the WTCCC GWAS, in 
particular the results for RA, T1D and Crohn’s 
disease compared to the WTCCC blood donor 
control group. Two of the variants were found 
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Figure 3 Location of the signals in the four autoimmune diseases associated to the OLIG3/TNFAIP3 locus. The figure shows 
the linkage disequilibrium (LD) block between the OLIG3 and TNFAIP3 genes (NCBIb36, 137 559 184 bp to 138 486 672 bp) 
associated with multiple diseases. The plot is based on HapMap CEU data; the D’ plot was generated by Haploview. Single 
nucleotide polymorphims (SNPs) associated per disease are: SLE*a,b,c and SLE** (SNPs reported to be associated with 
SLE (Graham et al16 and Musone et al,17 respectively); RA* and RA** (SNPs associated with RA in Plenge et al14 and 
Thomson et al,15 respectively); T1D (SNP associated to T1D in the WTCCC study7); coeliac disease (SNP associated to 
coeliac disease in the current study). RA, rheumatoid arthritis; SLE, systemic lupus erthymatosus; T1D, type 1 diabetes; 
WTCCC, Wellcome Trust Case Control Consortium.
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to be associated to T1D and RA in the WTCCC 
GWAS: the OLIG3/TNFAIP3*rs2327832 SNP 
and the AFF3-LONRF2*rs1160542 SNP. All 
associations in the WTCCC dataset were 
observed to the same allele as in our coeliac 
disease analysis. Combining the analysis of 
all inflammatory diseases (including coeliac 
disease, T1D, RA and Crohn’s disease) 
rs2327832 in OLIG3/TNFAIP3 (p = 3.78 x 10-
12) showed genome-wide significance to 
immune-related diseases (table 2). A second 
SNP, rs1160542 in AFF3-LONRF2, showed 
modest association (p = 2.49 x 10-06). The AFF3-
LONRF2 locus has previously been nominally 
replicated in T1D in an independent case/
control (p=0.02)and a family (p=0.01) datasets,5 
further strengthening a role for this locus in 
immune-related disorders.
DISCUSSION
In this study we performed an extensive 
replication of moderately associated genetic 
variants from the GWAS study in coeliac 
disease, including variants located in immune-
related genes, and potentially shared 
autoimmune SNPs. The strongest association 
to both coeliac disease and immune-related 
diseases was seen for rs2327832, located in 
a 60 kb block of linkage disequilibrium (LD) 
between the OLIG3 and TNFAIP3 genes. 
Interestingly, two independent SNPs located 
in the same LD block have been previously 
associated to RA;14, 15 one of the RA associated 
SNPs (rs6920220) is a perfect proxy (r2 = 1 in 
CEU HapMap samples) for rs2327832, the SNP 
found to be associated in this study. Recently, 
the same region was found to be associated to 
systemic lupus erythematosus (SLE), another 
immune-related disease.16 17 For SLE a second, 
independent variant in the TNFAIP3 gene was 
also found to be associated.16 This indicates 
the TNFAIP3 gene region as a new, shared 
autoimmune locus. The scheme of association 
among different autoimmune disorders is 
presented in Fig 3, indicating the complexity of 
the association pattern within this locus. Both 
the same and different variants are associated 
to various autoimmune traits.
TNFAIP3 is an attractive candidate for both 
inflammatory and autoimmune pathogenesis. 
The TNFAIP3 gene product A20 is required 
for termination of the NF-kB signal mediated 
by innate immune receptors via the 
de-ubiquitylation of several NF-kB signalling 
factors.18 Genetic deficiency of A20 in mice 
leads to persistent activation of NF-kB by 
toll-like receptors, resulting in multi-organ 
inflammation, cachexia and neonatal 
lethality.19, 20 It has been suggested that loss of 
A20 breaks down the tolerance of the innate 
immune system to the commensal intestinal 
microflora.21 Although we could not observe 
an effect of the associated polymorphisms 
on expression, this does not exclude a role for 
A20 in coeliac disease; there might well be 
an effect on the protein level. A20 regulation 
is rather complex and can be modified by 
A20-binding proteins such as ABINs or TAX1BP1, 
as well as by post-translational modifications in 
A20 protein.22 We do not exclude that subtle 
changes in the protein structure could lead 
to modification of A20 activity and, together 
with other coeliac-associated risk variants, 
cause the disease. Further extensive studies, 
including fine mapping with sequencing as 
well as functional studies (including those on a 
protein level), are required to identify the true 
causal variants.
The second new gene associated with coeliac 
disease – REL – is a component of the NF-kB 
transcription complex that plays a critical 
role in promoting immune and inflammatory 
responses including through the production of 
pro-inflammatory cytokines. In another study 
we observed a moderate association of REL 
polymorphisms to ulcerative colitis (p = 0.001), 
another intestinal inflammatory disorder,3 
suggesting that this gene may not be unique 
to coeliac disease pathogenesis. Association of 
coeliac disease to both TNFAIP3 and REL points 
to a role for innate signalling via NF-kB in the 
pathology of coeliac disease, this is a novel 
finding and has not been reported before.
In this study we have extended the replication 
of our GWAS in coeliac disease and searched 
for genes shared by coeliac disease and other 
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autoimmune and inflammatory intestinal 
disorders. We discovered two new loci 
associated to coeliac disease: REL and OLIG3/
TNFAIP3. The OLIG3/TNFAIP3 locus can be 
considered to be a general immune-related 
locus as it has now been associated to four 
autoimmune disorders (Fig 3). This supports 
the recent observation that many disease 
susceptibility genes contribute to multiple 
diseases.23 So far, the pathways associated with 
coeliac disease have pointed to T cell signalling 
and multiple cytokine involvement. Our 
observation that the NF-kB signalling pathway 
is also important adds a new player to the field.
NF-kB is a transcription complex that plays 
a key role in regulating the cellular immune 
response to infections, stress, cytokines and 
other stimuli. Activation of NF-kB in various 
inflammatory disorders, including asthma, 
arthritis and inflammatory bowel disease (IBD) 
has been described.24
Coeliac disease can now be added to the list 
of complex disorders that show association 
to the 6q23 region. This strengthens the 
importance of A20 in controlling inflammation 
in autoimmune diseases and points to A20 as 
an attractive candidate for drug targeting, as 
suggested recently by Coornaert et al.22
How the newly discovered genes interplay with 
the previously identified coeliac loci can only 
be speculated. On the one hand, activation of 
the NF-kB complex leads to overexpression 
of inflammatory cytokines and, together with 
previously identified cytokines and cytokine 
receptor genes such as CCR5, RGS1, IL12A and 
IL18RAP, this pathway would be important 
in fine-tuning the immune response. On the 
other hand, the NF-kB pathway may play an 
independent role in the innate mechanisms of 
disease development. Strikingly, genes involved 
in the innate immune response have recently 
been associated with various autoimmune 
diseases, suggesting a role for microbial and 
viral triggers in disease development. In coeliac 
disease an increased frequency of rotaviral 
infections have been observed, suggesting 
that viral infections may, for example, trigger 
an innate immune response.25
It is interesting that the knockdown studies 
of A20 in dendritic cells show a shift in the 
subset of activated T cells, hyperactivation of 
cytotoxic T lymphocytes and T helper cells, 
and suppression of regulatory T cells. This 
shift results from enhanced expression of 
co-stimulatory signals and proinflammatory 
cytokines when inhibiting A2026 and would fit 
in celiac disease being a Th1 mediated disease.
These two novel loci can be added to the list 
of eight known, non-HLA, genetic risk factors 
for coeliac disease that have a smaller risk 
effect than HLA. Extending the list of common 
variants that account for coeliac disease will 
improve the genetic prognosis of patients and 
may help to predict the likelihood of individuals 
from the at-risk group developing coeliac 
disease.
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Recent genome-wide association studies (GWAS) have revealed genetic risk factors in autoimmune 
and inflammatory disorders. Several of the associated genes and underlying pathways are shared 
by various autoimmune diseases. Rheumatoid arthritis (RA) and coeliac disease (CD) are two 
autoimmune disorders which have commonalities in their pathogenesis. We aimed to replicate 
known RA loci in a Dutch RA population, and to investigate whether the effect of known RA and CD 
risk factors generalize across the two diseases. We selected all loci associated to either RA or CD 
in a GWAS and confirmed in an independent cohort, with a combined P-value cut-off P < 5 x 10-6. 
We genotyped 11 RA and 11 CD loci in 1368 RA patients, 795 CD patients and 1683 Dutch controls. 
We combined our results in a meta-analysis with UK GWAS on RA (1860 cases; 2938 controls) and 
CD (767 cases; 1422 controls). In the Dutch RA cohort, the PTPN22 and IL2/IL21 variants showed 
convincing association (P = 3.4 x 10-12 and P = 2.8 x 10-4, respectively). Association of RA with 
the known CD risk variant in the SH2B3 was also observed, predominantly in the subgroup of 
rheumatoid factor-positive RA patients (P = 0.0055). In a meta-analysis of Dutch and UK data sets, 
shared association with six loci (TNFAIP3, IL2/IL21, SH2B3, LPP, MMEL1/TNFRSF14 and PFKFB3/
PRKCQ) was observed in both RA and CD cohorts. We confirmed two known loci and identified 
four novel ones for shared CD–RA genetic risk. Most of the shared loci further emphasize a role for 
adaptive and innate immunity in these diseases.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic 
inflammatory disorder affecting 1% of the adult 
population. The disease is characterized by 
inflammation of the synovial tissue of multiple 
joints leading to pain, deformities and a reduced 
quality of life. The aetiology of RA is complex 
and largely unknown; however, epidemiologic 
data support a polygenic susceptibility model1. 
Besides this, environmental factors may also 
play a role in the pathogenesis of RA2.
RA shares common pathogenic mechanisms 
with other autoimmune disorders. This is 
reflected by the co-occurrence of several 
autoimmune disorders in some patients 
and families, and the shared genetic 
background of autoimmune diseases3,4. One 
of the autoimmune disorders showing similar 
pathogenic mechanisms to those seen in 
RA is coeliac disease (CD). This is a chronic 
intestinal inflammatory disorder which 
develops through an intolerance to gluten, the 
major dietary protein in wheat, and related 
proteins from barley and rye5. Although the 
diseases are clearly distinct in their phenotype, 
common features in RA and CD include the 
association of the HLA molecules with the 
diseases, T-cell infiltration in the target organs, 
the development of disease-specific auto-
antibodies and the role of enzymes involved 
in post-translational modifications in the 
pathogenesis of the diseases6. In addition, 
several studies show co-occurrence of CD and 
RA7–10. However, there are no well-designed 
studies to assess the true prevalence of RA and 
CD co-morbidity.
Recently performed genome-wide association 
studies (GWAS) have identified 11 loci 
associated with RA and 10 loci associated with 
CD, in addition to the already known HLA 
loci11–21 (Supplementary Material, Table S1). 
These GWAS showed that, besides HLA, two 
chromosomal regions are shared between 
RA and CD: a region on chromosome 4q27 
(including the genes IL2 and IL21) and the 
6q23.3 locus containing the OLIG3 and TNFAIP3 
genes22. Interestingly, the IL2/IL21 locus has also 
been associated with psoriatic arthritis, Grave’s 
disease and type 1 diabetes, whereas the 
OLIG3/TNFAIP3 locus has also been associated 
to systemic lupus erythematosus and type 1 
diabetes13,23–27. These results strongly suggest 
that overlapping genetic mechanisms underlie 
the development of multiple autoimmune 
disorders4. We therefore hypothesize that other 
susceptibility genes identified for RA might 
also contribute to the development of CD and 
vice versa. In this study, we investigated a total 
of 22 SNPs associated with either RA (11 SNPs) 
or CD (11 SNPs) by association testing in Dutch 
RA and CD cohorts and by meta-analyses 
including well-comparable data sets from two 
earlier GWAS on RA and CD.
RESULTS
In this study, we performed an association 
analysis with all SNPs showing replicated 
association to either RA or CD with a P-value 
cut-off of 5 x 10-6. In total, 22 SNPs (11 primary 
CD-related and 11 primary RA-related SNPs) 
were genotyped or imputed in 1368 Dutch RA 
cases, 795 Dutch CD cases and 1683 controls. 
Since the distribution of males and females was 
substantially different in our cases and control 
cohort (frequency female in both case cohorts 
60%, whereas only 20% of controls were 
female, see Supplementary Material, Table S2), 
we first compared the allele frequency of all 
the SNPs in males and females in our control 
cohort. None of the SNPs showed a significant 
difference (Supplementary Material, Table S4), 
which we took as evidence for the comparability 
of the samples.
Replication of RA loci in Dutch RA cohort
A replication of known RA variants in a Dutch 
RA cohort has not been performed previously. 
From a total of 11 RA loci, only the well-
established risk variant in PTPN22 (rs2476601) 
showed a clear association with RA in our cohort 
(P = 3.43  x 10-12; OR = 1.70 (95% confidence 
interval (CI): 1.46–1.98)). Three other RA SNPs 
(rs3890745, rs4810485 and rs3218253 located 
in the MMEL1/TNFRSF14, CD40 and the IL2RB 
gene regions, respectively) were nominally 
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replicated in Dutch RA samples (P < 0.05). The 
remaining RA loci were not associated in our 
RA data set (Table 1).
Association of CD loci in Dutch CD cohort
All previously confirmed coeliac variants, except 
the LPP SNP rs1464510, showed association to 
CD in the Dutch cohort. This is not surprising 
since we used 508 of the 795 cases, and 833 of 
the 1683 controls as part of the multi-national 
cohorts in our previous studies to establish the 
association of the CD loci14,20,21.
Cross-disease association study in the Dutch 
cohorts
Three out of 11 primary CD-related SNPs were 
associated with RA in the Dutch cohort. The 
IL2/IL21 variant rs13151961 showed the 
strongest association to RA [P=0.0003; OR=0.78 
(95% CI: 0.68–0.89)]. This association was 
reported previously in a subset of our cohort22. 
We now confirmed the association of IL2/21 
variants in an extended group of RA and CD 
cases. The other two variants, SH2B3 rs3184504 
and LPP rs1464510, showed a moderate 
association with RA [P=0.024; OR = 1.12 (95% 
CI: 1.02–1.25) and P=0.012; OR=1.14 (95% 
CI: 1.03–1.26), respectively]. Opposing allelic 
association for RA and CD was observed for the 
LPP variant: the frequency of LPP rs1464510*C 
allele was increased in RA compared with 
controls, whereas the rs1464510*A allele was 
more frequent in CD patients than controls.
From the RA-specific variants, only rs3890745 
from the MMEL1/TNFRSF14 locus showed a 
trend for association to CD [P=0.04, OR=0.87 
(95% CI: 0.77–0.99)]. The rs10499194 variant in 
the TNFAIP3 locus, previously reported only in 
RA samples, also showed moderate association 
to CD [P=0.018; OR=0.84 (95% CI: 0.73 – 0.97)] 
(Table 1).
Stratification of RA samples for rheumatoid 
factor
As the association of several known RA genetic 
risk variants has been shown to be different in 
autoantibody positive and negative cases28, 
we performed a separate association analysis 
in rheumatoid factor (RF)-positive and RF-
negative cases. We had information on RF 
status available for a sub- group of Dutch RA 
cases: 776 cases were RF positive and 204 RF 
negative. In the RF-positive group the SH2B3 
variant rs3184504 showed stronger association 
compared to the total RA cohort (P=0.0055, 
OR=1.19 (95% CI: 1.05– 1.34) (Table 2). We did 
not perform stratification on anti-CCP auto-
antibodies, as the anti-CCP status was only 
available for a minority of cases.
Gene(s) present 
in risk locus           
Reported 
association       
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0.19              0.18 
0.36              0.34 
0.23                0.24 
0.32                 0.31 
0.12                 0.11 
0.45                0.44 
0.49                0.53 
0.18                0.15 
0.40                0.39 
0.46                0.49 
0.21                0.22 
0.24                0.24 
0.32                0.29 
0.10                0.16 
0.24                0.24 
0.25                0.26 
0.35                 0.37 
0.44                0.45 
0.19                0.21 
0.33                 0.34 
0.24                0.21 





0.797              0.98 
0.106             0.92 
0.628              1.03 
0.855             0.99 
0.613              0.96 
0.566              0.97 
0.013              1.14 
0.0003           0.78 
0.579              0.97 
0.024              1.12 
0.230              1.08 
0.987              1.00 
0.014              0.87 
3.43E-12        1.70 
0.930              1.01 
0.462             1.06 
0.167              1.08 
0.829              1.01 
0.094              1.12 
0.331              1.06 
0.015             0.86 
0.030              1.13
0.86 – 1.12 
0.82 – 1.02 
0.91 – 1.17 
0.89 – 1.10 
0.82 – 1.13 
0.88 – 1.08 
1.03 – 1.26 
0.68 – 0.89 
0.88 – 1.08 
1.02 – 1.25 
0.95 – 1.22 
0.89 – 1.13 
0.78 – 0.97 
1.46 – 1.98 
0.89 – 1.13 
0.91 – 1.22 
0.97 – 1.20 
0.91 – 1.12 
0.98 – 1.27 
0.95 – 1.18 




































































0.61 – 0.84 
0.66 – 0.86 
1.17 – 1.54 
1.16 – 1.49 
1.31 – 1.84 
1.08 – 1.37 
0.80 – 1.02 
0.54 – 0.77 
1.06 – 1.34 
1.16 – 1.47 
0.99 – 1.32 
0.73 – 0.97 
0.77 – 0.99 
0.78 – 1.16 
0.85 – 1.13 
0.88 – 1.22 
0.93 – 1.19 
0.88 – 1.12 
0.74 – 1.02 
0.86 – 1.11 
0.93 – 1.23 
0.94 – 1.23
Table 1. Results of association analysis in Dutch RA and CD cohorts
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CHR, chromosome; RF, rheumatoid factor; MAF, minor allele frequency; OR, odds ratio. 
ars42041 was genotyped in a subgroup of controls (n=833) 






























































































C               0.19 
G               0.36 
A               0.23 
A               0.32 
G               0.12 
G               0.45 
C               0.49 
G               0.18 
A               0.40 
A               0.46 
G               0.21 
T               0.24 
G              0.32 
A               0.10 
A               0.24 
G               0.25 
G               0.35 
G               0.44 
C               0.19 
G               0.33 
T               0.24 
A               0.27
























0.640   0.96 
0.070   0.89 
0.234   1.09 
0.824   1.02 
0.693   0.96 
0.066   0.89 
0.161   1.09 
0.0004  0.74 
0.104   0.90 
0.0055  1.19 
0.990   1.00 
0.602   1.04 
0.016   0.85 
1.45-11  1.81 
0.982   1.00 
0.818   0.98 
0.150   1.10 
0.712   1.02 
0.024   1.19 
0.322   1.07 
0.413   0.94 
0.245   1.08
OR
0.82 – 1.13 
0.78 – 1.01 
0.95 – 1.26 
0.89 – 1.16 
0.80 – 1.17 
0.79 – 1.01 
0.97 – 1.23 
0.62 – 0.87 
0.80 – 1.02 
1.05 – 1.34 
0.86 – 1.16 
0.90 – 1.20 
0.75 – 0.97 
1.52 – 2.15 
0.87 – 1.15 
0.83 – 1.16 
0.97 – 1.24 
0.91 – 1.16 
1.02 – 1.38 
0.94 – 1.21 




To increase the power of the study, we 
combined our data with those of a GWAS in 
RA and CD patients from the UK into a meta-
analysis. The UK cohorts included 1860 cases 
and 2938 controls from the WTCCC study on 
RA, and 767 CD cases and 1422 controls from a 
UK GWAS in CD13,21. In the meta-analysis, four 
risk loci showed association to both RA and CD 
with P < 0.01, including the genes IL2/IL21, LPP, 
TNFAIP3 and SH2B3 (Table 3). Association with 
the LPP locus in CD and RA was observed for 
opposing alleles. A trend for association with 
SNPs in MMEL1-TNFRSF14 and PRKCQ was 
observed for both diseases (P < 0.05) (Table 
3). An overview of the common and separate 
associations of the tested genes with RA and 
CD is shown in Figure 1.
DISCUSSION
In this study, we (i) performed the replication 
of known RA associated loci in our Dutch 
cohort of RA cases and controls; (ii) performed 
the cross-study of RA and CD associated 
variants in Dutch RA and CD cohorts and (iii) 
combined our results in a meta-analysis with 
the UK GWAS in RA and CD13,21. We were able 
to replicate 4 out of 11 RA loci in our Dutch 
RA cohort, and identified 6 loci which showed 
shared association to CD and RA in the meta-
analysis. Strikingly, most of the previously 
established RA SNPs were not replicated. 
There are several reasons for this observation. 
First, the endophenotyping difference might 
be the major reason for non-replication: 
several of the RA loci were established 
mainly in subgroups of ACPA-positive 
RA patients. Differential association in auto-
antibody positive and negative subgroups of 
RA has been reported previously28. We could 
not stratify for ACPA in our cohort due to lack 
of ACPA status for most patients. However, 
when stratified for RF, we were able to observe 
a stronger effect for the variant in the SH2B3 
gene. Secondly, population heterogeneity 
might be another explanation for lack of 
association with the initial reported variants. To 
control for the heterogeneity of the association 
test, we included the Breslow–Day test in 
our analysis. Two of the SNPs (rs4750316 and 
rs1678542, the PFKFB3/PRKCQ and KIF5A locus, 
respectively) showed significant results for this 
test, indicating the presence of heterogeneity 
between the two populations. Further 
replication in other populations is essential for 
establishing the true risk effect of these genes. 
Since we only tested a single marker (the most 
associated one for each locus), we may have 
Table 2. Association of RA and CD SNPs in rheumatoid factor-positive subgroup of RA patients (n=775), compared to con-
trols (n=1683)
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missed the association due to low/other linkage 
disequilibrium (LD) between the established 
‘tagging’ SNP and the true causal variant in 
the Dutch population. Finally, the relative risk 
of associated regions in the initial studies was 
rather low (OR between 0.75 and 1.32 for most 
SNPs). Moreover, similar to the single gene 
association studies, the effect of some of the 
established loci might be overestimated and 
our study might not have had enough power 
to replicate all loci. Depending on the SNP, 
the power of our study ranged from 0.2 – 1 in 
the Dutch cohorts and increased in the meta-
analysis to a range of 0.34 – 1 (Supplementary 
Material, Table S5). The power was at 80% or 
above for 16 out of 22 SNPs for the RA NL-UK 
combined analysis and above 80% for 8 out of 
22 SNPs for the CD NL-UK analysis. All these 
factors, or combinations of them, might explain 
the negative results for most of the genes we 
tested. Further replication studies in various 
populations and endophenotypes would 
shed light on the effect and heterogeneity of 
associated loci in RA.
In the combined Dutch and UK data sets, we 
observed a convincing shared association 
of four genes to RA and CD (P < 0.01 in both 
diseases), and suggestive association of two 
more loci (P < 0.05 in both diseases). Two of the 
shared loci, IL2/IL21 and TNFAIP3, are already 
known to be involved in both diseases and were 
confirmed in our study.
Both genes show association with several 
other immune-related diseases: IL2/IL21 
with inflammatory bowel disease29–31, type 
1 diabetes22,24 and psoriasis23, and TNFAIP3 
with systemic lupus erythematosus26, type 
1 diabetes25 and psoriasis32. This points to a 
general role for these genes in the development 
of autoimmunity.
The association of IL2-IL21 locus to several 
immune-related diseases is especially 
interesting, although strong LD in this locus 
makes it difficult to locate the true associated 
gene. Both IL2 and IL21 are important in 
T- regulatory and Th17 cells, respectively. Both 
CD and RA show high levels of Th17 in affected 
tissues33,34. Interestingly, IL21 is produced by 
Th17 cells and is important for maintaining 
Th17 cells35. High levels of IL21 have been found 
in the intestine of patients with CD21, whereas 
IL21 receptor is overexpressed in synovial 
tissues of RA patients36. Blockading the 
IL21/IL21R pathway ameliorates disease in a 
murine model of RA37.
pCMH, P-value Mantel–Haenszel chi-square.
































































































0.6349   0.98 
0.1470   0.95 
0.1071   1.06 
0.2672   1.04 
0.4926   0.97 
0.9945   1.00 
0.0054   1.10 
1E-05    0.83 
0.0839   0.94 
0.0011   1.11 
4E-05    1.17 
0.0419   0.93 
5E-07    0.84 
2E-27    1.67 
0.1041   1.06 
0.008    1.11 
0.0007   1.12 
0.9508   1.00 
0.0390   0.92 
0.0076   0.91 
0.0033   0.89 
2E-05    1.17
0.90- 1.06
0.89 – 1.02 
0.99 – 1.15 
0.97 – 1.11 
0.88 – 1.07 
0.94 – 1.07 
1.03 – 1.17 
0.76 – 0.90 
0.88 – 1.01 
1.04 – 1.19 
1.09 – 1.27 
0.86 – 1.00 
0.78 – 0.90 
1.52 – 1.84 
0.99 – 1.15 
1.03 – 1.20 
1.05 – 1.20 
0.94 – 1.06 
0.85 – 1.00 
0.85 – 0.98 
0.83 – 0.96 
1.09 – 1.26
1.76E2-07    0.73 
2.87E2-06   0.80 
8.62E2-09   1.34 
2.46E2-07   1.27 
1.45E2-09    1.47 
1.16E2-05    1.21 
0.00010   0.84 
6.61E2-12   0.65 
1.81E2-05   1.21 
4.42E2-08   1.27 
0.00069   1.19 
0.0419   0.93 
0.0275   0.90 
0.2623   1.08 
0.3319   1.05 
n/a      n/a 
0.3189   1.05 
0.6610   0.98 
0.0135   0.87 
0.8002   0.99 
0.2007   1.07 
0.0568   1.10
0.65 – 0.82 
0.73 – 0.88 
1.21 – 1.48 
1.16 – 1.39 
1.30 – 1.67 
1.11 – 1.32 
0.77 – 0.92 
0.58 – 0.74 
1.11 – 1.32 
1.17 – 1.39 
1.08 – 1.32 
0.86 – 1.00 
0.82 – 0.99 
0.94 – 1.25 
0.95 – 1.16 
n/a
0.96 – 1.15 
0.90 – 1.07 
0.77 – 0.97 
0.90 – 1.08 
0.97 – 1.18 
1.00 – 1.21
Table 3. Meta-analysis of SNPs in Dutch and UK RA and CD populations
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Figure 1. Association of 20 investigated loci to CD and RA. From the IL12A-SHIP locus and OLIG3-TNFAIP3 locus, one of 
two SNPs (the most associated one, rs17810546 and rs2327832, respectively) are included in the figure. The SNP rs42041 
was excluded from the meta-analysis due to poor imputation quality. Blue dots and corresponding line-OR and 95% CI for 
RA. Red dots and lines-OR and 95% CI for CD. OR was calculated for the minor allele of associated SNP.
The association of SH2B3 with both RA and CD 
has not been reported previously. The SH2B3 
rs3184504 variant is a non-synonymous SNP 
R262W located in exon 3 of the gene, and has 
previously been associated with CD, type 1 
diabetes and myocardial infarction14,24,38. It 
encodes the T-cell adapter protein LNK, which 
regulates T-cell receptor-, growth factor- and 
cytokine receptor-mediated signalling, and 
is therefore an attractive candidate gene for 
shared autoimmune susceptibility39.
Another shared gene identified in this study, 
LPP (LIM domain containing preferred 
translocation partner in lipoma), is involved 
in cell adhesion, cytoskeletal remodelling 
and maintaining cell shape and motility40,41. 
Chromosomal aberrations including the LPP 
region have been observed in leukaemia, 
indicating a potential role for this chromosomal 
region in regulating the immune system42. The 
exact function of LPP in autoimmunity has not 
yet been defined. Interestingly, in our study, 
LPP shows a differential association for RA and 
CD. The effect of LPP rs1464510*A allele confers 
protection in RA, and susceptibility in CD. The 
reason for the opposing allelic associations 
could be the presence of distinct RA- and 
CD-causing variants, located on different 
haplotypes and tagged by the opposite alleles 
of the same SNP. Another possibility is that the 
same variant confers truly susceptibility to one 
disease and protection from another, similar 
to the PTPN22 functional variant Arg620Trp, 
which confers susceptibility to several 
autoimmune diseases, but protection from 
Crohn’s disease43,44. Sequencing of the whole 
associated block in both diseases is required 
to define the RA and CD causal variants and 
explain the exact nature of this observation. 
Association of opposite alleles to different 
autoimmunities has been also observed for 
IL18RAP and TAGAP variants in CD and type 1 
diabetes45.
Two loci showed moderate association 
to both diseases- the PFKFB3/PRKCQ and 
MMEL1-TNFRSF14 (P < 0.05). The PFKFB3/
PRKCQ variant was originally reported in a 
meta-analysis including RA patients17. In 
addition, the same locus has recently been 
associated with type 1 diabetes in a meta-
analysis46. Thus, our findings, although only 
moderately significant, provide additional 
support for this locus being a shared 
autoimmune gene. PRKCQ is involved in 
regulating and controlling T-cell-mediated 
signalling and is therefore a plausible 
candidate for autoimmune traits47. The MMEL1/
TNFRSF14 locus includes the TNFRSF14 
(HVEM, herpes virus entry mediator) gene, 
which functions as a co-stimulatory molecule 
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during T-cell activation48, and enhances the 
bactericidal activities of human monocytes and 
neutrophils49. In antiviral responses, TNFRSF14 
is involved in NF-kB activation.
Overall, from six shared CD-RA loci, five contain 
genes directly involved in immune function. 
Association to the SH2B3, PRKCQ, IL2/21 and 
TNFRSF14 genes points to the role of T-cell-
mediated signalling, whereas both the TNFAIP3 
and TNFRSF14 genes are linked to NF-kb 
signalling, innate immunity and the response 
to pathogens. The association of innate 
molecules to RA and CD may now explain the 
link of mucosal immunity state and infections 
in predisposition to both diseases50-52.
Our study extends the knowledge on genes 
that are shared between RA and CD. Most 
of the shared genes fit with the current 
hypotheses on the pathogenesis of these 
diseases, involving both innate and adaptive 
immunity. Several of the shared genes also 
contribute to the susceptibility to additional 
autoimmune diseases. Creating genetic 
profiles for autoimmunity may help understand 
the basic mechanisms of pathogenesis and 
predict common immune-related risk factors/ 
phenotypes. Furthermore, it will open up 
possibilities for the development of new drug 




Rheumatoid arthritis cohorts. We combined 
two independent Dutch RA inception cohorts: 
from Nijmegen (n=960) and Groningen 
(n=408). Both cohorts have been described 
elsewhere22,53,54. All patients were diagnosed 
according to the American College of 
Rheumatology (ACR) criteria for RA55. Due to 
the lack of whole genome data, we ascertained 
subjects were of Dutch descent based on their 
surname.
Coeliac disease cohorts. Our study analysed 
795 unrelated Dutch individuals with CD. All 
affected individuals were diagnosed according 
to the revised ESPGAN criteria56. The cohort 
encompassed individuals that showed a Marsh II 
or Marsh III lesion in the initial diagnostic small-
bowel biopsy specimens upon re-evaluation 
by one of two experienced pathologists, or 
presented with dermatitis herpetiformis and 
were HLA-DQ2 positive.
Control cohort. The control cohort comprised 
unrelated blood bank donors (n=833) and 
NELSON controls (n=850). The blood bank 
control cohort was described earlier14,20. Other 
controls were included from the NELSON 
project-an ongoing population-based, 
randomized multi-centre lung cancer screening 
trial, studying male smokers57. These controls 
were collected from the north and centre of the 
Netherlands (Groningen, Utrecht and Drenthe, 
The Netherlands). All the control subjects were 
heavy smokers or ex-smokers (a minimum of 
16 cigarettes/day for 25 years or 11 cigarettes/
day for 30 years), but did not develop airway 
obstruction or emphysema suggesting chronic 
obstructive pulmonary disease (COPD) until 
the end of a 4 year observation period.
The current study was approved by the local 
ethics committees and all the patients and 
controls gave their written informed consent. 
Information on male/female ratio of the cohorts 
is shown in Supplementary Material, Table S2.
SNP selection and genotyping
We selected SNPs with confirmed association 
to either RA or CD with P < 5 x 10-06 from 
existing literature. Information on the original 
studies and the associated SNPs is given in 
Supplementary Material, Table S1. In total, 
we tested 22 SNPs from 20 loci, 11 known for 
association to CD and 11 primarily associated 
to RA, with two of the genes known to be 
associated to diseases.
Genotyping of Dutch RA samples. All 22 SNPs 
were genotyped in the Dutch RA cohort using 
TaqMan probes and primers developed by 
Applied Biosystems, on an ABI 7900HT system 
(Applied Biosystems, Nieuwerkerk a/d IJssel, 
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The Netherlands). Genotyping was performed 
following the manufacturer’s specifications. 
DNA samples were processed in 384-well plates, 
each plate contained 8 negative controls and 
5 duplicated samples. All duplicates showed 
consistent results for all SNPs.
Genotyping of Dutch CD samples and controls. 
Of the 22 SNPs, 15 were present on the 
Illumina HAP550 platform. The genotyping 
data of CD cases and controls for these 15 
SNPs were extracted from an ongoing GWAS 
in the Dutch population, performed on the 
Human670-QuadCustom Illumina BeadChips, 
which contains the HumanHap550 SNP set 
(manuscript in preparation). The remaining 
seven SNPs were not present on the genotyping 
platforms. In these cases, a 4 MB window 
around the SNP of interest was imputed 
using Plink v1.05 (http://pngu.mgh.harvard.
edu/purcell/plink/) and the phase 2, HapMap 
CEU samples, release 23a, as the imputation 
reference panel58. We included the imputed 
genotypes only if the imputation quality was 
above 0.8 (Supplementary Material, Table 
S3). The SNP rs42041 showed deviation from 
Hardy–Weinberg equilibrium (HWE) in the 
Dutch GWAS imputed data set, so this SNP was 
genotyped by TaqMan in Dutch CD cases and 
the blood bank control group (n=833). NELSON 
controls (n=850) were not genotyped for the 
rs42041. TaqMan genotyping was performed 
following the manufacturer’s specifications. 
DNA samples were processed in 384-well 
plates; each plate contained 8 negative controls 
and 16 genotyping controls [four duplicates 
of four different samples obtained from the 
Centre d’Etude du Polymorphisme Humain 
(CEPH)].
UK data sets. For RA, we used freely available 
genotype data for 9 SNPs from RA patients 
from the GWAS preformed by the Wellcome 
Trust Case Control Consortium (WTCCC) in 
200713, comprising 1860 UK RA cases and 2938 
UK controls. For the remaining 13 SNPs, we 
used imputed genotypes, all with imputation 
quality > 0.8 (https://www.wtccc.org.uk/ccc1/
summary_stats.shtml data access 21 August 
2008).
For CD, genotyping results for 15 SNPs were 
extracted from the UK GWAS study21. The non-
genotyped SNPs were imputed in the UK cases 
and controls (imputation quality (info) > 0.8, 
except for the SNP rs42041, which could not 
be imputed with sufficient quality and was 
therefore excluded from the meta-analysis 
(Supplementary Material, Table S3).
The genotyping method and imputation quality 
in each cohort is presented in Supplementary 
Material, Table S3A-C. The frequency of missing 
genotypes was below 5% for all the SNPs in all 
the genotyped cohorts.
Population substructure analysis
Multidimensional scaling analysis 
(implemented in Plink) was applied to all the 
samples for which genome-wide genotype 
data were available. The values of the first five 
components were further plotted against each 
other. We detected outlying samples only for 
the first three components. Samples exceeding 
two standard deviations from the mean for 
the first three components were excluded, 
ensuring that only the most homogeneous 
samples were included in our final analysis and 
that there was no population stratification.
As a part of the ongoing GWAS in celiac 
disease, we applied a multidimensional scaling 
(MDS) analysis to assess whether there was 
a large population substructure between the 
UK and Dutch cohorts. Both cohorts created 
tight clusters and, as expected, the two first 
components could distinguish between the two 
populations. However, over 40% of the samples 
shared a common part in the plot. Both cohorts 
were also merged with the HapMap2 data and 
the MDS analysis was repeated. Both cohorts 
mapped perfectly to the CEU population, any 
outlying samples that mapped outside the 
cluster were excluded from further analysis.
Statistical analysis
We calculated HWE for all the genotyped SNPs 
by comparing the expected and observed 
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genotypes in a 2x3 chi-squared table. None 
of the markers deviated significantly from 
HWE in cases or controls (P > 0.01) in any of 
the populations. Association analysis was 
performed using chi-squared statistics with 
two-tailed P-values (implemented in Plink 
v1.05)58. In the meta-analysis, we combined the 
information on allele counts for the Dutch and 
UK cohorts separately for CD and RA, in the 
Mantel-Haenszel chi-squared association test 
with two clusters. P-values, odds ratios (ORs) 
and 95% confidence intervals (95% CIs) were 
calculated using Plink v1.05.
To estimate the heterogeneity of the 
association tests between the populations, we 
performed the Breslow-Day test. All except 
two SNPs described in this study were negative 
for this test. Rs4750316 and rs1678542 showed 
significant results for the Breslow-Day test in 
the RA cohort and we therefore applied the 
random-effect model for non-heterogeneous 
studies (the DerSimonia-Laird method 
implemented in the rmeta package for R; 
www.r-project.org).
Power calculation
We calculated the power of our sample size to 
detect significant associations using the Genetic 
Power Calculator (http://pngu.mgh.harvard.
edu/~purcell/gpc/)59. The calculations were 
performed separately for the Dutch cohort and 
for the meta-analysis with UK collections and 
are summarized in Supplementary Material, 
Table S5.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online. 
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We performed a second-generation genome-wide association study of 4,533 individuals with 
celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with PGWAS 
<10−4 and 18 SNPs from 14 known loci in a further 4,918 cases  and 5,684 controls. Variants from 
423 new regions reached genome-wide significance (Pcombined < 5 × 10−8); most contain genes  with 
immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, 
RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence 
to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis 
of 42,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated 
(P < 0.0028, FDR 5%) with cis gene expression.
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Celiac disease is a common heritable chronic 
inflammatory condition of the small intestine 
induced by dietary wheat, rye and barley, as well 
as other unidentified environmental factors, in 
susceptible individuals. Specific HLA-DQA1 and 
HLA-DQB1 risk alleles are necessary, but not 
sufficient, for disease development1,2. The well-
defined role of HLA-DQ heterodimers encoded 
by these alleles is to present cereal peptides 
to CD4+ T cells, activating an inflammatory 
immune response in the intestine. A single 
genome-wide association study (GWAS) 
has been performed in celiac disease, which 
identified the IL2-IL21 risk locus1. 
Subsequent studies probing the GWAS 
information in greater depth have identified a 
further 12 risk regions. Most of these regions 
contain a candidate gene that functions in the 
immune system, although only in the case of 
HLA-DQA1 and HLA-DQB1 have the causal 
variants been established3–5. Many of the 
known celiac disease–associated loci overlap 
with those of other immune-related diseases6. 
To identify additional risk variants, particularly 
those with smaller effect sizes, we performed 
a second-generation GWAS using more than 
six times as many samples as the previous 
GWAS and a denser genome-wide SNP set. 
We followed up promising findings in a large 
collection of independent samples. 
RESULTS
Overview of study design
The GWAS included five European celiac 
disease case and control sample collections, 
including the celiac disease dataset reported 
previously1. We performed stringent data 
quality control (see Online Methods), including 
calling genotypes using a custom algorithm on 
both large sample sets and, where possible, 
cases and controls together (see Online 
Methods). We tested 292,387 non-HLA SNPs 
from the Illumina Hap300 marker set for 
association in 4,533 individuals with celiac 
disease and 10,750 control subjects of European 
descent (Table 1). A further 231,362 additional 
non-HLA markers from the Illumina Hap550 
marker set were tested for association in a 
subset of 3,796 individuals with celiac disease 
and 8,154 controls. All markers were from 
autosomes or the X chromosome. Genotype 
call rates were >99.9% in both datasets. 
The overdispersion factor of association 
test statistics, λGC = 1.12, was similar to that 
observed in other GWASs of this sample size7,8. 
Findings were not substantially altered by 
imputation of missing genotypes for 737 cases 
with celiac disease genotyped on the Hap300 
BeadChip and corresponding controls (Table 1, 
collection 1). Here we present results for directly 
genotyped SNPs, as around half the additional 
Hap550 markers cannot be accurately imputed 
from Hap300 data9 (including the new ETS1 
locus reported in this study). Results for the top 
1,000 markers are available in Supplementary 
Data 1; however, because of concerns regarding 
the detection of individuals’ identities10, results 
for all markers are available only on request to 
the corresponding author.
For follow-up, we first inspected genotype 
clouds for the 417 non-HLA SNPs that met 
P
GWAS < 10
−4, being aware that top GWAS signals 
might be enriched for genotyping artifact, 
and excluded 22 SNPs from further analysis 
using a low threshold for possible bias. We 
selected SNPs from 113 loci for replication. 
Markers that passed design and genotyping 
quality control included (i) 18 SNPs from all 
14 previously identified celiac disease risk 
loci (including a tag SNP for the major celiac 
disease–associated HLA-DQ2.5cis haplotype1); 
(ii) 13 SNPs from all 7 newly discovered regions 
with P
GWAS < 5 × 10
−7; (iii) 86 SNPs from 59 of 
68 newly discovered regions with 5 × 10−7 < P 
< 5×10−5 in stage 1; and (iv) 14 SNPs GWAS 
from 14 of 30 newly discovered regions with 
5×10−5 < P
GWAS 
< 10−4 in stage 1 (for this last 
category, we mostly chose regions with immune 
system genes). Two SNPs were selected per 
region for regions with stronger association, 
regions with possible multiple independent 
associations and/or regions containing genes 
of obvious biological interest. We successfully 
genotyped 131 SNPs in 7 independent follow-
up cohorts comprising 4,918 individuals with 
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aSample numbers attempted for genotyping, before any quality control (QC) steps were applied. bSample numbers after all quality control (QC) steps (used in 
the association analysis). cAll platforms contain a common set of Hap300 markers; the Hap550, 610-Quad, 670-Quad and 1.2M contain a common set of Hap550 
markers. dAs an additional quality control step, we performed case-case and control-control comparisons for collection 1 versus 2, and collection 3 versus 12, for 
the 40 SNPs in table 2 and observed no markers with P < 0.01. We did observe (as expected) differences for collection 5 versus 11, from northern and southern Italy, 
respectively. eAll 737 post-QC cases reported in a previous GWAS1. f690 of the post-QC cases and 1,150 of the post-QC controls were included in previous GWAS 
follow-up studies22,32. g498 of the post- QC cases and 767 of the post-QC controls were included in previous GWAS follow-up studies22,32. h352 of the post-QC cases 
and 921 of the post-QC controls were included in previous GWAS follow-up studies22,32. iSome of these data were generated elsewhere, and some prior quality 
control steps (information not available) had been applied. jFinnish stage 2 controls were individuals within the Finrisk collection for whom Illumina 610-Quad 
genotype data became available after the completion of stage 1.
celiac disease and 5,684 control subjects of 
European descent (Table 1). Genotype call 
rates were >99.9% in each collection. Primary 
association analyses of the combined GWAS 
and follow-up data were performed with a two- 
sided 2 × 2 × 12 Cochran-Mantel-Haenszel test. 
Finally, we examined associated risk loci for cis 
expression-genotype correlations; a summary 
of subjects used for expression quantitative 
trait locus (eQTL) analyses is reported in 
Supplementary Table 1.
Celiac disease risk variants
The HLA locus and all 13 other previously 
reported celiac disease risk loci showed 
evidence for association at a genome-wide 
significance threshold (P
combined 
< 5 × 10−8; Table 
2 and Supplementary Fig. 1). We note that 
some loci were previously reported using less 
stringent criteria (for example, the P < 5 × 10−7 
recommended by the 2007 WTCCC study11); 
however, in the current, much larger sample 
set, all known loci meet recently proposed P < 
5 × 10−8 thresholds12,13. We identified 13 new risk 
regions with genome-wide significant evidence 
(P
combined < 5 × 10
−8) of association, including 
regions containing the BACH2, CCR4, CD80, 
CIITA-SOCS1-CLEC16A, ETS1, ICOSLG, RUNX3, 
THEMIS, TNFRSF14 and ZMIZ1 genes, which 
have obvious immunological functions (Table 2 
and Supplementary Fig. 1). A further 13 regions 
met ‘suggestive’ criteria for association (10−6 > 
P





up < 0.01; Table 2 and Supplementary Fig. 1). 
Table 1 Sample collections and genotyping platforms
Chapter 4                                Multiple common variants for celiac disease influencing immune gene expression
45
Previously reported risk variants        
1 190803436 rs2816316 190.73-190.81  C 0.160 1.45 x 10-12 1.56 x 10-6 2.20 x 10-17 0.80 [0.76-0.84]   22                    1  RGS1
2 61040333 rs13003464 60.78-61.74  G 0.401 4.92 x 10-8 1.57 x 10-6 3.71 x 10-13 1.15 [1.11-1.20] yes  32                    8                REL, AHSA2
2 102437000 rs917997 102.22-102.57  A 0.236 5.97 x 10-15 7.83 x 10-4 1.11 x 10-15 1.19 [1.14-1.25]   22                    5                IL18RAP, IL18R1, 
                IL1RL1, IL1RL2
2 181704290 rs13010713 181.50-181.97  G 0.448 2.02 x 10-8 3.21 x 10-4 4.74 x 10-11 1.13 [1.09-1.18]   33                     1                ITGA4, UBE2E3
2 204510823 rs4675374 204.40-204.52  A 0.223 8.80 x 10-8 4.94 x 10-3 5.79 x 10-9 1.14 [1.09-1.19]   17                     2            CTLA4, ICOS, 
                 CD28
3 46210205 rs13098911 45.90-46.57  A 0.097 2.53 x 10-11 1.96 x 10-7 3.26 x 10-17 1.30 [1.23-1.39] yes  22                   11   CCR1, CCR2, 
        CCRL2, CCR3, 
        CCR5, CCR9
3 161147744 rs17810546 161.07-161.23  G 0.125 4.56 x 10-18 9.57 x 10-12 3.98 x 10-28 1.36 [1.29-1.44] yes  22                     1    IL12A
3 189595248 rs1464510 189.55-189.62  A 0.485 9.49 x 10-24 3.63 x 10-18 2.98 x 10-40 1.29 [1.25-1.34]   22                     1   LPP
4 123334952 rs13151961 123.19-123.78  G 0.142 6.31 x 10-18 4.45 x 10-11 2.18 x 10-27 0.74 [0.70-0.78]   1                       4                 IL2, IL21
6 32713862 rs2187668 gene identiﬁed A 0.258 <10-50  <10-50     <10-50  6.23 [5.95-6.52] (yes)  1,3                    6              HLA-DQA1, 
                        HLA-DQB1
6 138014761 rs2327832 137.92-138.17  G 0.216 1.41 x 10-14 1.97 x 10-6 4.46 x 10-19 1.23 [1.17-1.28]   32            0   TNFAIP3
6 159385965 rs1738074 159.24-159.45  A 0.434 3.14 x 10-8 1.56 x 10-8 2.94 x 10-15 1.16 [1.12-1.21]   22            2   TAGAP
12 110492139 rs653178 110.19-111.51  G 0.495 6.03 x 10-14 1.47 x 10-8 7.15 x 10-21 1.20 [1.15-1.24]   22                   13   SH2B3
18 12799340 rs1893217 12.73-12.91  G 0.165 5.52 x 10-7 1.04 x 10-4 2.52 x 10-10 1.17 [1.12-1.23]   17                      1   PTPN2
             
New loci, genome-wide signiﬁcant evidence (Pcombined <5 x 10-8)      
1 2516606 rs3748816 2.40-2.78  G 0.339 4.93 x10-7 1.17 x 10-3 3.28 x 10-9 0.89 [0.85-0.92]    4 TNFRSF14, 
                 MMEL1
1 25176163 rs10903122 25.11-25.18  A 0.480 3.21 x 10-5 8.44 x 10-7 1.73 x 10-10 0.89 [0.85-0.92]    1 RUNX3
1 199158760 rs296547 199.12-199.31  A 0.357 6.46 x 10-5 1.34 x 10-5 4.11 x 10-9 0.89 [0.86-0.92]    2 ?
2 68452459 rs17035378f 68.39-68.54  G 0.278 1.34 x 10-5 1.41 x 10-4 7.79 x 10-9 0.88 [0.84-0.92]    2 PLEK
3 32990473 rs13314993f 32.90-33.06  C 0.464 6.87 x 10-6 1.09 x 10-4 3.27 x 10-9 1.13 [1.08-1.17]    2 CCR4
3 120601486 rs11712165f 120.59-120.78  C 0.394 5.40 x 10-7 1.72 x 10-3 8.03 x 10-9 1.13 [1.08-1.17]    5 CD80, KTELC1
6 90983333 rs10806425 90.86-91.10  A 0.397 9.46 x 10-6 9.25 x 10-6 3.89 x 10-10 1.13 [1.09-1.17]    1 BACH2, MAP3K7
6 128320491 rs802734 127.99-128.38  G 0.311 1.36 x 10-6 1.70 x 10-9 2.62 x 10-14 1.17 [1.12-1.22] yes   2 PTPRK, THEMIS
8 129333771 rs9792269 129.21-129.37  G 0.238 8.14 x 10-6 1.00 x 10-4 3.28 x 10-9 0.88 [0.84-0.91]    0 ?
10 80728033 rs1250552 80.69-80.76  G 0.466 5.80 x 10-8 1.81 x 10-3 9.09 x 10-10 0.89 [0.86-0.92]    1 ZMIZ1
11 127886184 rs11221332f 127.84-127.99  A 0.237 4.74 x 10-11 9.98 x 10-7 5.28 x 10-16 1.21 [1.16-1.27] yes   1 ETS1
16 11311394 rs12928822 11.22-11.39  A 0.161 1.07 x 10-5 7.59 x 10-4 3.12 x 10-8 0.86 [0.82-0.91]    4 CIITA, SOCS1, 
                 CLEC16A
21 44471849 rs4819388 44.42-44.47  A 0.280 3.42 x 10-5 1.66 x 10-5 2.46 x 10-9 0.88 [0.84-0.92]    2 ICOSLG            
New loci, suggestive evidence (either  10-6>Pcombined>5x10-8  and/or PGWAS<10-4 and Pfollow-up<0.01)      
1 7969259 rs12727642 7.84-8.13  A 0.185 3.06 x 10-5 8.21 x 10-4 9.11 x 10-8 1.14 [1.09-1.20]    4 PARK7, TNFRSF9
1 61564451 rs6691768 61.52-61.62  G 0.378 2.63 x 10-5 1.16 x 10-3 1.19 x 10-7 0.90 [0.87-0.94]    1 NFIA
1 165678008 rs864537 165.43-165.71  G 0.391 1.01 x 10-7 9.25 x 10-2 3.80 x 10-7 0.91 [0.87-0.94]    1 CD247
1 170977623 rs859637 170.87-171.20  A 0.486 8.15 x 10-5 5.68 x 10-3 1.75 x 10-6 1.10 [1.06-1.14]    1 FASLG, TNFSF18, 
                 TNFSF4
3 69335589 rs6806528f 69.27-69.37  A 0.097 4.84 x 10-5 7.66 x 10-4 1.46 x 10-7 1.19 [1.12-1.27]    1 FRMD4B
3 170974795 rs10936599 170.84-171.09  A 0.252 2.99 x 10-7 6.63 x 10-2 4.57 x 10-7 1.12 [1.07-1.16]    3 ?
01 x 41.9 080.0 A  04.0-23.0 g0813301sr 645823 6 -6 1.48 x 10-3 5.58 x 10-8 1.21 [1.13-1.29] yes   1 IRF4 g
7 37341035 rs6974491 37.32-37.41  A 0.170 1.37 x 10-5 2.63 x 10-3 1.56 x 10-7 1.14 [1.09-1.20]    1 ELMO1
13 49733716 rs2762051 49.63-49.96  A 0.184 3.35 x 10-5 5.06 x 10-3 6.64 x 10-7 1.13 [1.08-1.18]    0 ?
14 68347957 rs4899260 68.24-68.39  A 0.263 4.55 x 10-5 2.21 x 10-3 3.92 x 10-7 1.12 [1.07-1.16]    2 ZFP36L1
17 42220599 rs2074404 41.40-42.25  C 0.250 5.03 x 10-5 5.96 x 10-3 1.23 x 10-6 0.90 [0.86-0.94]    10 ?
22 20312892 rs2298428 20.14-20.35  A 0.201 2.49 x 10-7 4.13 x 10-2 1.84 x 10-7 1.13 [1.08-1.19]    6 UBE2L3, YDJC
X 12881445 rs5979785 12.82-12.93  G 0.263 6.32 x 10-6 2.18 x 10-3 6.36 x 10-8 0.88 [0.84-0.92]    1 TLR7, TLR8
Chr   Position
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aThe most significantly associated SNP from each region is shown. bLD regions were defined by extending 0.1 cM to the left and right of the focal SNP as defined 
by the HapMap3 recombination map. All chromosomal in the combined dataset, odds ratios (shown for combined dataset) defined with respect to the minor allele 
in all controls. dEvidence from positions are based on NCBI build-36 coordinates. cMinor allele in all samples logistic regression at a genome-wide significant or 
suggestive level of significance after conditioning on other associated SNPs (see supplementary table 2). HLA region not tested, but previously known. eSelected 
named genes within or adjacent to the same LD block as the associated SNPs; causality is not proven. In particular, other genes and other causal mechanisms 
may exist. Gene names underlined are identified from GRAIL15,16 analysis (see Online Methods) with P
text < 0.01. 
fThese markers were present on the Hap550 
but not Hap300 SNP sets, and are not genotyped for 737 cases and 2,596 controls in the stage 1 GWAS, and combined dataset analyses. Only minor changes 
in P values were observed when these genotypes were imputed and included in analysis. gThe IRF4 region (specifically rs9738805, r2 = 0.08 with rs1033180 in 
HapMap CEU) was previously identified as showing strong geographical differentiation11. Association with celiac disease was still observed after correction for 
population stratification using either a structured association approach34 (corrected PGWAS = 5.16 × 10−6, 478 × 2 × 2 CMH test) or principal components correction 
(uncorrected PGWAS = 7.05 × 10−6, corrected PGWAS = 2.28 × 10−5, Cochran-Armitage trend tests combined using weighted Z scores; see Online Methods). 
However, definitive exclusion of population stratification would require family-based association studies. 
Table 2 Genomic regions with the strongest association signals for celiac disease
These regions also contain multiple genes with 
immunological functions, including CD247, 
FASLG-TNFSF18-TNFSF4, IRF4, TLR7-TLR8, 
TNFRSF9 and YDJC. Six of the 39 non-HLA 
regions show evidence for the presence of 
multiple independently associated variants 
in a conditional logistic regression analysis 
(Supplementary Table 2).
We tested the 40 SNPs with the strongest 
association (Table 2) from each of the known 
genome-wide significant, new genome-
wide significant and new suggestive loci 
for evidence of heterogeneity across the 12 
collections studied. Only the HLA region was 
significant (Breslow-Day test P < 0.05 per 
40 tests, rs2187668 P = 4.8 × 10−8), which is 
consistent with the well-described North-South 
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Gene name eQTL P valued 
Loci with g enome-wide signiﬁcant  evidence (Pcombined <5 x 10
-8) 
rs3748816 1 2516606 2412221 650452 HT-12 PLCH2  1.66 x 10 -5 
rs3748816 1 2516606 2482955 6520725 Ref-8v2 + HT -12 TNFRSF14  1.30 x 10 -3 
rs3748816 1 2516606 2510429 6250338 Ref-8v2 C1orf93  1.16 x 10 -4 
rs3748816 1 2516606 2533115  2070246 Ref-8v2 + HT -12 MMEL1  1.03 x 10 -20 
        
rs296547 1 199158760 198880146 1300279  Ref-8v2 + HT -12 DDX59  2.45 x 10-5 
        
rs842647 2 60972975 61263810 1170220  Ref-8v2 + HT -12 AHSA2 3.30 x 10 -10 
rs13003464e 2 61040333  61263810 1170220  Ref-8v2 + HT -12 AHSA2 6.39 x 10 -11 
        
rs3816281f 2 68461451 68461957 4810020 Ref-8v2 + HT -12 PLEK  7.97 x 10 -26 
        
rs917997  2 102437000 102418571  6520180 Ref-8v2 + HT -12 IL18RAP  7.35 x 10 -87 
        
rs13010713  2 181704290 181593865  1780433  HT-12 UBE2E3  4.93 x 10 -5 
        
rs13098911  3 46210205 45964449 6550333  Ref-8v2 + HT -12 CXCR6  9.66 x 10 -6 
rs13098911  3 46210205 46255176 g 2190671 HT-12 CCR3  5.50 x 10 -10 
rs13098911  3 46210205 46255176 g 7570670  Ref-8v2 CCR3  5.69 x 10 -4 
rs6441961d 3 46327388 46255176 h 2190671 HT-12 CCR3  2.87 x 10 -19 
rs6441961d 3 46327388 46255176 h 7570670  Ref-8v2 CCR3  1.02 x 10 -4 
        
rs11922594f 3 120608512 120683364i 6550288 Ref-8v2 + HT -12 KTELC1  5.09 x 10 -17 
rs11922594f 3 120608512 120683364i 3850161  Ref-8v2 + HT -12 KTELC1  7.34 x 10 -6 
        
rs10806425 6 90983333  90878075 3520349 HT-12 BACH2  1.92 x 10 -3 
        
rs1738074  6 159385965 159380068 5890739 Ref-8v2 + HT -12 TAGAP  1.99 x 10 -3 
rs1738074  6 159385965 159381094 j 5360364 HT-12 TAGAP  3.23 x 10 -4 
rs1738074  6 159385965 159381094 j 4860242 HT-12 TAGAP  2.18 x 10 -3 
        
rs1250552 10 80728033 80622540 2450131  Ref-8v2 + HT -12 ZMIZ1  1.80 x 10 -3 
        
rs653178  12 110492139  110399552  6560301 Ref-8v2 + HT -12 SH2B3  9.24 x 10 -12 
rs653178  12 110492139  110710447  840253 Ref-8v2 + HT -12 ALDH2  1.44 x 10 -4 
rs653178  12 110492139  110894406 k 2070736  HT-12 TMEM116  3.68 x 10 -4 
rs653178  12 110492139  110894406 k 3190129 Ref-8v2 TMEM116  1.51 x 10 -3 
        
rs12928822 16 11311394  11335627  4540072 Ref-8v2 + HT -12 C16orf75  1.02 x 10 -8 
        
rs4819388 21 44471849 44049567 7200373  Ref-8v2 RRP1  2.62 x 10 -3 
 
Loci with suggestive evidence (either A. 10-6>Pcombined>5x10
-8  and/or B. PGWAS <10 -4 and Pfollow-up<0.01)  
rs12727642 1 7969259 7956138  610193 Ref-8v2 + HT -12 PARK7  9.76 x 10 -15 
        
rs864537 1 165678008 165710482  l 6290400 Ref-8v2 + HT -12 CD247  1.77 x 10 -9 
rs864537 1 165678008 1657 10482 l 3890689 HT-12 CD247  2.93 x 10 -7 
        
rs6974491 7 37341035  37157761  2750154  Ref-8v2 + HT -12 ELMO1  5.40 x 10 -6 
        
rs2074404 17  42220599 41824345 3520672 Ref-8v2 + HT -12 LRRC37A  1.17 x 10 -4 
rs2074404 17  42220599 42106695 m 5260138 Ref-8v2 + HT -12 NSF  1.20 x 10 -5 
rs2074404 17  42220599 42106695 m 1410484 HT-12 NSF  4.28 x 10 -4 
rs2074404 17  42220599 42223012 4070615 HT-12 WNT3 2.77 x 10 -3 
rs2074404 17  42220599 42485154 4880037 HT-12 LOC388397  1.78 x 10 -9 
        
rs2298428 22 20312892 20308188 1230242 Ref-8v2 + HT -12 UBE2L3  1.96 x 10 -90 
        
rs5979785 X  12881445 12842944 n 6480360 Ref-8v2 + HT -12 TLR8  3.88 x 10 -13 
rs5979785 X  12881445 12842944 n 3390612 Ref-8v2 + HT -12 TLR8  1.07 x 10 -7 
 See supplementary Figures 2 and 3 for detailed results and supplementary table 3 for more details of Illumina expression probes.
aWe tested the SNP with the strongest association from 34 of 39 non-HLA loci (Pcombined < 10−6, table 2), Hap300 proxy SNPs for 4 further loci, and a second 
independently associated SNP from 6 loci, for correlation with gene expression in PAXgene blood RNA in up to 1,349 individuals. One locus (containing ETS1) 
where an adequate proxy SNP was not available was not included for the eQTL analysis. SNP-gene expression correlations were tested for probes within a 1-Mb 
window. Results are presented for SNPs showing significant correlations with cis gene expression after controlling false-discovery rate at 5% (corresponding to 
P < 0.0028). bAll chromosomal positions are based on NCBI build-36 coordinates. Probe center position was determined by re-mapping probe sequences to 
the human transcriptome and calculated from the midpoint of the transcript start and transcript end positions in genomic coordinates. cHT-12’ comprise 1,240 
individuals with blood gene expression assayed using Illumina Human HT-12v3 arrays; ‘Ref-8v2’ comprise 229 individuals with blood gene expression assayed using 
Illumina Human-Ref-8v2 arrays (see Online Methods). dSpearman rank correlation of genotype and residual variance in transcript expression. Meta-analysis eQTL 
P value shown if both datasets had identical probes. eSecond, independently associated SNP from this locus. fProxy SNP, r2 = 0.61 in HapMap CEU with most 
associated SNP rs11712165. g–nDifferent Illumina probe sequences with the same probe center position.
Table 3 Celiac risk variants correlated with cis gene expression
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gradient in HLA allele frequency in European 
populations, and more specifically for HLA-DQ 
in celiac disease14.
We observed no evidence for interaction 
between each of the 26 genome-wide 
significant non-HLA loci, which is consistent 
with what has been reported for other complex 
diseases so far. However, we did observe weak 
evidence for lower effect sizes at non-HLA loci 
in high risk HLA-DQ2.5cis homozygotes, similar 
to what has been observed in type 1 diabetes7.
To obtain more insight into the functional 
relatedness of the celiac disease risk loci, we 
applied GRAIL, a statistical tool that uses 
text mining of PubMed abstracts to annotate 
candidate genes from loci associated with 
common disease risk15,16. To assess the 
sensitivity of this tool (using known loci as 
a positive control), we first performed a 
‘leave-one-out’ analysis of the 27 genome-
wide significant celiac disease loci (including 
HLA-DQ). GRAIL scores of P
text < 0.01 were 
obtained for 12 of the 27 loci (44% sensitivity; 
Table 2). Factors that limit the sensitivity of 
GRAIL include biological pathways being 
both known (a 2006 dataset is used to avoid 
GWAS-era studies) and published in the 
literature. We then applied GRAIL analysis, 
using the 27 known regions as a seed, to all 49 
regions (49 SNPs) with 10−3 > P
combined > 5 × 10
−8 
and obtained GRAIL P
text < 0.01 for 9 regions 
(18.4%). As a control, only 5.5% (279 of 5,033) of 
randomly selected Hap550 SNPs reached this 
threshold. In addition to the five ‘suggestive’ 
loci shown in Table 2, GRAIL annotated four 
further interesting gene regions with lower 
significance in the combined association results: 
rs944141-PDCD1LG2 (P




= 2.1 × 10-4), 
rs4682103-CD200- BTLA (P
combined = 6.8 × 10
-6) 
and rs4919611-NFKB2 (P
combined = 6.1 × 10
-5). 
There appeared to be further enrichment for 
genes of immunological interest that are not 
GRAIL-annotated in the 10−3 > P
combined > 5 × 10
−8 
significance window, including rs3828599-
TNIP1 (P
combined = 1.55 × 10
−4), rs8027604-PTPN9 
(P
combined = 1.4 × 10
−6) and rs944141-CD274 
(P
combined = 4.4 × 10
−6). Some of these findings, 
for which neither genome-wide significant nor 
suggestive association is achieved, are likely 
to comprise part of a longer tail of disease-
predisposing common variants with weaker 
effect sizes. Definitive assessment of these 
biologically plausible regions would require 
genotyping and association studies using much 
larger sample collections than the present 
study.
We previously showed that there is considerable 
overlap between risk loci for celiac disease and 
type 1 diabetes17, as well as between risk loci 
for celiac disease and rheumatoid arthritis18, 
and more generally, there is now substantial 
evidence for shared risk loci between the 
common chronic immune-mediated diseases6. 
To update these observations, we searched ‘A 
Catalog of Published Genome Wide Association 
Studies’ (accessed 18 November 2009)19 and 
the HuGE database20. We found some evidence 
(requiring a published association report of 
P < 1 × 10−5) of shared loci with at least one other 
inflammatory or immune-mediated disease for 
18 of the current 27 genome-wide significant 
celiac disease risk regions. We defined shared 
regions as the broad linkage disequilibrium 
block; however, different SNPs are often 
reported in different diseases, and at only 3 of 
the 18 shared regions are associations across all 
diseases with the same SNP or a proxy SNP in 
r2 > 0.8 in HapMap CEU. Currently, nine regions 
seem to be specific to celiac disease and might 
reflect distinctive disease biology, including 
the regions containing rs296547 and rs9792269 
and the regions around CCR4, CD80, ITGA4, 
LPP, PLEK, RUNX3 and THEMIS. In fact, locus 
sharing between diseases is probably greater 
because of both stochastic variation in results 
from sample size limitations and regions that 
have a genuinely stronger effect size in one 
disease and weaker effect size in another.
Genetic variation in ETS1 has recently been 
reported to be associated with systemic 
lupus erythematosus (SLE) in the Chinese 
population, although it is not associated with 
SLE in European populations21. The most 
Chapter 4                                Multiple common variants for celiac disease influencing immune gene expression
48
strongly associated celiac disease (European 
population) SNP, rs11221332, and the most 
strongly associated SLE (Chinese population) 
SNP, rs6590330, map 70 kb apart. Inspection 
of the HapMap phase II data shows broadly 
similar linkage disequilibrium patterns between 
Chinese (CHB) and European (CEU) populations 
in this region, with the two associated SNPs in 
separate nonadjacent linkage disequilibrium 
blocks. Thus, distinct common variants within 
the same gene can predispose to different 
autoimmune diseases across different ethnic 
groups.
Exploring the function of celiac disease risk 
variants
Celiac disease risk variants in the HLA genes 
alter protein structure and function4. However, 
we identified only four nonsynonymous SNPs 
with evidence for association with celiac disease 
(P
GWAS < 10
−4) from the other 26 genome-wide 
significant associated regions (rs3748816-
MMEL1, rs3816281-PLEK, rs196432-RUNX3, 
rs3184504-SH2B3). Although comprehensive 
regional resequencing is required to test the 
possibility that coding variants contribute 
to the observed association signals, more 
subtle effects of genetic variation on gene 
expression are the more likely functional 
mechanism for complex disease genes. With 
this in mind, we performed a meta-analysis 
of new and published genome-wide eQTL 
datasets comprising 1,469 human whole 
blood (PAXgene) samples reflecting primary 
leukocyte gene expression. We applied a 
new method, transcriptional components, 
to remove a substantial proportion of inter-
individual nongenetic expression variation and 
performed eQTL meta-analysis on the residual 
expression variation (Online Methods).
We assessed 38 of the 39 genome-wide 
significant and suggestive celiac disease-
associated non-HLA loci (Table 2) for cis 
expression-genotype correlations. We tested 
the SNP with the strongest association from 
each region. However, for five regions the 
most associated SNP was not genotyped in 
the eQTL samples (Hap300 data); instead, for 
four of these, we tested a proxy SNP (r2 > 0.5 in 
HapMap CEU). In addition, for six loci showing 
evidence of multiple independent associations 
in conditional regression analyses, we tested 
a second SNP that showed independent 
association with celiac disease for eQTL 
analysis. In total, we assessed 44 independent 
non-HLA SNP associations in peripheral whole 
blood samples genotyped on the Illumina 
Hap300 BeadChip and either Illumina Ref8 or 
HT12 expression arrays, correlating each SNP 
with data from gene probes mapping within a 
1-Mb window.
We identified significant (Spearman P < 0.0028, 
corresponding to 5% false-discovery rate) 
eQTLs at 20 of 38 (52.6%) non-HLA celiac 
loci tested (Table3 and Supplementary Figs. 2 
and 3). Some loci had evidence of eQTLs with 
multiple probes, genes or SNPs (Table 3). We 
assessed whether the number of SNPs with 
cis-eQTL effects out of the 44 SNPs that we 
tested was significantly higher than expected. 
On average, eQTL SNPs had a substantially 
higher minor allele frequency (MAF) than 
non-eQTL SNPs in the 294,767 SNPs tested. 
To correct for this, we selected 44 random 
SNPs that had an equal MAF distribution 
and determined for how many of these 
MAF-matched SNPs eQTLs were observed. 
There were a significantly higher number of 
eQTL SNPs (P = 9.3 × 10−5, 106 permutations) 
among the celiac disease–associated 
SNPs than expected by chance (22 observed 
eQTL SNPs versus 7.8 expected eQTL SNPs). 
Therefore, the celiac disease–associated 
regions are greatly enriched for eQTLs. These 
data indicate that some risk variants might 
influence celiac disease susceptibility through 
a mechanism of altered gene expression. 
Candidate genes with a significant eQTL where 
the peak eQTL signal and peak case- control 
association signal are similar (Supplementary 
Fig. 3) include MMEL1, NSF, PARK7, PLEK, 
TAGAP, RRP1, UBE2L3 and ZMIZ1.
We also assessed the coexpression of genes 
that mapped within 500 kb of SNPs that 
showed the strongest case-control association 
Chapter 4                                Multiple common variants for celiac disease influencing immune gene expression
49
from the 40 genome-wide significant and 
suggestive celiac disease loci in an analysis of 
the 33,109 human Affymetrix Gene Expression 
Omnibus dataset. This analysis loses power to 
detect tissue-specific correlations from the use 
of numerous tissue types, but it greatly gains 
power from the large sample size. We detected 
several distinct coexpression clusters (Pearson 
correlation coefficient between genes >0.5), 
including four clusters of immune-related 
genes that contain at least one gene from 37 of 
the 40 genome-wide significant and suggestive 
loci (Fig. 1). These data further demonstrate 
that genes from celiac disease risk loci map 
to multiple distinct immunological pathways 
involved in disease pathogenesis.
DISCUSSION
We previously reported that most celiac 
genetic risk variants mapped near genes that 
are functional in the immune system22, and 
this remains true for the 13 new genome-
wide significant and 13 new suggestive risk 
variants from the current study. We can now 
refine these observations and highlight specific 
immunological pathways that are relevant to 
the pathogenesis of celiac disease.
One key pathway worth highlighting is T-cell 
development in the thymus. The rs802734 
linkage disequilibrium block contains the 
recently identified gene THEMIS (thymus-
expressed molecule involved in selection). 
THEMIS has a key regulatory role in both 
Figure 1 Coexpression analysis of genes mapping to 40 genome-wide significant and suggestive celiac disease regions 
in 33,109 heterogenous human samples from the Gene Expression Omnibus. Genes mapping within a 1-Mb window of 
associated SNPs (table 2) were tested for interaction with genes from other loci. Interactions with Pearson correlation > 0.5 
are shown (P < 10−100). Only the genes known to contain causal mutations (HLA-DQA1, HLA-DQB1) were analyzed from 
the HLA region; HLA-DQB2/HLA-DQB1 is a single expression probeset mapping to both genes. No probe for THEMIS was 
present on the earlier version of the U133 array; however, in a subset analysis of U133 Plus2.0 data, THEMIS is coexpressed 
in the major immune gene cluster.
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positive and negative T-cell selection during 
late thymocyte development23. Furthermore, 
the rs10903122 linkage disequilibrium block 
contains RUNX3, a master regulator of CD8+ 
T lymphocyte development in the thymus24,25. 
TNFRSF14 (LIGHTR, rs3748816 linkage 
disequilibrium block) has widespread functions 
in peripheral leukocytes and a crucial role 
in promoting thymocyte apoptosis26. The 
ETS1 transcription factor (rs11221332 linkage 
disequilibrium block) is also active in peripheral 
leukocytes; however, it is also a key player in 
thymic CD8+ lineage differentiation, acting in 
part by promoting RUNX3 expression27.
The importance of the thymus in the 
pathogenesis of autoimmune diseases has 
been previously emphasized by the established 
role of thymectomy in the treatment of 
myasthenia gravis. In type 1 diabetes, disease-
associated genetic variation in the insulin gene 
INS causes altered thymic insulin expression 
and subsequent T-cell tolerance for insulin as 
a self-protein28. However, the importance of 
thymic T-cell regulation in the etiology of celiac 
disease has not been previously recognized. 
It is conceivable that the associated variants 
might alter biological processes before thymic 
MHC-ligand interactions. Alternatively, 
it is now clear that exogenous antigen 
presentation and selection occurs in the 
thymus through migratory dendritic cells; 
this has been demonstrated for skin and has 
been hypothesized for food antigens29,30. 
These findings suggest that it would be 
worthwhile to investigate immunological and 
pharmacological modifiers of T-cell tolerance 
more generally in autoimmune diseases.
A second pathway worth noting is the innate 
immune detection of viral RNA. Although the 
association signal at rs5979785 (P
combined = 6.36 
× 10−8) in the TLR7-TLR8 region is just outside 
our genome-wide significance threshold, 
we observe a strong effect of rs5979785 on 
TLR8 expression in whole blood. Both TLRs 
recognize viral RNA. Taken together with the 
recent observation that rare loss-of-function 
mutations in the enteroviral response gene 
IFIH1 are protective against type 1 diabetes31, 
these findings implicate viral infection (and the 
nature of the host response to infection) as a 
putative environmental trigger that could be 
common to these autoimmune diseases.
A third pathway involves T- and B-cell 
co-stimulation (or co-inhibition). This class 
of molecules controls the strength and 
nature of the response to T-cell or B-cell 
(immunoglobulin) receptor activation by 
antigens. We observe multiple regions with 
genes (CTLA4-ICOS-CD28, TNFRSF14, CD80, 
ICOSLG, TNFRSF9, TNFSF4) from this class 
of ligand-receptor pairs, indicating that fine 
control of the adaptive immune response might 
be altered in individuals at risk of celiac disease.
A final pathway involves cytokines, 
chemokines and their receptors. Our previous 
report discussed the function of the 2q11–12 
interleukin receptor cluster (IL18RAP and 
so on), the 3p21 chemokine receptor cluster 
(CCR5 and so on) and the loci containing IL2-
IL21 and IL12A22. We now report additional loci 
containing TNFSF18 and CCR4.
We estimate that the current celiac disease 
variants, including the major celiac disease-
associated HLA variant, HLA-DQ2.5cis, less 
common celiac disease–associated haplotypes 
in the HLA (HLA-DQ8; HLA-DQ2.5trans; 
HLADQ2.2), and the additional 26 definitively 
implicated loci explain about 20% of total celiac 
disease variance, which would represent 40% of 
genetic variance, assuming a heritability of 0.5. 
A long tail of common variants with low effect 
size, along with highly penetrant rare variants 
(both at the established loci and elsewhere in 
the genome), might contribute substantially to 
the remaining heritability.
We observed different haplotypes within the 
ETS1 region associated with celiac disease in 
Europeans and SLE in the Chinese population. 
For some autoimmune diseases studied in 
European origin populations, although the 
same linkage disequilibrium block has been 
associated, the association is with a different 
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haplotype. In some cases, the same variants 
are associated, but the direction of association 
is opposite (for example, rs917997-IL18RAP 
in celiac disease versus type 1 diabetes). We 
believe further exploration of these signals 
might reveal critical differences in the nature 
of the immune system perturbation between 
these diseases.
Previously, investigators have observed that 
only a small proportion of GWAS signals involve 
coding variants and have suggested that these 
variants might instead influence regulation of 
gene expression. Here we show that over half 
the variants associated with celiac disease are 
correlated with expression changes in nearby 
genes. This mechanism is likely to explain 
the function of some risk variants for other 
common, complex diseases. Further research is 
needed to definitively determine at each locus 
both the variants that can cause celiac disease 
and their functional mechanisms.
METHODS
Methods and any associated references are 
available in the online version of the paper at 
http://www.nature.com/naturegenetics/.
Accession numbers. Expression data are 
available in GEO (http:// www.ncbi.nlm.nih.
gov/geo/) as GSE20142 and GSE20332.
Note: Supplementary information is available 
on the Nature Genetics website.
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ONLINE METHODS
Subjects. Written informed consent was 
obtained from all subjects, with Ethics 
Committee/Institutional Review Board 
approval. All individuals are of European 
ancestry. Affected celiac individuals were 
diagnosed according to standard clinical, 
serological and histopathological criteria, 
including small intestinal biopsy. DNA samples 
were from blood, lymphoblastoid cell lines or 
saliva. A more detailed description of subjects 
is provided in a Supplementary Note.
GWAS genotyping. For an overview, see Table 
1. UK(1) case and control genotyping has been 
described1,7. Illumina 670-Quad and 1.2M-Duo 
(custom chips designed for the WTCCC2 and 
comprising Hap550/1M and common CNV 
content) and 610-Quad genotyping was 
performed in London, Hinxton and Groningen. 
Bead intensity data was normalized for each 
sample in BeadStudio, R and theta values 
exported and genotype calling performed using 
a custom algorithm1,35. A detailed description 
of genotype calling steps is provided in a 
Supplementary Note.
Quality control steps were performed in the 
following order. First, very low call rate samples 
and SNPs were excluded. SNPs were excluded 
from all sample collections if any collection 
showed call rates <95% or deviation from 
Hardy-Weinberg equilibrium (P < 0.0001) in 
controls. Samples were excluded for call rate 
<98%, incompatible recorded gender and 
genotype-inferred gender, ethnic outliers 
(identified by multi-dimensional scaling plots 
of samples merged with HapMap Phase II 
data), duplicates and first-degree relatives. 
We excluded 22 of 417 SNPs showing apparent 
association (P
GWAS < 10
−4) after visual inspection 
of R theta plots suggested possible bias.
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The over-dispersion factor of association test 
statistics (genomic control inflation factor), λ
GC
, 
was calculated using observed versus expected 
values for all SNPs in PLINK.
Follow-up genotyping. For an overview, see 
Table 1. Finnish controls (12) were genotyped 
on the 610-Quad BeadChip; other samples 
were genotyped using Illumina GoldenGate 
BeadXpress assays in London and Groningen. 
Genotyping calling was performed in 
BeadStudio for combined cases and controls 
in each separate collection, with the exception 
of the Finnish collection, and whole genome 
amplified samples (89 Irish cases and 106 
Spanish controls). Quality control steps were 
performed as for the GWAS. In total, 131 of 
144 SNPs passed quality control and visual 
inspection of genotype clouds.
SNP association analysis. Analyses were 
performed using PLINK v1.0736, mostly using 
the Cochran-Mantel-Haenzel test. Logistic 
regression analyses were used to define the 
independence of association signals within the 
same linkage disequilibrium block, with group 
membership included as a factorized covariate.
Genotype imputation was performed for 
samples genotyped on the Hap300 using 
BEAGLE and CEU, TSI, MEX and GIH reference 
samples from HapMap3. Association analysis 
was performed using logistic regression on 
posterior genotype probabilities, with group 
membership included as a factorized covariate.
Structured association tests were performed 
using PLINK as described using genetically 
matched cases and controls within collections 
identified by identity by state similarity across 
autosomal non-HLA SNPs34 (settings–ppc 
0.001–cc, clusters constrained by the five 
collections). Principal components analysis 
was performed using EIGENSTRAT and a set 
of 12,810 autosomal non-HLA SNPs chosen 
for low LD and ancestry information37,38; 
association tests were corrected for the top 
10 principal components and combined using 
weighted Z scores.
The fraction of additive variance was calculated 
using a liability threshold model39 assuming 
a population prevalence of 1%. Effect sizes 
and control allele frequencies were estimated 
from the combined replication panel. Genetic 
variance was calculated assuming 50% 
heritability.
GRAIL analysis. We performed GRAIL analysis 
(http://www.broadinstitute. org/mpg/grail/
grail.php) using HG18 and Dec2006 PubMed 
datasets, default settings for SNP rs number 
submission, and the 27 genome-wide significant 
celiac disease risk loci (most associated SNP) as 
seeds. As a query, we used either associated 
SNPs or 101 × 50 randomly chosen Hap550 SNP 
datasets (5,050 SNPs, of which 5,033 mapped 
to the GRAIL database). 
Identification of transcriptional components. 
We noted that the power of eQTL studies in 
humans is limited by substantial observed 
interindividual variation in expression 
measurements due to nongenetic factors, and 
therefore developed a method, ‘transcriptional 
components’, to remove a large component 
of this variation (manuscript in preparation). 
Expression data from 42,349 heterogeneous 
human samples hybridized to Affymetrix HG-
U133A (GEO accession number: GPL96) or 
HG-U133 Plus 2.0 (GEO accession number: 
GPL570) Genechips were downloaded40. 
Samples missing data for >150 probes were 
excluded, and only probes available on 
both platforms were analyzed, resulting in 
expression data for 22,106 probes and 41,408 
samples. We performed quantile normalization 
using the median rank distribution41 and log2 
transformed the data, ensuring an identical 
distribution of expression signals for every 
sample, discarding previous normalization and 
transformation steps.
Initial quality control (QC) was performed by 
applying principal component analysis (PCA) 
on the sample correlation matrix (pair-wise 
Pearson correlation coefficients between all 
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samples). The first principal component (PC), 
explaining ~80–90% of the total variance42,43, 
describes probe-specific variance. 6,375 
samples with correlation R < 0.75 of the sample 
array with this PC were considered outliers of 
lesser quality and excluded from analysis. We 
excluded entire GEO datasets where >25% of 
the samples were outliers (prob- ably expression 
ratios versus a reference, not absolute data). 
The final dataset comprised 33,109 samples 
(17,568 GPL96 and 15,541 GPL570 samples), 
and we repeated the normalization and 
transformation on the originally deposited 
expression values of these post-quality control 
samples.
We next applied PCA on the pairwise 22,106 × 
22,106 probe Pearson correlation coefficient 
matrix assayed on the 33,109 sample dataset 
(our fast C++ tool, MATool, is available 
upon request), attempting to simplify the 
structure of the data. Here, PCA represents a 
transformation of a set of correlated probes 
into sets of uncorrelated linear additions of 
probe expression signals (eigen- vectors) that 
we name transcriptional components (TCs). 
Each TC is a weighted sum of probe expression 
signals and eigenvector probe coefficients. 
These TC scores can be calculated for each 
observed expression array sample (reflecting 
the TC activity per sample).
Subjects for expression-genotype 
correlation. We obtained peripheral blood 
DNA and RNA (PAXgene) from Dutch and UK 
individuals who were disease cases or controls 
for GWAS studies (Supplementary Table 1). All 
samples had been genotyped for a common 
SNP set on Illumina platforms. Analysis was 
confined to 294,767 SNPs that had a MAF ≥ 
5%, call-rate ≥ 95% and exact HWE P > 0.001. 
RNA from the samples was hybridized to either 
Illumina HumanRef-8 v2 arrays (229 samples, 
Ref-8v2) or Illumina HumanHT-12 arrays (1,240 
samples, HT-12), and raw probe intensity 
extracted using BeadStudio. The Ref-8v2 
samples were jointly quantile normalized and 
log2 transformed, as were the HT-12 samples. 
Subsequent analyses were also conducted 
separately for these datasets, up to the 
eventual eQTL mapping, which uses a meta-
analysis framework, combining eQTL results 
from both arrays. HT-12 and Ref-8v2 arrays are 
different, but share many probes with identical 
probe sequences. Illumina sometimes use 
different probe identifiers for the same probe 
sequences; in meta-analysis and Table 3, the 
label HT-12 was used if both HT-12 and Ref-8v2 
had the same sequence.
Re-mapping of probes. If probes mapped 
incorrectly or cross-hybridized to multiple 
genomic loci, it might be that an eQTL would 
be detected that would be deemed a trans-
eQTL. To prevent this, we used a mapping 
approach versus a known reference that we 
developed for high-throughput short sequence 
RNAseq data44. We took the DNA sequence as 
synthesized for each cDNA probe and aligned 
it against a transcript masked gDNA genome 
combined with cDNA sequences. A more 
detailed description of probe re-mapping is 
provided in a Supplementary Note. Probes 
that did not map or that mapped to multiple 
different locations were removed.
Affymetrix transcriptional components 
applied to Illumina expression data. TC 
scores can be inferred in new (non-Affymetrix) 
datasets for every new individual sample. For 
the Illumina samples (used for the cis-eQTL 
mapping), only Illumina probes that could 
be mapped to any of our 22,106 Affymetrix 
probes were used (www.switchtoi.com/
probemapping.ilmn). The TCscore t=n of 
sample i for the jth TC is defined as: TCscoreij 
= ∑ ati × vtj , where vtj is t=1 defined as the tth 
Affymetrix probe coefficient for the jth TC; ati 
is the Illumina expression measurement for the 
tth mapped probe for sample i. We inferred the 
Illumina TC scores for the top 1,000 TCs.
Removal of transcriptional component effects 
from Illumina expression data. Because our 
Illumina eQTL dataset (n = 1,469) is much less 
hetero- geneous than the Affymetrix dataset 
(n = 33,109), we expect that some TCs will 
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hardly vary. We therefore performed a PCA on 
the covariance matrix of the top 1,000 inferred 
TC scores for the Illumina dataset to effectively 
compress the TC data into a small set of 
‘aggregate TCs’ (aTCs). As aTCs are orthogonal, 
we used linear regression to eliminate the effect 
of the top 50 aTCs. We correlated the TC-scores 
for each peripheral blood sample with probe 
expression levels. We then used the resulting 
residual gene expression data for subsequent 
cis-eQTL mapping.
cis-eQTL mapping. We used the residual 
gene expression data in a meta-analysis 
framework, as described45,46. In brief, analyses 
were confined to those probe-SNP pairs for 
which the distance from probe transcript 
mid-point to SNP genomic location was less 
than 500 kb. To prevent spurious associations 
due to outliers, a nonparametric Spearman’s 
rank correlation analysis was performed. When 
a particular probe-SNP pair was present in 
both the HT12 and H8v2 datasets, an overall, 
joint P value was calculated using a weighted 
Z-method (square root of the dataset sample 
number). To correct for multiple testing, we 
controlled the false-discovery rate (FDR). The 
distribution of observed P values was used to 
calculate the FDR, by permuting expression 
phenotypes relative to genotypes 1,000 times 
within the HT12 and H8v2 dataset. Finally, 
we removed any probes from analysis which 
contained a known SNP (1000Genomes CEU 
SNP data, April 2009 release).
Chapter 4                                Multiple common variants for celiac disease influencing immune gene expression
57
Chapter 4                                Multiple common variants for celiac disease influencing immune gene expression








Trends Mol Med. 2010 Nov;16(11):537-50
Gosia Trynka, Cisca Wijmenga
 
and David A van Heel
60
Coeliac disease is an inflammatory disorder of the small intestine with an autoimmune component 
and strong heritability. Genetic studies have confirmed strong association to HLA and identified 39 
nonHLA risk genes, mostly immune-related. Over 50% of the disease-associated single nucleotide 
polymorphisms are correlated with gene expression. Most of the coeliac disease-associated 
regions are shared with other immune-related diseases, as well as with metabolic, haematological 
or neurological traits, or cancer. We review recent progress in the genetics of coeliac disease and 
describe the pathways these genes are in, the functional consequences of the associated markers 
on gene expression and the genes shared between coeliac disease and other traits. 
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Chapter 5                       A genetic perspective on coeliac disease
Coeliac disease
Coeliac disease is an inflammatory disorder with 
an autoimmune component. The prevalence 
of coeliac disease in populations of white 
European origin is estimated at 1–3%1. The 
classic manifestation of coeliac disease includes 
diarrhoea, abdominal distension, failure 
to thrive and short stature2. Many patients 
present with extraintestinal manifestations, 
such as dermatitis herpetiformis, anaemia, 
neurological symptoms or osteoporosis3,4. 
This wide spectrum means coeliac disease is 
correctly diagnosed in only one in seven cases, 
hence only a minority of patients receives 
treatment. Coeliac disease is a life-long 
condition and the only known treatment is 
to completely exclude gluten from the diet. 
Approximately 5% of patients do not respond 
to a gluten-free diet and have a higher risk 
of developing enteropathy-associated T cell 
lymphoma5. Some but not all studies suggest 
that there is a higher mortality rate in patients 
who remain untreated6–8.
The key molecule in mediating disease 
pathogenesis is gluten, a dietary protein found 
in wheat, barley and rye. Gluten peptides 
pass through the epithelial barrier of the 
intestine into the lamina propria, where they 
can be deamidated by the enzyme tissue 
transglutaminase. This enzymatic modification 
gives a negative charge to the gluten peptides 
and increases their immunogenicity9.
In genetically predisposed individuals, gluten 
peptides trigger a cascade of innate and 
adaptive immune responses and lead to the 
destruction of the intestinal epithelium and 
mucosa as well as to lymphocytic infiltration 
in the proximal part of the small bowel10. 
In the lamina propria, gluten peptides are 
recognised by antigen-presenting cells (APCs) 
and presented by HLA class II DQ2 or DQ8 
molecules11,12. Deamidated gluten peptides 
bind strongly to the specific HLA molecules13. 
The subsequent adaptive response is mediated 
by CD4+ T cells that recognise the HLA–
gluten complex and produce proinflammatory 
cytokines, mainly interferon (IFN)-g14. This 
response leads directly to tissue remodelling 
and flattening of the intestinal mucosa15. 
Gluten peptides also trigger an innate immune 
response characterised by the elevated 
expression of interleukin (IL)-15 by intestinal 
enterocytes16. Consequently, patients with 
coeliac disease develop antibodies to gluten 
and autoantibodies to endogenous tissue 
transglutaminase, the dominant autoantigen17. 
Our knowledge of coeliac disease pathogenesis 
is expanding and we are beginning to 
understand certain parts of the disease process 
better, such as the pathogenicity of various 
gluten epitopes18. Although wheat products 
contain many different gluten pep- tides, only 
a small subset seems to be toxic to patients18, 
which opens up new avenues for future 
therapies, such as vaccination. There are, 
however, many details of the disease process 
that remain unclear, such as the translocation 
of gluten peptides across the intestinal barrier 
and the process of flattening the intestinal 
mucosa.
Coeliac disease is a complex disorder in which 
genetic factors play an important role. The 
best characterised and most important genetic 
risk factor for coeliac disease is an HLA class 
II gene. Although HLA is necessary for coeliac 
disease to develop, it is not sufficient. Genome-
wide association studies (GWAS) of coeliac 
disease have identified 39 nonHLA loci that 
also predispose to coeliac disease. The majority 
of these loci are not specific for coeliac disease 
but are also associated with other disorders.
Here, we summarise the latest achievements in 
coeliac disease genetics and describe the risk 
loci identified, the most likely disease genes in 
these loci, their pathways and their potential 
functional consequences on gene expression. 
We also discuss the genetic background shared 
between coeliac disease and other disorders.
Genetic insights into coeliac disease
The risk of HLA 
HLA class II molecules are the major risk factors 
predis- posing individuals to coeliac disease 
and account for ~35% of the genetic risk19. Over 
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90% of patients with coeliac disease express 
the HLA-DQ2 heterodimer and the remainder 
express HLA-DQ8 molecules. HLA-DQ2 is 
encoded by the HLA-DQA1*05 allele (a chain) 
and HLA-DQB1*02 allele (b chain). The two 
alleles are often present in the cis conformation 
on the DR3 haplotype, which is also common to 
many other autoimmune disorders20. The small 
proportion of patients with coeliac disease 
who do not express HLA-DQ2 molecules are 
HLA-DQ8-positive, where the a and b chains of 
the HLA-DQ8 molecule are encoded by HLA-
DQA1*03 and HLA-DQB1*0302, respectively.
GWAS findings
Although the role of HLA molecules  and the 
association to particular genotypes has been 
well established and explains their role in the 
disease pathogenesis, the frequency of coeliac 
risk HLA genotypes in the general population 
is ~30%, whereas only 1–3% actually develop 
the disease. As the heritability of coeliac 
disease is estimated to be ~80%21 and HLA 
is estimated to contribute 35% of the genetic 
risk19,22, there must be more genetic risk factors 
involved in coeliac disease susceptibility. This is 
corroborated by twin studies that show a large 
discrepancy in the concordance rate of coeliac 
disease in monozygotic twins compared to 
HLA-identical dizygotic twins21.
A breakthrough in finding non-HLA coeliac 
risk genes was achieved with the advent of 
GWAS (Box 1) and their application to complex 
diseases. Thus far, the two GWAS that have 
been conducted on coeliac disease have 
reported definite associations to 26 nonHLA 
loci and have suggested another 13 loci as 
predisposing to coeliac disease (Table 1)19,22–26.
Understanding the functional role of coeliac 
risk variants: coeliac e-QTL mapping 
Although GWAS have identified common 
variants underlying susceptibility for common 
complex traits, the interpretation of the findings 
requires further study to identify causal variants 
and genes. GWAS utilise a tag single nucleotide 
polymorphism (SNP) approach, meaning 
that the genetic markers that are tested for 
association to a trait or disease are selected to 
capture the majority of the genetic variation. 
This is possible because of the extensive allelic 
association between SNPs in close proximity to 
each other in the human genome [i.e. linkage 
disequilibrium (LD)] (Box 1). Consequently, only 
a subset of SNPs that are informative enough 
to capture the majority of the variation of the 
untyped SNPs needs to be genotyped. The 
obvious drawback of this approach is that when 
an association is observed, it is unclear what 
the underlying causal variant is. Moreover, 
if the association maps within a region with 
multiple genes in strong LD with each other, 
it is difficult to pinpoint the true risk gene. 
Sequence analysis of entire associated regions 
can help identify causal variants27, although the 
nature of causal variants in complex diseases 
remains to be established.
One way to suggest possible causal genes is by 
assessing the correlation between genotypes 
of the associated SNPs and the levels of 
expression of genes in this same region (e- QTL 
mapping, Box 2). Such a functional genomics 
approach has shown that 53% of the coeliac 
disease-associated risk regions (i.e. 20 of 38 
tested non-HLA loci) contain SNPs with a 
significant cis e-QTL effect in peripheral blood 
mononuclear cells (PBMCs). To date, many 
eQTL studies have been performed using 
PBMCs because of the ease of collecting them. 
Consequently, the expression data comes from 
a limited set of cell types, which might not 
always be relevant to the disease under study. It 
cannot be excluded that genes with expression 
specific to intestinal epithelial cells, for 
example, are also relevant for coeliac disease 
pathogenesis and these will be missed using 
PBMCs. It also is important to acknowledge 
that e-QTL mapping does not prove causality, 
but identifying a SNP with a functional effect 
on a nearby gene can help to prioritise genes 
for functional follow-up studies, for example in 
regions where there are multiple genes in tight 
LD. One such example is 2q12.1, where several 
genes encoding IL receptors are present but 
an e-QTL effect is only detected for IL18RAP. 
Interestingly, for some regions, an associated 
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SNP has both a negative and a positive e-QTL 
effect: for example at 1p36.32, the rs3748816*A 
allele corresponds to down-regulation of PLCH 
and TNFRSF14 but upregulation of MMEL1 and 
C1orf93. For 71% of coeliac e-QTL SNPs, the 
associated coeliac risk allele corresponds to a 
downregulation of gene expression (Table 2), 
suggesting that most coeliac risk alleles lead 
to a reduction in gene expression. However, 
although e-QTL mapping helps to indicate 
possible causal genes, the results need to be 
interpreted with caution. There is a greater 
overrepresentation of the e-QTL SNPs among 
coeliac-associated loci than would be expected 
by chance (22 of 44 tested SNPs compared to 
7.8 expected eQTL SNPs by chance), but some 
of the detected effects are still likely to result 
from chance thus some of them are probably 
not related to the disease aetiology.
Coeliac disease pathways
The 39 nonHLA coeliac loci together 
encompass 115 different genes (based on LD 
blocks19). At least 28 of the non-HLA coeliac loci 
harbour immune-related genes, pointing to an 
altered immune system response underlying 
coeliac disease. Based on our knowledge of 
coeliac disease biology, the most plausible 
immune-related genes from these 28 regions 
can be grouped into several immune-related 
pathways. Many of these genes have broad 
functions and regulate several pathways. 
Below we describe how GWAS findings have 
enhanced our knowledge of the key coeliac 
disease pathways identified so far.
Adaptive immune response
Coeliac disease has long been recognised as a 
T cell disease, with a strong adaptive immune 
response. This view was mainly based on 
the genetic association with HLA, which was 
established more than 30 years ago. Based on 
the GWAS results, specific genes can now be 
identified that provide a much broader picture, 
including the triggering and activation of T cells 
and a role for the thymus. The latter observation 
is intriguing as it provides a possible link to the 
lack of oral tolerance to dietary gluten seen in 
patients with coeliac disease.
Immune cell signalling
Immune cell signalling is a dynamic process that 
involves immune cells interacting with other 
cells, presenting antigens as well as responding 
to secreted factors such as cytokines. Among 
the coeliac disease-associated genes are 
those that modulate immune cell signalling 
at different levels (Figure 2a). Genes such as 
CTLA4, SH2B3, PTPN2 or CD80 encode factors 
that negatively regulate T cell responses, 
whereas others are involved in the T cell 
mediated cell apoptosis (such as FASLG). Many 
of the coeliac loci contain genes encoding 
factors affecting chemokines (CCR1, CCR3, 
CCR4, CCR5, CCR9, CXCR1, CXCR6), which in 
turn regulate immune responses by directing 
cellular migration towards sites of inflammation 
or to wards lymphoid tissues. By blocking the 
Jak (Janus kinase)/STAT (signal transducers 
and activators of transcription) signalling 
pathway, SOCS1 (suppressor of cytokine 
signalling-1), encoded by another coeliac gene, 
negatively regulates cytokine signalling28. The 
SH2B3 locus, which shows signs of positive 
selection, encodes a factor likely to be involved 
in inhibiting cytokine responses. This gene 
was recently implicated in NOD2 (nucleotide- 
binding oligomerisation domain containing 2) 
signalling as carriers of the SH2B3-rs3184504*A 
risk allele show an increased proinflammatory 
immune response upon lipopolysaccharide 
and muramyl dipeptide stimulation. This 
increased response also suggests that SH2B3-
rs3184504*A carriers are protected against 
bacterial infections29, which might have driven 
evolutionary selection. Another coeliac gene, 
ICOSLG, encodes a ligand for the ICOS receptor 
that blocks the interaction between T cells 
and APCs and therefore inhibits the antibody-
specific T cell response. This ligand is expressed 
on activated T cells and regulates expression 
of IL-21 in the development of Th17 cells30. 
ICOSLG costimulation induces production of 
IL-10 or IFN-g31. CD247 encodes the zeta chain, 
which is part of the T cell receptor CD3 complex 
and plays an important role connecting 
antigen recognition with downstream signal 
transduction32.
T cell maturation and differentiation
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Figure I Cis e-QTL mapping. GWAS test hundreds of thousands of SNPs for the association with the disease. Genes that map in the proximity to the SNP of interest 
(e.g. genes falling within boundaries of 500 Kb around the associated SNP) are tested for the correlation between the expression levels and genotypes. Multiple 
scenarios are possible including positive, negative or no correlation with the genotype. In regions of tight LD this approach might help to suggest best disease 
candidate gene.
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Box 1. GWAS and e-QTL
GWAS
GWAS genotype hundreds of thousands to millions of SNPs 
across a large set of DNA samples, with the aim of identifying 
SNPs with signiﬁcantly diﬀerent frequencies between cases 
(carriers of the trait of interest) and controls. A p-value of 
5x10–8 is generally the level needed for statistical signiﬁcance. 
Genotyped SNPs are selected to capture the majority of 
common variation in the human genome. This is possible 
because of the LD patterns seen in the human genome, which 
means that SNPs in proximity generally provide information 
about each other. Thus, it is not necessary to genotype all of 
the SNPs; a subset are genotyped and the remainder of the 
genetic information is inferred by imputation methods. These 
methods compare the patterns of genotyped markers (from 
GWAS data) with those present in a reference panel (e.g. 
HapMap) and the missing genotypes are predicted based on 
the observed similarities60.
cis e-QTL mapping for disease-associated SNPs
Associated SNPs that reach a genome-wide signiﬁcance level 
(p<5x10–8) often map within regions of tight LD, where several 
genes can be present. Correlation between the genotypes of 
the associated SNP and the expression levels of the genes in its 
proximity can help to pinpoint the best candidate gene. In this 
type of analysis, there are three possible scenarios: positive, 
negative or no correlation. Assuming B is the risk allele, the 
most associated SNP can correlate positively with expression 
of gene X, have no eﬀect on the expression level of gene Y, or 
result in low expression of gene Z. A single SNP can aﬀect the 
expression of one or more genes in the locus; the SNP can 
aﬀect the expression of multiple genes in the same direction or 
in the opposite direction. Conversely, the expression of a single 
gene can be aﬀected by multiple SNPs and can be negatively 
regulated by one SNP but positively by another. Although the 
correlation between genotype and gene expression shows a 
functional relationship between a SNP and a gene, it is not 

































































SH2B3: regulation of T-cell 
receptor, growth factor and 
cytokine receptor-mediated 
signalling 
Immune cell signalling 
17 
Chronic kidney disease 58 
Diastolic blood pressure 59,60 






Plasma eosinophil count 64 
Systolic blood pressure 59 
Type 1 diabetes 65 
Coeliac disease 
10q22.3 ZMIZ1 
ZMIZ1: member of the family of 
protein inhibitor of activated 
STAT; regulates activity of 
several transcription factors, 
modulates transforming growth 
factor-β signalling 
Immune cell signalling 
17 
Inflammatory bowel 
disease (early onset)  
66 
Multiple sclerosis 67 
Coeliac disease 
18p11.21 PTPN2  
T cell protein tyrosine 
phosphatase-non receptor 2, 
suppresses IL6 induced STAT3 
tyrosine phosphorylation and 
activation 
Immune cell signalling 
17 
Crohn's disease 68-70 




2q33.2 CTLA4, ICOS 
CTLA4: negative regulator of T 
cell responses. ICOS: inducible 
T-cell co-stimulator precursor, 
belongs to CTLA-4 cell-surface 
receptor family 
Immune cell signalling 
17 
Rheumatoid arthritis 73 
Type 1 diabetes 65,72 
Coeliac disease 
14q24.1 ZFP36L1 
ZFP36L1: putative nuclear 
transcription factor may function 
in regulating the response to 
growth factors 
Immune cell signalling 
17 
Type 1 diabetes 65 
Coeliac disease 
16p13.13 
TNP2, PRM3, PRM2,  
PRM1, SOCS1, 
CLEC16A 
SOCS1: suppressor of cytokine 
signalling 1; its expression can 
be induced by IL2 and IFNγ. 
Takes part in a negative 
feedback loop to attenuate 
Immune cell signalling 
17 
Type 1 diabetes 72 
Coeliac disease 
1q24.2 CD247 
Part of the CD3 receptor 
complex where it plays an 
important role in coupling antigen 
recognition to several 
intracellular signal-transduction 
pathways. Low expression of 
CD247 results in the impaired 
immune response 
Immune cell signalling 
17 
Systemic sclerosis 74 
Coeliac disease 
21q22.3 ICOSLG, RRP1///AP001053.1 
ICOSLG: inducible T cell co-
stimulator ligand; regulates T cell 
activation, up-regulates IL10 
expression. ICOS receptor is a 
member of CTLA4/CD28 family. 
RRP1: involved in the late stages 
of nucleologenesis at the end of 
mitosis 
Immune cell signalling 
17 
Crohn's disease 69 
Coeliac disease 1q31.2 RGS1 
Regulates chemokine receptor 
signalling 
and is involved in B-cell 
activation and proliferation. 
Specifically expressed in 
intestinal intra-epithelial 
lymphocytes 
Immune cell signalling 17 
Coeliac disease 3q13.33 CDGAP, TMEM39A, KTELC1, CD80 
CD80: can bind to CTLA-4 which 
results in the decreased 
response of the T-cells. CD80 is 
expressed on activated B cells 
and monocytes 
Immune cell signalling 17 
Coeliac disease 6q25.3 RSPH3, TAGAP 
TAGAP: a RhoGTPase-activating 
protein, expressed in activated T-
cells and important for 
modulating cytoskeleton changes 
Immune cell signalling 17 
Coeliac disease 
1q24.3 FASLG, TNFSF18, TNFSF4 
FASLG: cytokine that binds to 
FAS. Involved in cytotoxic T-cell 
mediated apoptosis and in T-cell 
development. TNFSF18: 
modulates T cell survival in the 
peripheral tissues. TNFSF4: 
involved in T cell antigen-
Immune cell signalling 
17 
Crohn's disease 68,69 
Table 1. Coeliac disease susceptibility genes: function, pathways and associations to other traits




A key player during CD8 lineage 
differentiation in the thymus via 
direct promotion of RUNX3 
expression 











MMEL1: member of the 
membrane metallo-
endopeptidase (MME) family.  
TFRSF14; tumor necrosis factor 
receptor superfamily member 14, 
part of herpes simplex virus 
(HSV) entry mechanism, 
promotes apoptosis of double-
positive thymocytes 
T-cell maturation and 
differentiation 
17 
Rheumatoid arthritis 77 
Coeliac disease 1p36.11 RUNX3 
Promotes differentation of CD4+ 
cells into Th1 cells. Master 
regulator of CD8+ T lymphocyte 
developement in the thymus 
T-cell maturation and 
differentiation 
17 
Coeliac disease 6q22.33 PTPRK, THEMIS 
THEMIS: plays a regulatory role 
in both positive and negative T-
cell selection during late 
thymocyte development. The 
protein functions through T-cell 
antigen receptor signalling, and 
is necessary for lineage 
commitment and maturation of T-
cells. 








IL18RAP: subunit of IL18 
receptor. Cytokine of broad 
function including stimulation of 
interferon gamma production by 
T-cells. Role in activation of NF-
кB and JNK in response to IL18 
T-cell maturation and 
differentiation 
17 
Plasma eosinophil count 64 
 Coeliac disease 
3q25.33* SCHIP1, IL12A 
IL12A: required for the T-cell-
independent induction of IFNγ; 
involved in differentiation of Th1 
and Th2 cells 
T-cell maturation and 
differentiation 
17 
Multiple sclerosis 67 
Coeliac disease 
4q27 IL2, IL21, ADAD1, KIAA1109 
IL2: T-cell growth factor; 
activation and proliferation of NK 
cells, monocytes, macrophages, 
differentiation of B cells. IL21: 
Amplification of Th17 response 
T-cell maturation and 
differentiation 
17 
Type 1 diabetes 65,70 
Celiac disease 
22q11.21 CCDC116, UBE2L3, HIC2, LOC150223 
UBE2L3: ubiquitin-conjugating 
enzyme E2L3, participates in the 
ubiquitination of p53, c-Fos, and 










2p16.1 REL, PUS10, PEX13, AHSA2 
REL: a component of the NF-kB 
transcription complex that plays 
a 
critical role in promoting immune 
and inflammatory responses 
through the production of pro-
inflammatory cytokines AHA1: 




Rheumatoid arthritis 73 
Ulcerative colitis 78 
Ankylosing spondylitis 
2q31.3 UBE2E3, ITGA4 
UBE2E3: by conjugating with 
SUMO-1 negatively regulates 
NF-kB activity.  
ITGA4: encodes an alpha 
subunit of the integrin, acts as 




Coeliac disease 17 
Coeliac disease 
6q23.3 OLIG3, TNFAIP3 
OLIG3: neuronal developement. 
TNFAIP3: zinc finger protein, 
inhibits NF-кB activation as well 
as TNF-mediated apoptosis; 
limits inflammation by terminating 
TNF-induced NF-кB responses. 
Innate: NF-kB 
17 
Rheumatoid arthritis 77,80 
 
Celiac disease 1p36.23 TNFRSF9, PARK7, ERRFI1 
TNFRSF9: member of the TNF 
receptor superfamily. T 
lymphocyte co-stimulation to 
promote Th1 response. Activates 
NF-кB. PARK7: protects neurons 
against oxidative stress and cell 
death. 
Innate: NF-kB 17 
Brain structure 
3p21.31 
CCR5, CCR3, LTF, 
CCRL2, CCR1, 
CCR9, CXCR6, 
XCR1, CCRL2, g 
Chemokine receptor cluster, 
chemokines are involved in 
recruitment of effector immune 
cells to the site of inflammation 
Chemokines 
81 
Coeliac disease 17 
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Underlined genes have a detected e-QTL effect; genes in green are downregulated and in red are upregulated in association with the risk allele. Independent SNPs 
that have an e-QTL effect on the same gene but with opposite effects are in blue. Genes identified from GRAIL analysis [19] are in bold font. Regions with signatures 
of positive selection are marked with asterisks.
Individuals with immune-related diseases 
have a high number of T cells as well as an 
imbalance in T cell subsets compared to normal 
individuals. From the perspective of immune-
related diseases, there are three subtypes 
of CD4 cells of particular interest: Th1, Th17 
and regulatory T cells (Tregs). T helper cells 
coordinate the adaptive immune response 
against pathogens by producing specific 
cytokines and thereby mediating different 
types of tissue inflammation. Both the IL-12 and 
IL-18 pathways induce IFN-g secretion by Th1 
cells; IFN-g is the key cytokine involved in the 
mucosal inflammation in coeliac disease. The 
GWAS results suggest an important role for Th1 
cells as they identified two regions associated 
with coeliac disease that harbour genes in both 
the IL-12 and IL-18 path- ways: the 2q12.1 region 
containing the IL18RAP and IL18R1 genes, and 
the 3q25.33 region containing IL12A, which 
encodes a subunit of the heterodimeric IL-12 
cytokine. Th17 cells might be potent inducers 
of autoimmunity and tissue inflammation33. 
The GWAS results suggest a role for either 
Coeliac disease 3p22.3 TRIM71, CCR4, GLB1 
CCR4: chemokine receptor, one 
of the ligands is RANTES which 
recruits leukocytes into 
inflammatory sites. 
Chemokines 17 
Black vs. blond hair color 
6p25.3 IRF4 
IRF4: transcriptional activator, 
binds to the interferon-stimulated 
response element (ISRE) and 
plays a role in ISRE-targeted 
signal transduction mechanisms. 
Activated in TLR7 and TLR9 
signalling pathways, expression 
of TRF4 is specific to T-, B- cells 
and macrophages. Also crucial 
for IL-21 mediated activation and 
stabilization of Th-17 cells. 
Innate: response to 
virus infection 
82 
Black vs. red hair color 82 








Transcriptional repressor in B-
cells, a key regulator of antibody 
response. Regulator of nucleic 
acid-triggered antiviral responses 
Innate: response to 
virus infection 
17 
Type 1 diabetes 
65,72,
86 
Coeliac disease Xp22.2 TLR8, TMSL3, TLR7, TMSB4X 
TLR7/TLR8: play fundamental 
role in recognition of single 
stranded viral RNA and activation 
of innate immunity. 








NSF: participates in vesicle-
mediated transport.  
WNT: WNT family encodes 
secreted signalling proteins. 





Parkinson's disease 87 
 Coeliac disease 
2p14 PLEK 
Pleckstrin: platelet and leukocyte 
C kinase substrate, associates 
with membranes in human 




Serum metabolites 88 
Coeliac disease 
3q28 LPP 
LPP: localizes to the cell 
periphery in focal adhesions and 
may be involved in cell-cell 




Coeliac disease 1p31.3 NFIA Plays a role in regulation of human granulopoiesis. Other 
17 
Coeliac disease 3p14.1 FRMD4B 
FERM domain-containing protein 
4B. May provide a link between 
membrane to cytoskeleton and 
be involved in signal transduction  
Other 17 







The function of these genes is 
unknown Unknown 
17 
Telomere length 90 
Coeliac disease 
1q32.1 Intergenic Unknown Unknown 
17 
Crohn's disease 69 
Ulcerative colitis 69,78 
Coeliac disease 13q14.2 Intergenic Unknown Unknown 17 
Coeliac disease 8q24.21 Intergenic Unknown Unknown 17 
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Th17 or Treg cells as the chromosome 4q27 
locus contains both the IL2 and IL21 genes. 
IL-21 stimulates expansion of Th17 cells30 and 
regulates inflammation and Th17 responses in 
the gut34. IL-2 is a general T cell growth factor 
and activates Treg cells, a subset of T cells that 
can suppress the responses of effector T cells 
and other immune cells. Decreased activity or 
altered functional properties of Treg cells result 
in severe autoimmunity35.
Thymus
The induction of central tolerance as well 
as CD4 and CD8 lineage commitment from 
thymocytes takes place in the thymus36. The 
GWAS results implicate the thymus in the 
pathogenesis of coeliac disease (Figure 2). For 
example, THEMIS encodes a protein involved 
in T cell maturation and in regulating lineage 
commitment of thymocytes into CD4 or 
CD837 cells, whereas ETS1 and RUNX3 genes 
both encode regulators of CD8 T lymphocyte 
development38. TNFRSF14 encodes a protein 
that promotes apoptosis of double-positive 
thymocytes39. 
Innate immune response
The role of the innate immune response in 
coeliac disease has been unclear; however, 
the release of IL-15 by intestinal epithelial 
cells in direct response to one of the gluten 
peptides has been described40. In addition, viral 
infections have been implicated as triggering 
factors in coeliac disease, although this is mainly 
anecdotal. The GWAS findings point to a causal 
role for the innate immune system as multiple 
genes are involved in NF (nuclear factor)-kB 
and Toll-like receptor (TLR) signalling.
Innate response to infection
GWAS point to the importance of the innate 
response to exogenous factors, such as 
infection (Figure 2). Genes such as TLR7/TLR8, 
BACH2 and IRF4 indicate the involvement of an 
immune response triggered by viral infection. 
TLRs play a key role in activating the innate 
immune response in response to molecules 
from pathogens: TLR7 and TLR8 recognise viral 
RNA, whereas IRF4 is a transcriptional activator 
in the TLR7 signalling pathway. IRF4 is specific 
to macrophages, T and B cells41. BACH2 is the 
key regulator of antibody response in nucleic 
acid-triggered antiviral response. Interestingly, 
BACH2 is also associated with type 1 diabetes, 
which makes it tempting to speculate that viral 
infection could be a trigger for both of these 
diseases; such a mechanism triggers a multiple 
sclerosis phenotype in a mouse model42,43. A 
high frequency of rotavirus infections might 
increase the risk of developing coeliac disease 
in susceptible individuals44.
Innate NF-kB signalling
NF-kB is a transcriptional complex that 
regulates adaptive and innate immune 
responses, inflammation through cytokine 
production and cell death45. Genomic regions 
associated with coeliac disease contain 
genes encoding factors that regulate NF-kB 
signalling. For example, REL encodes a 
component of the NF-kB complex, whereas 
the TNFAIP3 gene product A20 terminates 
NF-kB activity. UBE2E3, through conjugation 
with SUMO-1, negatively regulates NF-kB 
and UBE2L3 ubiquitinates an NF-kB precursor 
in vitro, possibly affecting protein stability. 
Chapter 5                       A genetic perspective on coeliac disease
Box 2. Pathway analysis tools
Recent advances in technology have provided researchers 
with high-throughput methods, such as GWAS, genome-wide 
gene expression analysis and whole-exome sequencing, 
providing a great capacity to study biological processes 
involved in disease pathogenesis. However, such analyses 
often results in long lists of potentially interesting genes. 
Applying pathway analysis tools such as DAVID to a list of 
candidate genes can help in interpreting the results. Such 
tools map the genes of interest to the associated, annotated 
biological pathways and reveal the most enriched 
annotations. Pathway analysis tools utilise diﬀerent 
biological annotation resources (e.g. KEGG, BioCarta and 
gene ontology) all of which aim to integrate gene information 
into biological pathways. DAVID, the Database for 
Annotation, Visualisation and Integrated Discovery 
(http://david.abcc.ncifcrf.gov/), provides a comprehensive set 
of functional annotation tools to understand biological 
meaning behind large lists of genes61. The application of any 
pathway analysis tool has limitations. The major drawback is 
that analysis of a random selection of genes emerging from 
GWAS ﬁndings will always result in signiﬁcantly 
overrepresented pathways. Therefore, any results should be 
treated with caution and as an indication of biologically 
relevant pathways for the disease rather than as proof of 
causality55.
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TNFRSF9 encodes a member of the tumour 
necrosis factor (TNF) receptor superfamily that 
can activate NF-kB. The association of these 
genes strongly suggests that NF-kB signalling 
plays a role in the development of coeliac 
disease pathology.
Other coeliac disease pathways
For a subset of genes, little is known about 
the function of their products, and for others 
association signals map to intergenic regions 
(Table 1). Because these genes and loci do not 
immediately fit into our current understanding 
of coeliac disease pathogenesis, they present 
new leads for studying the disease aetiology.
Individual risk profiling for coeliac disease
Similar to the majority of complex traits 
evaluated so far by GWAS, the non-HLA 
genes show a modest individual risk and all 
39 loci together explain only ~5% of the risk 
for coeliac disease19. Although 5% might seem 
to account for only a small proportion of the 
total genetic risk, it can be used to assess 
an individual’s risk for coeliac disease. The 
first step in determining individual risk is to 
assess their HLA status because the absence 
of HLA-DQ2/DQ8 is a strong predictor of not 
developing coeliac disease (close to zero risk). 
One or two copies of HLA-DQ2 give an a priori 
intermediate or high risk for disease. However, 
the non-HLA risk alleles determine the 
absolute risk, which can increase to >30%46,47. 
Before genetic profiling can be implemented in 
clinical practice, the specificity and sensitivity 
of the genotyping profiles must be improved 
and the positive predictive value needs to be 
determined using prospective and longitudinal 
cohort studies. Nevertheless, if in the future, 
we can identify individuals at risk, this might 
allow for early intervention48, especially in 
families that already have patients with coeliac 
A total of 22 coeliac disease-associated SNPs with e-QTL effects19. In total, 23 e-QTL events result in downregulation of gene expression and 9 in upregulation. 
SNPs affecting expression of several probes located within the same gene were counted only once.
Chromosome                   SNP     Risk allele   eQTL gene     Expression change
 1    rs3748816   A 
1     rs3748816  A 
1     rs3748816   A 
 1    rs3748816    A
1     rs12727642   A 
1     rs864537   A 
1     rs864537   A
1     rs296547   G
2     rs842647   A
2     rs13003464   G 
2     rs3816281   C 
 2    rs917997    A
2     rs13010713   G
3     rs13098911   A
3     rs13098911   A 
3     rs13098911   A 
3     rs13098911   A 
3     rs6441961   A  
3     rs11922594   G 
3     rs11922594   G 
6     rs10806425   A 
6     rs1738074   A 
6     rs1738074   A
6     rs1738074   A
7     rs6974491   A
10     rs1250552  A 
12     rs653178   G 
12     rs653178   G 
12     rs653178   G 
12     rs653178  G
16    rs12928822  G
17     rs2074404   A
17     rs2074404   A 
17     rs2074404   A 
17     rs2074404   A 
17     rs2074404   A
21     rs4819388   G
22     rs2298428   A
X     rs5979785   A
 X     rs5979785   A
                                                                                                                                          
C1orf93     Up 
PLCH                    Down 
MMEL1     Up 
TNFRSF14     Down 
PARK7     Up 
CD247      Down 
CD247      Down 
Probe-rs296547    Down 
AHSA2     Down 
AHSA2     Down 
PLEK      Down 
IL18RAP     Down 
UBE2E3     Up 
CCR3      Down 
CCR3-probe2190671    Down 
Probe-6550333    Down 
CCR3      Down 
CCR3      Up 
KTELC1     Down 
KTELC1-probe6550288   Down 
BACH2     Down 
probe-5890739    Down 
TAGAP     Down 
TAGAP-probe5360364   Down 
ELMO1     Down 
ZMIZ1      Down 
SH2B3///ATXN2    Up 
ALDH2     Down 
TMEM116     Down 
TMEM116-probe2070736   Down 
Probe-4540072    Down 
ARL17///LRRC37A///LRRC37A2  Down 
NSF-probe5260138    Down 
WNT3      Down 
NSF     Down 
Probe-4880037    Up 
RRP1///AP001053.1    Down 
Probe-1230242    Up 
TLR8     Up 
TLR8-probe3390612    Up
Table 2. eQTL effects of the coeliac disease associated SNPs


















































































































































































Figure 1. Genetic sharing of coeliac disease. The disease associations that fall to the same LD blocks as the 39 nonHLA 
coeliac disease loci were extracted from ‘A Catalogue of Published Genome-Wide Association Studies’. A total of 26 loci 
were shared by one or more traits (presented in the modules in the circle). The size of the ‘gene module’ corresponds to 
the number of connections with traits. SH2B3 is the most shared locus; it is associated with most of the haematological 
traits, metabolic traits and esophageal cancer. The size of the ‘disease module’ corresponds to the genetic sharing with 
coeliac disease, the bigger the module the more genes are in common. Immune-related diseases are overrepresented; in 
particular, type 1 diabetes, rheumatoid arthritis and Crohn’s disease associate with four or more genes that are shared with 
coeliac disease. In total, 13 genes (in the central circle, orange) are specific for coeliac disease.
disease. Alternatively, risk profiling might 
assist monitoring by identifying individuals 
who should be repeatedly screened for 
coeliac disease-associated antibodies and, if 
necessary, have a biopsy taken.
Genetic sharing of coeliac disease with other 
traits
Many coeliac disease risk loci are shared with 
other immune-related diseases25,49,50, which 
supports observations that autoimmune 
diseases co-occur in families and individuals51. 
Coeliac disease often co-occurs with type 1 
diabetes, rheumatoid arthritis, ulcerative coli- 
tis or Crohn’s disease51–53.
A shared genetic background among these 
diseases points to common biological 
pathways underlying their aetiology. To obtain 
an unbiased picture of the shared genetics, 
we used ‘A Catalogue of Published Genome-
Wide Association Studies’ (data freeze 19 May, 
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Figure 2. Possible mechanisms underlying coeliac disease pathogenesis. (a) Gluten peptides pass from the intestinal lumen 
through the impaired epithelial barrier into the lamina propria, where they undergo deamidation and are recognised by 
APCs. Deamidated gluten peptides bind efficiently to the HLA-DQ2 or DQ8 molecules on the surface of the APCs and 
are presented to T cells. This initiates the cascade of innate and adaptive immune responses and leads to inflammation 
of the small intestine, villous atrophy, crypt hyperplasia and infiltration of intraepithelial lymphocytes. Coeliac disease-
associated genes might alter the immune response at different levels (associated candidate genes are in red). The GWAS 
findings indicate the causal role for the innate immune system. Multiple associated genes are involved in regulating the 
activity of NF-kB. Association of disease with loci harbouring genes involved in immune response to infection, TLR7/TLR8, 
BACH2 and IRF4, indicate viral infection is a potential trigger for coeliac disease. (b) Induction of central tolerance together 
with CD4/CD8 lineage commitment from thymocytes occurs in the thymus. Genes associated with coeliac disease indicate 
that the thymus might be involved in the pathology. Associated genes regulate the fate of thymocytes by directing them 
towards negative or positive selection (e.g. TNFRSF14 promotes apoptosis of double-positive thymocytes). Genes such as 
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2010)54 to extract all the reported trait and 
disease associations that map to the same LD 
blocks as the 39 coeliac disease-associated loci 
(for LD blocks definition see19). Overall, 26 loci 
were shared by one or more traits. The largest 
genetic sharing occurred between coeliac 
disease and type 1 diabetes (seven regions), 
followed by rheumatoid arthritis and Crohn’s 
disease (four regions) (Figure 1). Interestingly, 
the SH2B3 locus was associated with nine traits 
(apart from coeliac disease), most of which are 
haematologically related (Figure 1). The IRF4 
region was associated with five traits, most 
of which are unlikely to be relevant to coeliac 
disease (e.g. hair colour or freckles). Genes 
that are shared by three traits include ZMIZ1, 
PTPN2, an intergenic region on 1q32.1, UBE2L3, 
REL and CTLA4; all but the 1q32.1 locus are 
immune-related genes. Apart from its classic 
presentation, coeliac disease can also manifest 
as a skin phenotype (dermatitis herpetiformis), 
a neurology-related disorder (e.g. ataxia) and a 
disorder progressing into cancer (enteropathy-
associated T cell lymphoma). Loci such as CCR3/
CCR5 or WNT3 are shared with neurological 
traits, whereas IRF4 and SH2B3 are shared 














associated with coeliac disease could be partly 
explained by the shared genetics.
At this time, 13 loci remain private for coeliac 
disease. These results might be temporary as 
not all the disease-associated loci have been 
identified and different studies might have 
variable power to identify these loci because 
of sample size limitations or the effect sizes of 
one trait compared to another.
Pathway classification
We used our GWAS results to further our 
understanding of known pathways involved in 
coeliac disease by selecting relevant, immune-
related genes from the different associ- ated 
loci. As such an approach is highly biased, we 
also applied DAVID, a pathway analysis tool 
(Box 2). We acknowledge that these tools are 
especially biased towards detecting the well-
defined pathways55 when analysing a random 
selection of SNPs. Although this analysis can 
indicate the biological processes involved in 
the disease aetiology, the results should be 
interpreted with caution.
Cellular processes involved in coeliac disease 
pathology
We applied DAVID analysis to the set of 115 
genes selected from the 39 nonHLA loci. 
Of the 115 genes, 27 mapped to the KEGG 
(Kyoto encyclopaedia of genes and genomes) 
pathways and 17 genes lie on the cytokine–
cytokine receptor interaction pathway 
(CCR1, CCR3, CCR9, CCR4, CCR5, XCR1, 
CXCR6) and on the TNF family subpathways 
(FASLG, TNFSF4, TNFSF18, TNFRSF14, 
TNFRSF9). Chemokine signalling involves 
the activation of the Jak/STAT, NF-kB and 
MAPK (mitogen-activated protein kinase) 
signalling pathways. The activation of NF-kB 
results in cytokine production, cell growth, 
differentia- tion, migration and apoptosis. The 
Jak/STAT signalling pathway is the main signal 
transduction mechanism down-stream of many 
cytokines and growth factors. Upon activation 
via Jak, STATs modulate the expression of 
the target genes. SOCS1, IL12A, IL21, IL2 and 
PTPN11 are implicated in this pathway.
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CD80, CCR9, ICOSLG, ICOS, ITGA4 and IL-2 
mapped within the intestinal immune network 
for immunoglobulin (Ig)A production, the 
second most significant pathway emerging 
from this analysis. IgAs are a class of 
noninflammatory immunoglobulins that is 
largely produced in the intestine and serves as 
the first-line defence against microorganisms. 
Multiple cytokines such as IL-10, IL-4, IL-5, 
IL- 6 and TGF (transforming growth factor)-b 
promote IgA production. Secreted IgAs capture 
dietary antigens and microorganisms in mucus 
and neutralise them. This result validates 
observations that selective IgA deficiency is 
often associated with coeliac disease56 and now 
points to its genetic basis.
Other gene-enriched pathways identified 
by this approach include allograft rejection, 
type 1 diabetes mellitus, autoimmune thyroid 
disease, cell adhesion molecules, graft-versus-
host disease and TLR signalling.
Shared pathways driving immune-related and 
inflammatory diseases
To investigate whether the pathways that drive 
coeliac disease are common to other immune-
related diseases, we used ‘A Catalogue of 
Published Genome-Wide Association Studies’ 
(data freeze 19 May, 2010), focusing on the ten 
immune-related traits that share part of their 
genetics with coeliac disease and extracting 
all of the associated genes for pathway 
analysis that have been reported (using DAVID 
annotation).
Excluding HLA, there were 203 unique genes. 
Similar to coeliac disease, the cytokine-cytokine 
interaction pathway is the most enriched 
and includes almost 10% of the genes tested, 
followed by the Jak/STAT signalling pathway. 
Interestingly, two pathways enriched for 
coeliac disease genes, the chemokine and 
TLR signalling pathways, were not significant 
in this analysis. By contrast, T cell receptor 
signalling and sulphur metabolism pathways 
were significantly enriched for immune-
related genes but not for coeliac disease genes. 
Identifying further risk genes will most likely 
allow us to distinguish the higher-specificity 
pathways that are the genuine drivers for 
immune-related diseases from those that are 
specific to particular conditions.
Concluding remarks and future perspectives 
At this time, 39 nonHLA genes are known to 
contribute to the susceptibility for coeliac 
disease. Although the findings account for a 
rather modest amount (~5%) of the total genetic 
risk, these genetic studies have expanded our 
understanding of the biology of coeliac disease 
and broadened the repertoire of immune 
pathways driving disease development. Genetic 
findings have now not only confirmed the 
well-established role of the adaptive immune 
response but have also indicated a clear role 
for the innate immune system, in particular 
by identifying genes involved in NF-kB 
signalling and viral infection. The genetic 
findings are now awaiting functional follow-up 
studies. One of the major remaining challenges 
is to pinpoint the true causal risk variants and 
to elucidate the consequences of these variants 
on RNA or proteins.
A GWAS comprising ~15,000 subjects was 
required to identify the loci that explain only 
5% of the genetic variation. Hence, future 
studies will require much larger cohorts to 
uncover the remaining common variants 
with small effect sizes57. Analysis of 100,000 
individuals might detect 10–15% of the genetic 
variance underlying coeliac disease58. It might 
be difficult to collate such a large collection of 
patient samples, but because many genes are 
shared with other diseases the joint analysis of 
multiple diseases might be one way forward.
Along with common variants, rare variants with 
a frequency of <10% are also likely to contribute 
to the missing heritability. Detecting rare 
variants will require different techniques, such as 
whole-exome or whole-genome sequencing59. 
Furthermore, structural variations, gene-gene 
interactions and epigenetic signatures are also 
likely to contribute to the genetic background 
of coeliac disease.
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Because we have observed a large amount of 
shared genetics between coeliac disease and 
other immune-related traits, it is possible that 
the genetic background of immune diseases 
is generally shared to a greater degree than 
anticipated, and it is possible that the unique 
type of trigger determines whether coeliac 
disease develops rather than another disease. 
The roles of exogenous factors, such as 
infectious disease or gut microbiota, also need 
to be elucidated to better understand the 
interaction between the genetic background 
and environmental triggers. Once this 
information is available, a more complete 
picture of the disease pathogenesis will 
emerge. Only then can we begin to understand 
the heterogeneous clinical presentation of 
this disease and to translate our knowledge to 
benefit individual patients.
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We densely genotyped, using 1000 Genomes Project pilot CEU and additional re-sequencing 
study variants, 183 reported immune-mediated disease non-HLA risk loci in 12,041 celiac 
disease cases and 12,228 controls. We identified 13 new celiac disease risk loci at genome wide 
significance, bringing the total number of known loci (including HLA) to 40. Multiple independent 
association signals are found at over a third of these loci, attributable to a combination of 
common, low frequency, and rare genetic variants. In comparison with previously available data 
such as HapMap3, our dense genotyping in a large sample size provided increased resolution of 
the pattern of linkage disequilibrium, and suggested localization of many signals to finer scale 
regions. In particular, 29 of 54 fine-mapped signals appeared localized to specific single genes 
- and in some instances to gene regulatory elements. We define a complex genetic architecture 
of risk regions, and refine risk signals, providing a next step towards elucidating causal disease 
mechanisms.
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INTRODUCTION
Celiac disease is a common complex chronic 
immune-mediated disease with seroprevalence 
of ~1%1,2 in individuals of white European origin. 
A T-cell mediated small intestinal immune 
response is generated against gliadin fragments 
from wheat, rye and barley cereal proteins 
leading to villous atrophy. Its aetiology is poorly 
understood. Association with HLA variants 
was first shown in 1972, and predisposing 
HLA-DQ2 and -DQ8 sub-types are necessary 
but not sufficient to cause disease. Recent 
genome wide association studies (GWAS) 
have identified a further 26 non-HLA risk 
loci3-6. Many of these loci are also associated 
with other autoimmune or chronic 
immune-mediated diseases (albeit sometimes 
different markers and effect directions7), with 
particular overlap observed between celiac 
disease, type 1 diabetes8 and rheumatoid 
arthritis9.
Currently unanswered questions regarding the 
genetic predisposition to celiac disease, which 
are also relevant for other immune-mediated 
diseases, include explaining the remaining 
major fraction of heritability, including rare 
and additional common risk variants; and 
identification of causal variants and causal 
genes (or at least more finely localizing the 
risk signal). The Immunochip Consortium10 
developed to explore these questions, taking 
advantage of emerging comprehensive 
common, low frequency, and rare variation 
datasets, and of a commercial offer of much 
lower per-sample custom genotyping costs 
for a very large project comprised of related 
diseases.
The Immunochip, a custom Illumina Infinium 
HD array, was designed to densely genotype, 
using 1000Genomes and any other available 
disease specific resequencing data, immune-
mediated disease loci identified by common 
variant GWAS. The 1000 Genomes Project 
pilot CEU low-coverage whole genome 
sequencing dataset captures 95% of variants 
of MAF=0.05, and although underpowered to 
comprehensively detect variants of rarer allele 
frequency, still identifies 60% of variants of 
MAF=0.02, and 30% of variants of MAF=0.0111. 
The Consortium selected 186 distinct loci 
containing markers meeting genome wide 
significance criteria (P<5x10-8) from twelve 
such diseases (autoimmune thyroid disease, 
ankylosing spondylitis, Crohn’s disease, celiac 
disease, IgA deficiency, multiple sclerosis, 
primary biliary cirrhosis, psoriasis, rheumatoid 
arthritis, systemic lupus erythematosus, 
type 1 diabetes and ulcerative colitis). All 
1000 Genomes Project low-coverage pilot 
CEU population sample variants11 (Sept 
2009 release) within 0.1cM (HapMap3 CEU) 
recombination blocks around each GWAS 
region lead marker were submitted for array 
design. No filtering on correlated variants 
(linkage disequilibrium) was applied. Further 
case and control regional resequencing data 
were submitted by several groups (Online 
Methods, Supplementary Note), as well as 
a small proportion of investigator-specific 
undisclosed content including intermediate-
significance GWAS results. 
Most GWAS have been performed using 
common SNPs (typical minor allele 
frequency (MAF) >5%), further selected for 
low inter-marker correlation and/or even 
genomic spacing. In contrast to GWAS, the 
Immunochip presents a comprehensive in-
depth opportunity to dissect the architecture 
of both rare and common genetic variation, at 
immuno-biologically relevant genomic regions, 
in human diseases. Due to the presence in our 
final Immunochip dataset of the majority of 
1000 Genomes Project pilot CEU polymorphic 
genetic variants (and additional resequencing 
at some loci), the true causal variants from many 
risk loci may have been directly genotyped and 
analysed.
RESULTS
A total of 207,728 variants were submitted for 
Immunochip assay design and 196,524 passed 
manufacturing quality control at Illumina. After 
extensive and stringent data quality control 
(Online Methods), we analysed a near-complete 
dataset (overall 0.008% missing genotype calls) 
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comprising 12,041 celiac disease cases and 
12,228 controls (from 7 geographic regions, 
Table 1) and 139,553 polymorphic (defined here 
as ≥2 observed genotype groups) markers. 
634 biallelic SNPs were assayed in duplicate, 
at these we observed 189 of 15,384,884 
(0.0012%) genotype calls to be discordant. 
Considering the intended 207,728 variants 
submitted for design, and an observed ~9.1% 
non-polymorphic rate in our post-quality 
control data, we estimate we have high quality 
genotype data on ~74% of the complete 1000 
Genomes Project pilot CEU true polymorphic 
variant set at the fine-mapped regions.
We observed that 36 of the 183 non-HLA 
immune-mediated disease loci selected 
for Immunochip dense 1000Genomes-
based genotyping achieved genome-wide 
significance (P<5x10-8) for celiac disease in 
either the current study or our previous GWAS5 
(summary association statistics for all markers 
are available in T1DBase). All variants reaching 
genome wide significance were common 
(MAF >5%). We also observed marked 
enrichment for intermediate significance level 
celiac disease association signals (e.g. rs6691768, 
NFIA locus, P= 5.3x10-8) at a proportion of the 
remaining 147 dense-genotyped non-celiac 
autoimmune disease regions (Supplementary 
Figure 1). Variants from 3 dense-genotyped 
regions selected on Immunochip for a non-
immune-mediated trait (bipolar disorder) 
showed no excess of association signals 
(Supplementary Figure 1). 
We identified 13 new celiac risk loci (P<5x10-8, 
Figure 1, Table 2, Supplementary Figure 2), 10 of 
which were from immune-mediated disease loci 
selected for Immunochip dense 1000Genomes-
based genotyping. Several of these new loci 
were reported at lesser significance levels in 
our previous studies5,9, and almost all have 
been reported in at least one other immune-
mediated disease. These, with HLA, bring to 
40 the total number of reported (current and/
or previous study5, which had an overlapping 
but slightly different sample set) genome wide 
significant celiac disease loci. Most contain 
candidate genes of immunological function, 
consistent with our previous findings at celiac 
disease loci3-5.
Effect sizes (odds ratios, inverting protective 
effects) for the most significant marker per 
locus were median 1.155 (range 1.124 – 1.360) 
for the top signals from 26 non-HLA loci 
measured using Illumina Hap300/Hap550-chip 
linkage disequilibrium-pruned tag SNPs in our 
2010 celiac disease GWAS5 and median 1.166 
(range 1.087 – 1.408) for the corresponding 
most significant marker (for the same signal) 
per locus in the current high density fine-
mapping Immunochip dataset (Wilcoxon test 
P=0.75, Supplementary Table 1). Although we 
observe no difference in effect sizes between 
GWAS lead SNPs and subsequent fine-mapped 
signals, we note that case resequencing in the 
current Immunochip dataset is limited (see also 
Discussion).
In all, we report 57 independent coeliac disease 
association signals (Table 2) from 39 separate 
loci, of which 18 (32%) were not efficiently 
(r2>0.9, Supplementary Table 2) tagged by our 
previous GWAS5 (Illumina Hap550, post quality 
control dataset) markers.
Multiple independent common and rare 
variant signals
In contrast to most GWAS chips, the 
Immunochip contains a substantial proportion 
of lower MAF polymorphic variants. Of 139,553 
variants in our 11,837 European-origin controls, 
24,661 variants are low frequency (defined11 as 
MAF 5% to 0.5%) and a further 22,941 variants 
are rare (MAF<0.5%). We investigated the 
possibility of multiple independently associated 
variants (of all allele frequencies) at each locus, 
using stepwise logistic regression conditioning 
on the most significant variant at the locus 
(Online Methods, Supplementary Table 3). This 
analysis can be sensitive to genotype miscalling 
and missing data12, hence our use of extremely 
rigorous quality control measures for the 
dataset and manual inspection of genotype 
clusters for all reported markers. 
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We observed two or more independent signals 
at 13 of 36 high-density genotyped non-HLA 
loci (Figure 2). Four of these loci each had three 
independent signals (STAT4, the chromosome 
3 CCR region, IL12A, SOCS1/PRM1/PRM2, Table 
2). Low frequency and/or rare variant signals 
were seen at four separate loci (RGS1, CD28/
CTLA4/ICOS, SOCS1/PRM1/PRM2, PTPN2). 
Notably, the strongest effect (OR 1.70) was seen 
at the rare variant imm_16_11281298 (SOCS1/
PRM1/PRM2 locus)  with genotype counts 
(AA/AG/GG) of 1/136/11904 (MAF 0.57%) in all 
celiac cases and 0/91/12136 (MAF 0.37%) in all 
controls (detailed genotype count and allele 
frequency data for top signals by collection are 
shown in Supplementary Table 4). 
We next performed haplotype analysis on 
all loci with multiple independent signals, to 
investigate whether the multiple signals were 
due to multiple causal effects or a single effect 
best tagged by several variants. For all but one 
locus (PTPN2) the haplotype association tests 
(not shown) were of similar significance to 
the single SNP association tests, suggesting 
that for each signal we have genotyped either 
the causal variant, or markers very strongly 
correlated with it. These findings contrast 
with those from a recent resequencing study13, 
probably because of the much greater variant 
density of our study. However, at the PTPN2 
locus, the imm_18_12833137(T) + ccc-18-
12847758-G-A(G) haplotype was considerably 
more associated (P=4.8x10-14, OR 0.84) 
than either SNP alone (imm_18_12833137 
P=1.9x10-10; ccc-18-12847758-G-A P= 0.0008). 
Interestingly at the SOCS1 locus, the third 
independent signal imm_16_11292457 shows 
association only after conditioning on the 
two other signals (P=2.0x10-4) but not in the 
single SNP non-conditioned association 
analysis (P=0.15). Further inspection revealed 
the protective imm_16_11292457(A) allele 
to be correlated (in linkage disequilibrium) 
with the risk (A) allele of the first signal 
imm_16_11268703, thus although there 
are indeed three independent signals, the 
effect of the third signal is only revealed after 
conditioning on the first. A similar statistical 
effect (Simpson’s paradox) was recently shown 
at a Parkinson’s disease locus14.
Fine-mapping to localize causal signals
GWAS signals are typically reported within 
relatively large linkage disequilibrium blocks. 
We tested whether our much denser genotyping 
strategy would allow finer-scale localization, 
and the pinpointing of association signals. We 
found that markers strongly correlated (r2>0.9) 
with the most significant independent variant 
clustered together, and defined regions that 
are a median 12.5x smaller than the relevant 
HapMap3 CEU 0.1cM linkage disequilibrium 
blocks (Table 2, Figure 2, Supplementary Figure 
2). Localization was highly successful for some 
regions (e.g. PTPRK, TAGAP), but not possible 
at others (e.g. IL2-IL21). At many loci, the 
aThe two Spanish population samples were considered separately due to genotyping in different laboratories. 
b5430 UK 1958 Birth Cohort participants, and 2844 UK Blood Services-Common Controls. Each of the collections from the UK, Netherlands, Poland, Spain (Madrid) 
and Italy contained essentially the same sample set as our 2010 celiac disease GWAS5, with now substantial additional samples from the UK and Netherlands 
and exclusion of amplified DNA samples from the Spanish collections. The Indian collection has not previously been studied. Our 2010 GWAS contained several 
collections not studied here. 
Population  sample Celiac cases  Controls  
   
UK  7728  8274b 
The Netherlands 1123  1147  
Poland 505 533  
Spain - CEGEC a 545 308 
Spain - Madrida  537  320 
Italy - Rome, Milan, Naples 1374  1255 
India - Punjab 229 391 
   
Total 12041 12228 
 
Table 1 Sample collections
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localized regions comprised only a handful of 
markers in close physical proximity. 
Considering the 36 high density genotyped 
loci, we have localized to a single gene 29 of the 
total 54 independent non-HLA signals (Table 
2, Supplementary Figure 2). We identified all 
markers strongly correlated (r2>0.9) with the 
independent non-HLA variants reported in 
our analyses (from Table 2), and on functional 
annotation (Supplementary Table 2) identified 
only a handful of markers in exonic regions 
and of these only three are protein altering 
variants (nsSNPs: imm_1_2516606 (MMEL1), 
imm_12_110368991 (SH2B3), 1kg_X_152937386 
(IRAK1). In contrast, a number of signals 
appeared to be more finely localized around 
the transcription start site of specific genes 
(which we defined as the first exon, and 10kb 
5’ of the first exon), including signals at RUNX3, 
RGS1, ETS1, TAGAP, ZFP36L1; and around the 
3’ UTR region (and 10kb 3’) including signals at 
IRF4, PTPRK and ICOSLG.
Overlap between multiple independent 
signal regions was seen at some loci (Figure 
2), suggesting that causal variants might be 
functioning through a shared mechanism e.g. 
within a 2kb region of the PTPRK 3’ UTR; within 
a 11kb region 5’ of IL12A; or within a 28kb region 
Figure 1 Manhattan plot of association statistics for known and novel celiac disease risk loci Novel loci indicated in blue, 
loci with multiple signals indicated with grey highlight. Significance threshold drawn at P=5x10-8.
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of TNFAIP3. In contrast, multiple independent 
signals were observed that spread between the 
three immune genes of the CD28/CTLA4/ICOS 
region.
DISCUSSION
We show that fine mapping of GWAS regions 
using dense resequencing data, e.g. (as here) 
from the 1000Genomes project, is feasible and 
generates substantial additional information at 
many loci. We identify a complex architecture 
of multiple common and rare genetic risk 
variants at around a third of the now 40 proven 
celiac disease loci. The design of our study has 
allowed us to find many more such complex 
regions than the ~10% with multiple signals 
seen in our previous study5 and a recent large 
GWAS for human height15. It seems probable 
that if larger sample sizes than in the current 
study were to be tested, additional loci might 
be shown to have a similarly rich multiple risk 
variant architecture. Multiple independent risk 
signals for celiac disease have also long been 
known in the HLA region16. Our success in celiac 
disease might be partly due to the extensive 
selective pressures for haplotypic diversity 
that have taken place at immune gene loci17. 
Previous studies have reported independently 
associated common and rare variants at 
individual loci for a handful of phenotypes e.g. 
fetal haemoglobin13, sick sinus syndrome18, 
Crohn’s disease19, hypertriglyceridemia20. To 
the best of our knowledge, ours is the first study 
to have comprehensively surveyed the genetic 
architecture of all known risk loci for a trait.
In part, our identification of rare variants at 
risk regions relies on the prior discovery of 
a genome-wide significant common variant 
association signal at each locus. This then 
permits a per-locus rather than genome-wide 
multiple testing correction when searching for 
additional independent association signals. 
Only particularly strong rare variant signals 
would, on their own, generate significance 
levels reaching the genome-wide threshold 
typically used in GWAS studies (P<5x10-8). 
Alternative methods, such as collapsing rare 
variant signals across a gene or functional 
categories of genes have therefore been 
suggested as approaches to the same 
problem21. Although a rare variant may have 
occurred on a recent haplotypic background, 
and thus show linkage disequilibrium at 
substantially longer range than common 
variants, we deliberately restricted our 
search to around the common variant linkage 
disequilibrium blocks as to do otherwise would 
have incurred a considerably greater penalty 
from multiple testing. Therefore, although our 
study provides considerable encouragement 
for exome and whole genome sequencing 
efforts aimed at identifying rare risk variants 
(not necessarily restricted to GWAS loci) in 
common complex diseases, it further highlights 
the statistical challenges of establishing rare 
variant associations.
We used a dense genotyping strategy and 
stepwise conditional association analysis, 
but did not identify any rare highly penetrant 
variants that might explain the genome-wide 
significant common SNP signals at any of the 
39 loci. Our study does have limitations in 
this regard, particularly i) analysis restricted 
to 0.1cM linkage disequilibrium blocks; ii) the 
limited control resequencing sample size of 
the 1000 Genomes Project pilot CEU dataset; 
iii) the limited case resequencing sample size; 
and iv) case resequencing limited to three 
loci for celiac disease, and selected loci for 
other immune diseases. We observed a weak 
trend towards lower MAF (P=0.042, Wilcoxon 
test, Supplementary Table 1) for the best 
fine-mapping SNP (Immunochip experiment) 
versus the lead SNP from our 2010 tag SNP 
GWAS (measuring MAF in a subset of samples 
genotyped in both datasets). One signal 
showed substantially higher MAF (>25% 
change) on fine-mapping, four signals showed 
substantially lower MAF on fine mapping 
(Supplementary Table 1), yet all fine-mapping 
variants corresponding to lead GWAS SNPs 
remained common (MAF>0.10). We suggest 
that these changes in MAF upon fine-mapping 
of lead GWAS SNPs simply reflect more 
precise measurement of common frequency 
risk haplotypes. Although we cannot exclude 
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Top variant  
(dbSNP130 id)  
Chr  HapMap3 CEU LD 
blockb 
positions (hg18) 
(n markers, size)  
MAF c P d OR  Highly correlated (r 2>0.9) 
variants  
positions (hg18) 
(n markers, size)  
L ocalization: protein coding 
genes 
(RefSeq track UCSC/ hg18) 
rs4445406 1 2396747 - 2775531  
(358, 379kb)  
0.344 5.4x10-12 0.87 2510162 - 2710035  
(27, 200kb) 
C1orf93 , MMEL1 , TTC34  
rs72657048 1 25111876 - 25180863 
(125, 69kb) 
0.498 3.8x10 -6 0.92 25162321 - 25177139  
(18, 15kb)  
0 - 10kb 5’ & 1 st exon RUNX3  
rs12068671  1 170917308 - 171207073  
(355, 290kb)  
0.185 1.4x10 -10 0.86 170940206 - 170948695 
(11, 8kb)  
35 - 43kb 5’ FASLG 
signal 2  
rs12142280  
1 “ 0.180 8.3x10 -9 d 0.87 171129607 – 171131275  
(2, 2kb) 
intergenic between FASLG  and 
TNFSF18  
rs1359062 1 190728935 - 190814664 
(181, 86kb)  
0.180 2.5x10 -25 0.77  190786488 - 190811722  
(17, 25kb)  
0 - 24kb 5’ & 1 st exon RGS1 
  signal 2 
rs72734930  
1 “ 0.022 3.7x10 -4 d 1.23 190779182  
(1)  
32kb 5’ RGS1 
rs10800746 1 199119734 - 199308949 
(331, 189kb)  
0.305 2.6x10-8 0.89 199148015 
(1)  
9th intron C1orf106  
rs13003464 2 60768233 - 61745913  
(1047, 978kb)  
0.388 4.3x10 -16 1.17  61040333 - 61058360 
(3, 18kb)  
exons 5-11 PUS10 
rs10167650 2 68389757 - 68535760 
(357, 146kb)  
0.266 1.3x10 -4 0.92 68493221 - 68499064 
(4, 6kb) 
intergenic between PLEK  and 
FBX048 
rs990171 2 102221730 - 102573468  
(894, 352kb) 
0.225 1.2x10 -16 1.20 102338297 - 102459513  
(45, 121kb)  
IL18R1 , IL18RAP  
rs1018326 2 181502502 - 181972196  
(898, 470kb) 
0.418 3.1x10 -16 1.16 181708291 - 181803246 
(24, 95kb) 
intergenic between UBE2E 3 and 
ITGA4 
rs6715106  2 191581798 - 191715979  
(203, 134kb)  
0.058 8.4x10-9 0.79 191621279 - 191643278  
(4, 22kb) 
exons 6-14 STAT4 
signal 2  
rs6752770  
2 “ 0.296 1.3x10 -6 d 1.10 191681808 
(1)  
intron 3 STAT4 
signal 3  
rs12998748  
2 “ 0.119 2.6x10-4 d 0.90 191656882 
(1)  
intron 3 STAT4 
rs1980422 2 204154625 - 204524627 
(642, 370kb)  
0.233 1.4x10 -15 1.19 204318641 - 204320303 
(2, 2kb) 




2 “ 0.217 1.6x10 -5 d 0.91 204470572 – 204478299 
(2, 8kb) 




2 “ 0.039 1.3x10 -4 d 1.20 204158521 - 204168206 
(5, 10kb)  
111  – 121 kb 5’ CD28 
rs4678523 3 32895606 - 33063377  
(260, 168 kb) 
0.313  2.4x10-7 1.11  33012725 - 33012756  
(2, 31bp)  
intergenic between CCR4  and 
GLB1  
rs2097282 3 45904804 - 46625997 
(1343 , 721kb)  
0.314 1.1x10 -20 1.20 46321275 - 46377631  
(27, 56kb)  




3 “ 0.361 8.6x10-9 d 1.12 46162711 – 46180690 
(2, 18kb) 
38 – 55 kb 3’ CCR1  
signal 3 
rs60215663 
3 “ 0.070 4.8x10-5 d 1.16 46458634 – 46480319 
(7, 22kb)  
exons 2-13 LTF  (NM_002343.3)  
rs61579022 3 120587671 - 120783345  
(372 , 196kb) 
0.390 9.9x10-9 1.11  120601187 - 120605968 
(4, 5kb) 
intron 10 ARHGAP31  
[imm_3_161120372]  3 161065075 - 161237201  
(423, 168kb)  
0.111  2.6x10-27 1.36 161112778  - 161147744  
(4, 35kb)  








3 “ 0.455 8.1x10 -8 d 1.12 161136316 – 161168494 
(6, 32kb) 
intergenic between SCHIP1  and 
IL12A  
rs2030519 3 189552054 - 189622323 
(142, 70kb) 
0.486 3.0x10 -49 0.76 189587750  - 189602595 
(8, 15kb)  
intron 2 LPP  
rs13132308  4 123192512 - 123784752  
(1294, 592kb) 
0.166 1.9x10 -38 0.71 123269042 - 123770564  
(11, 502kb)  
multiple genes 
(KIAA1109 , ADAD1 , IL2 , IL21 ) 
signal 2 
rs62323881 
4 “ 0.073 8.6x10-5 d 1.15  123257527 – 123722990 
(87, 465kb)  
multiple genes 
(KIAA1109 , ADAD1 , IL2 , IL21 ) 
rs1050976  6 315547 - 402748 
(199, 87kb)  
0.488 1.8x10 -9 0.89 353079 - 355417  
(3, 2kb)  
3’ UTR IRF4  
(NM_002460.3)  
signal 2  
rs12203592  
6 “ 0.183 2.6x10-4 d 0.91 341321  
(1)  
intron 4 IRF4  
(NM_002460.3) 
rs7753008  6 90863556 - 91096529 
(341, 233kb)  
0.380 2.7x10 -7 1.10 90866360 - 90875874 
(5, 10kb)  
intron 2 BACH2  
(NM_001170794.1)  
rs55743914  6 127993875 - 128382483 
(572, 389kb)  
0.239 1.1x10 -18 1.21 128332892 - 128335255  
(2, 2kb) 




6 “ 0.150 1.2x10 -5 d 0.89 128307943 - 128339304  
(15, 31kb)  
PTPRK  exons 28-30, 3’UTR , to 
24kb 3’  
rs17264332  6 137924568 - 138316778  
(864, 392kb) 
0.211 5.0x10-30 1.29 138000928 - 138048197  
(6, 47kb)  
intergenic between OLIG3  and 
TNFAIP3  
signal 2 
 [imm_6_138043754]  
6 “ 0.190 2.1x10 -7 d 0.88 138015797 – 138043754  
(4, 28kb) 
intergenic between OLIG3  and 
TNFAIP3  
rs182429 6 159242314 - 159461818 
(514, 220kb) 
0.427 8.5x10-16 1.16 159385965 - 159390046 
(4, 4kb) 




6 “ 0.071 2.8x10-6 d 1.18 159418255 
(1)  
32kb 5’ TAGAP (NM_152133.1)  
[1kg_7_37384979 ] 7 37330503 - 37406978 
(213, 76kb)  
0.101 2.1x10 -8 1.18 37366994 - 37404402 
(31, 37kb)  
intron 1 ELMO1  
rs10808568 8 129211716 - 129368419 
(400,157kb)  
0.256 2.2x10-5 0.91 129333242 - 129345888 
(4, 13kb)  
151 - 163kb 3' of PVT1 
rs2387397  10 6428077 - 6585110 
(411, 157kb)  
0.229 1.9x10 -8 0.88 6430198 
(1)  
intergenic between PFKFB3  and 
PRKCQ  
Table 2  Risk variant signals at genome-wide significant celiac disease loci.
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the possibility that a single high-penetrance 
lower-frequency variant explains most of the 
association signal at a locus, especially without 
more comprehensive case resequencing, we 
find no evidence in support this possibility in 
the current fine-mapping experiment. Nor 
can our stepwise selection procedure robustly 
refute the “synthetic association” hypothesis - 
in particular that a combination of multiple rare 
variants jointly explains the association signal22 
- although similarly we have not observed so far 
evidence supporting this possibility.
We established at genome wide significance 13 
new loci for celiac disease, most of which have 
been reported previously at lesser significance 
or for another immune-mediated disease. The 
Illumina Hap550 chip (used in our 2010 GWAS) 
should have detected 10 of the 13 new loci, 
and in total 39 of the 57 independent non-HLA 
signals that we report. A current genotyping 
platform, the Illumina Omni2.5 chip would 
have detected 12 of the 13 new loci, and in total 
50 of the 57 independent non-HLA signals that 
we report. Neither chip would have provided 
the finer scale localization of the Immunochip. 
The thirteen new loci contain many candidate 
genes of immunological function (P=0.0002 
for enrichment of the Gene Ontology term 
“immune system process”23), in line with 
expectations from our previous studies. We 
also show evidence suggesting substantial 
additional signals at other immune-mediated 
disease loci, which lie beneath the genome 
wide significance reporting threshold applied 
to the current dataset. It is a point of debate 
whether such strict (P<5x10-8) criteria should 
apply - a Bayesian analyst might apply a higher 
prior at a locus already reported in another 
immune-mediated disease. Alternatively, an 
Immunochip-wide P value with a Bonferroni 
correction for independent SNPs, as used 
recently for the Cardiochip custom genotyping 
project24, of P<1.9 x 10-6 (Online Methods) would 
yield 16 additional celiac disease loci. These 16 
loci also mostly contain immune system genes. 
An analysis of these currently intermediate 
significance signals would gain substantial 
additional power by a meta-analysis across 
the several hundred thousand samples from 
multiple immune-mediated disease collections 
presently being run on Immunochip.
Non-HLA loci meeting genome-wide significance (P<5x10-8) in the current Immunochip dataset, or previous GWAS/replication dataset5, are shown. Loci reported 
for the first time for celiac disease at genome wide significance are shown in bold in the Top variant column.
rs7104791  11  110682429 - 110815769  
(3, 133kb)  
0.209 1.9x10 -11 1.16 not high-density genotyped [region: POU2AF1 , C11orf93 ] 
rs10892258 11  117847131 - 118270810  
(466, 424kb) 
0.237 1.7x10 -11 0.86 118080536 - 118085075  
(5, 5kb)  
intergenic between TREH  and 
DDX6 
rs61907765  11  127754640 - 127985723  
(480, 231kb)  
0.213 3.4x10 -13 1.18 127886184 - 127901948 
(6, 16kb) 
5kb 5' & 1 st exon ETS1 
(NM_001162422.1)  
rs3184504 12 110183529 - 111514870  
(938, 1331kb)  
0.488 5.4x10-21 1.19 110368991 - 110492139  
(4, 123kb)  
5' UTR & exons 1 -3 SH2B3; 
exons 2-25 & 3' UTR ATXN2 
rs11851414  14 68238574 - 68387815  
(338, 149kb)  
0.221 4.7x10 -8 1.13  68329159 - 68341722 
(3, 13kb)  
1kb 5' & 1st exon ZFP36L1  
rs1378938  15 72397784 - 73270664 
(23, 873kb)  
0.278 7.8x10 -9 1.13  not high-density genotyped [region inc. CLK3 , CSK and 
multiple genes] 
rs6498114 16 10834038 - 10903351  
(8, 69kb) 
0.246 5.8x10-10 1.14 not high-density genotyped [region: CIITA ] 
rs243323 16 11220552 - 11385420  
(446, 165kb) 
0.300 2.5x10 -5 0.92 11254549 - 11268703  
(12, 14kb)  
11kb 5', all of SOCS1, 1kb 3'  
signal 2 
[imm_16_11281298]  
16 “ 0.004 1.3x10 -4 d 1.70 11281298 
(1)  




16 “ 0.169 2.0x10-4 d 1.10 11292457  
(1)  
10kb 5’ PRM1  
rs11875687  18 12728413 - 12914117  
(411, 186kb)  
0.150 1.9x10 -10 1.17  12811903 - 12870206 
(16, 58kb)  
exons 2-5 PTPN2 (NM_080422.1)  
signal 2 
rs62097857 
18 “ 0.040 5.2x10 -5 d 1.20 12847758  
(1)  
intron 2 PTPN2 
(NM_080422.1)  
rs1893592  21 42683153 - 42760214 
(226, 77kb)  
0.282 3.0x10 -9 0.88 42728136 
(1)  
intron 9 UBASH3A (NM_018961)  
rs58911644 21 44414408 - 44528088 
(239, 114kb)  
0.193 6.2x10-7 0.89 44446245 - 44453549 
(8, 7kb)  
18 - 25kb 3' ICOSLG  
rs4821124  22 20042414 - 20352005 
(131, 310kb)  
0.186 5.7x10 -11 1.16 20250903 - 20313260 
(36, 62kb) 
UBE2L3 , YDJC  
 
rs13397  X  152825373 - 153043675  
(88, 218kb) 
0.133  2.7x10 -8 1.18 152872114 - 152937386  
(4, 65kb) 
HCFC1 , TMEM187 , IRAK1  
 
rs1250552 10 80690408 - 80774414  
(223, 84kb) 
0.470 8.0x10-17 0.86 80728033 
(1)  
intron 14 ZMIZ1 



















































































































































































































































































Non-conditioned P values shown for loci with multiple independent signals (from Table 2). The most associated variant for a signal shown in bold colour, further 
variants in r2>0.90 (calculated from the 24,249 sample Immunochip dataset) shown in normal colour. First signal coloured blue, second coloured red, third coloured 
green. Squares indicate markers present in our previous celiac disease GWAS post quality control dataset (Illumina Hap550)5
Figure 2 Loci with multiple independent signals
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We found that our previous GWAS using tag 
SNPs gave very similar estimates of effect 
size to our current fine-mapping experiment 
(Supplementary Table 1), in contrast to a 
simulation study which suggested that GWAS 
markers often underestimate risk14. We 
have, however, found substantial evidence 
for multiple additional signals at known loci 
and report many new loci. In Europeans, the 
current 39 non-HLA loci now explain 13.7% of 
coeliac disease genetic variance (HLA accounts 
for a further ~40%). We also show a long tail of 
likely effects of weaker significance, which will 
explain substantial additional heritability.
Only one of the variants reported here was 
discovered by a disease-specific resequencing 
study: ccc-18-12847758-G-A (rs62097857), 
a marker identified by the WTCCC group’s 
resequencing of Crohn’s disease cases and 
controls (Supplementary Note) and also 
present in the Watson genome. We submitted 
for Immunochip ~4,000 variants from high 
throughput resequencing of pools of 80 
celiac disease cases for extended genomic 
regions at three loci (RGS1, IL12A, IL2-IL21, 
Supplementary Note). These did not contribute 
additional signals over and above those 
obtained from the 1000 Genomes Project 
pilot CEU variants, although did contribute to 
increase the numbers of variants correlated 
with each signal (i.e the set of markers that 
likely contains the causal variant(s)) and more 
precisely define the bounds of the signal 
localization. We note that larger scale case 
resequencing (e.g. many hundreds of samples) 
would identify a rarer spectrum of variants than 
the current study, and has previously been used 
with success at selected genes and phenotypes.
The possibility of performing fine-scale 
mapping of GWAS regions using e.g. 1000 
Genomes Project data has been discussed as a 
natural follow-on strategy for such studies25,26 
and has been recently used to identify risk 
variants in APOL1 in African-Americans with 
renal disease27. Our current report is the first 
to test such a strategy on a large scale in a 
complex disease. At multiple regions, we were 
able to refine the signal to a handful of variants 
over a few kilobases or tens of kilobases, 
although some regions (e.g. IL2-IL21) were 
resistant to this approach presumably due to 
particularly strong linkage disequilibrium. Most 
GWAS publications report signals mapping to 
a “LD block” based on HapMap recombination 
rates (sample size, 60 CEU families). In our 
data, where we have both i) much denser 
genotyping than GWAS chips (mean 13.6x at 
celiac loci versus the Illumina Hap550 chip) 
and ii) nearly 25,000 genotyped samples for 
the linkage disequilibrium calculations, we are 
able to observe much finer scale recombination 
and more precisely estimate of the bounds 
of nominimal recombination intervals. Our 
findings are similar in terms of genotyping 
density and the resulting fine-mapped region 
size and lack of haplotype-specific effects to 
an earlier study of the IL2RA locus in type 1 
diabetes26. At the majority of regions a tight 
block of highly correlated variants was seen, 
rather than a gradual decay of correlation (e.g. 
Figure 2 plots for IL12A, PTPRK). At many loci, we 
have now defined a handful of likely candidates 
to be the causal variant(s) to be taken forward 
into functional studies, although we may have 
missed candidate variants at some regions 
due to the sample size of the 1000 Genomes 
Project pilot CEU dataset (60 individuals), 
their status as controls, and our estimate that 
~25% of these variants were excluded from 
our final dataset. These might be assessed by 
imputation methods28, but our approach – 
particularly with regards to the more sensitive 
conditional regression analysis - has been to 
prefer the more accurate direct genotyping of 
all assayable variants. As and when much larger 
whole genome resequencing based reference 
datasets become available (e.g. the main 1000 
Genomes Project), these might be used to 
impute into our Immunochip dataset, including 
substantially lower frequency variants29. We 
also investigated whether our use of multiple 
ethnic subgroups within Europe (e.g. southern 
European Spanish versus northern European 
UK) or the relatively small Indian collection 
contributed to fine mapping, and found that 
in most cases, the same degree of localization 
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was possible with just the UK collection alone 
(data not shown).
Our data suggest that most common risk 
variants might function by influencing 
regulatory regions, consistent with those 
previously reported in other immune-
mediated diseases, and complex traits in 
general11. The exception is the SH2B3 nsSNP 
imm_12_110368991 (rs3184504), reported in 
our 2008 celiac GWAS4, which even with the 
fine-mapping of 938 polymorphic variants 
from the SH2B3 region remains the strongest 
signal at this locus thus suggesting it may be 
the causal variant. The same variant has been 
associated with other immune diseases, and a 
functional immune phenotype5. Interestingly, 
we observed a common ~980bp intergenic 
deletion between IL2 and IL21 (DGV40686, 
accurately genotyped by Infinium assay with 
control MAF 7.3%) correlated with the second 
independent signal at this region, although we 
have no evidence to suggest causality. 
Our fine-scale localization approach has 
identified likely causal genes at many loci, 
and at eight genes signals localized around 
the 5’ or 3’ regulatory regions. For example, at 
the THEMIS/PTPRK locus, two independently 
associated sets of variants cluster in the 3’ UTR 
of the PTPRK gene (one, imm_6_128332892/
rs3190930 in a predicted binding site for miRNA 
hsa-miR-1910). PTPRK, a TGF-beta target 
gene, is involved in CD4+ T cell development 
and a deletion mutation causes T helper 
deficiency in the LEC rat strain30. The signal at 
TAGAP lies within a 4kb region immediately 
5’ of the transcription start site, presumably 
containing promoter elements. At ETS1, the 
signal comprises 6 variants overlapping the 
promoter and 1st exon of the T cell expressed 
isoform NM_001162422.1, and one of the 
variants (imm_11_127897147/rs61907765) has 
predicted regulatory potential and overlaps 
multiple transcription factor binding sites 
(UCSC GenomeBrowser ChipSeq and ESPERR 
tracks, Supplementary Table 2). Similarly 
interesting variants are observed in regulatory 
regions of RUNX3 (imm_1_25165788/
rs11249212), and RGS1 (imm_1_190807644/
rs1313292, imm_1_190811418/rs2984920) 
(Supplementary Table 2). Such an approach to 
identify the functional potential of risk variants 
was recently successful used to define a 
causal systemic lupus erythematosus TNFAIP3 
variant31. Although we have localized signals 
at many loci, and recent research suggests 
the likely causal gene is often located near the 
most strongly associated variant15, only more 
detailed functional studies (e.g. transcription 
factor binding assays31 and transcriptional 
activity assays of constructs with individual 
single nucleotide alterations at risk SNPs32), will 
prove precisely which gene variants might be 
causal.
 
We conclude that dense fine mapping of 
regions identified through GWAS studies can 
uncover a complex genetic architecture of 
independent common and rare variants, and 
often successfully localize risk variant signals 
to a small set of SNPs to be taken forward into 
functional assays. Denser fine mapping studies, 
utilising larger resequencing sample sizes from 
both cases and controls over broader regions, 
might provide further resolution of GWAS 
signals.
ONLINE METHODS
Subjects. Written informed consent was 
obtained from all subjects, with Ethics 
Committee / Institutional Review Board 
approval. All individuals, except the Indian 
population sample, are of European ancestry. 
DNA samples were from blood, lymphoblastoid 
cell lines or saliva.
Affected celiac individuals were diagnosed 
according to standard clinical criteria, 
compatible serology and in all cases small 
intestinal biopsy - most cases were diagnosed 
using the revised ESPGHAN criteria as a 
minimum requirement34. More specific 
requirements were: UK cases3-5 (hospital 
outpatients, n=1145) required Marsh III stage 
intestinal biopsy (HLA-DQ2.5cis tag SNP 
rs2187668 MAF=0.4699); UK cases 4,5 (Coeliac 
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UK members, n=6583), self-reported diagnosis 
by intestinal biopsy (note the rs2187668 
MAF=0.4803 was similar to UK hospital cases, 
versus combined UK controls MAF 0.1419); Italy 
(Milan) 5,35 and Polish5 required Marsh III stage 
intestinal biopsy and positive endomysial/
tissue transglutaminase antibodies; Spain 
(CEGEC)36 required at least Marsh II stage 
intestinal biopsy; Netherlands cases5 required 
Marsh III stage intestinal biopsy, or Marsh II 
stage intestinal biopsy with compatible HLA-
DQ type; India (Punjab) cases required Marsh 
III stage intestinal biopsy and strongly positive 
tissue transglutaminase antibodies; Italy 
(Naples, Rome) required abnormal intestinal 
biopsy and positive tissue transglutaminase 
antibodies37.
The UK 1958 Birth Cohort and UK Blood 
Services-Common Controls are unselected 
population controls. Polish controls and Italian 
(Naples) controls excluded celiac serology 
positive samples. Spain (Madrid) controls 
were unselected blood donors and hospital 
employees. Spain (CEGEC), Italy (Rome), 
Indian (Punjab) controls were unselected blood 
donors. Italian controls (Milan) were unselected 
healthy individuals. Netherlands controls 
were unselected blood donors and population 
controls.
SNP selection: All 1000 Genomes Project low-
coverage whole genome sequencing pilot CEU 
variants within 0.1cM of the lead SNP for each 
disease and region were selected. The Sept 
2009 release comprising 60 CEU individuals 
was used (~5x mean read-depth whole genome 
sequencing) selecting markers called in at least 
two of the Broad Institute / Sanger Institute / 
University of Michigan algorithms. Additional 
genomic region re-sequencing content was 
submitted for Immunochip at specific loci from 
coeliac disease, Crohn’s disease and type 1 
diabetes cases and controls (Supplementary 
Note).
Genotyping. Samples were genotyped using 
the Immunochip as per Illumina’s protocols 
(at labs in London, Hinxton, Groningen and 
Charlottesville). NCBI build 36 (hg18) mapping 
was used (Illumina manifest file Immuno_
BeadChip_11419691_B.bpm). 
Data Quality Control. Very low call rate 
samples and variants were first excluded (and 
samples repeated). The Illumina GenomeStudio 
GenTrain2.0 algorithm was used to cluster an 
initial 2,000 UK samples. Subsequently with 
additional sample data (case and control data 
were analysed together) clusters were re-
adjusted or excluded (manual or automated) 
for variants with low quality statistics (call 
rate<99.5%, low GenCall score, many high-
intensity no-calls). This method was superior to 
the GenoSNP or Illuminus clustering algorithms 
(not shown). A cluster set based on 172,242 
autosome/X-chromosome variants (available 
on request) was then applied to all samples. 
Samples were excluded for call rate <99.5% 
across 172,242 markers. We then removed 
15,657 non-polymorphic markers (i.e. only one 
of three expected genotype clouds observed) 
which reflect a combination of ethnic-specific 
variants, allele-specific assay failure, as well as 
substantial false-positive rates in early next-
generation sequencing SNP calling algorithms.
Samples were excluded for incompatible 
recorded gender and genotype inferred gender, 
duplicates and first/second degree relatives. 
Potential ethnic outliers were identified by 
multi-dimensional scaling plots of samples 
merged with HapMap3 data, the subset of 
SNPs common to HapMap3 and Immunochip 
accurately identified the different HapMap3 
population samples. We considered the white 
European and Indian collections separately. 
Stepwise conditional logistic regression is 
sensitive to missing data and subtle genotyping 
error, and we therefore desired an ultra-high 
quality dataset. Markers were excluded from 
all sample collections for deviation from Hardy-
Weinberg equilibrium in controls (P<0.0001) 
and/or differential missingness in genotype no-
calls between cases and controls (P<0.001), in 
any of the seven collections. Finally we required 
a per-SNP call rate of >99.95% (a maximum of 
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12 no-call genotypes from 24,269 samples per 
autosomal marker), generating a dataset of 
139,553 markers (of which all but 372 indels are 
SNPs).
We visually inspected intensity plot genotype 
clouds for all markers described in Table 2 (and 
further potential loci with P<1.9x10-6), and 
confirmed all to be high quality.
Genotype data has been deposited at 
the European Genome-phenome Archive 
(EGA, http://www.ebi.ac.uk/ega/), which is 
hosted by the EBI, under accession number 
EGAS00000000053.
Statistical Analysis. Analyses were performed 
using PLINK v1.0738, using logistic regression 
tests with gender as a covariate, and collection 
membership (Table 1) as a factorized covariate. 
Stepwise conditional logistic regression was 
performed, in order of markers with the 
smallest P value. Graphs were plotted in R, and 
using a modified version of LocusZoom39.
We permuted affection status for the dataset 
at each region (Online Methods), to establish 
locus wide statistical significance thresholds for 
defining independently associated SNPs. For 
each locus, given by the linkage disequilibrium 
boundaries (Table 2) we calculated the 5th 
percentile based on the nominal P-value 
distribution for 1000 permutations controlling 
for multiple marker testing. This approach 
proved slightly more stringent than a per-
locus Bonferroni correction for independent 
(using an estimate for “independence” of 
pairwise r2<0.05) variants (Supplementary 
Table 3). We estimated our dataset contained 
26,146 completely uncorrelated variants 
(using pairwise r2<0.05 and a sliding 1000 SNP 
window). 
The fraction of additive variance was calculated 
using a liability threshold model40 assuming 
a population prevalence of 1%. Effect sizes 
and control allele frequencies were estimated 
from the UK dataset. Genetic variance was 
calculated assuming 50% heritability.
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ABSTRACT
Genome-wide association studies (GWAS) in coeliac disease have shown strong and replicable 
association to 26 non-HLA loci in individuals of European descent. Since coeliac disease is equally 
prevalent in northern India, we aimed to assess association to these 26 risk loci in a north Indian 
population and to see whether dense SNP genotyping in both populations could help refine the 
association signals. We first performed cross-ethnic mapping in 497 coeliac disease patients and 
736 controls from northern India and in 1150 Dutch cases and 1173 controls; we used Immunochip, 
a customized genotyping platform providing a higher SNP resolution than standard GWAS 
platforms. Due to differences in linkage disequilibrium (LD) structure between Europeans and 
north Indians, we applied two different strategies, which led to replication of 50% of the non-HLA 
loci. In an ‘exact’ analysis – directly testing for association of the index SNP – we replicated three 
loci, but in a ‘transferability’ analysis – testing the exact European SNP along with the variants in 
LD – we replicated 12 loci. The use of the densely probed Immunochip increased the replication 
rate by 15% compared to the standard GWAS platform. We also showed that four of the 26 non-
HLA loci were under positive selection pressure (IL18RAP, CCR1/5, SH2B3 and PLEK). Secondly, 
we narrowed down the association signals by using a cross-population analysis. We observed that 
the northern Indian population was characterized by less extensive long-range LD than our Dutch 
population. For five of the 26 non-HLA loci, this resulted in finer localization of the association 
signal and for another five loci we observed a shift in the association signal. Remarkably, the long-
range LD was broken down at the 592 kb IL2/IL21 locus and localized the association signal to a 
very small interval of 21 kb, near the promoter region of the KIAA1109 gene.
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INTRODUCTION
Over the past five years, genome-wide 
association studies (GWAS) have had 
tremendous success in mapping genetic loci for 
common, complex diseases. To date, more than 
4000 SNPs have been reported to be associated 
with the risk for more than 400 distinct traits1. 
Combining immune-mediated diseases has 
already established some 180 common variants 
with modest effect sizes and many more variants 
are expected to be identified that account for 
part of the remaining “hidden heritability”. The 
great majority of GWAS for immune-related 
diseases have been conducted in populations 
of European ancestry and it is likely that further 
risk alleles may be identified in populations 
with different ethnic backgrounds2. However, 
our knowledge of the genetic architecture of 
common complex diseases across multi-ethnic 
cohorts is rather limited and there is a clear 
need to replicate disease-associations across 
different ethnicities. A limited number of recent 
GWAS and replication studies in multi-ethnic 
cohorts, including African or Asian populations, 
suggest that Caucasian association signals 
can be generalized to populations with other 
ethnic backgrounds3-5. On the other hand, a 
literature search also showed that 25-55% 
of the association signals at shared loci are 
independent between populations (distance 
> 500 kb in each population). This suggests 
that disease aetiology is common between 
populations but that risk variants are often 
population-specific6. This observation has 
consequences for the design of cross-ethnicity 
replication studies.
Replication studies in ethnically different 
populations often attempt to replicate only 
the reported, and therefore most significant, 
SNP from a certain study or combined 
meta-analysis. Given the difference in linkage 
disequilibrium (LD) structure between distinct 
ethnic groups, such an approach may fail if 
this top-SNP ‘poorly’ tags the true risk variant 
in another population. Alternatively, the most 
significant and reported SNP, together with 
SNPs in LD with it, can be tested in additional 
and ethnically different samples7. One 
obstacle is, however, that  the available GWAS 
platforms have been designed to capture 
genetic variation in populations of Caucasian 
descent and have less power for other ethnic 
groups. We aimed to overcome some of these 
limitations by performing a cross-ethnic study 
of established risk loci in a northern Indian 
case-control cohort. 
Coeliac disease is an autoimmune 
inflammatory disease of the small intestine, 
caused by interaction with gluten in genetically 
predisposed individuals. It is the most common 
form of intestinal inflammatory disorder 
among Europeans with 1-3% prevalence8, 
and a similar 1% prevalence in the Indian sub-
continent9. The largest genetic risk to coeliac 
disease is conferred by variants in HLA genes, 
which  account for approximately 35-40% of the 
genetic risk10. Recent progress in understanding 
the genetic architecture of coeliac disease has 
led to the identification of 26 non-HLA loci in 
a meta-analysis of British, Dutch, Italian and 
Finnish populations, with replication in further 
cohorts of European origin10.
In this study, we focused on the 26 established 
non-HLA coeliac disease loci and assessed 
their replication in a north Indian population-
based sample of 497 patients and 736 unrelated 
controls. We combined our replication study 
with fine-mapping, as we used information 
on 15,851 SNPs across these 26 loci (i.e. on 
average 610 SNPs per locus) which were 
present on the Immunochip. The Immunochip 
is a custom-made genotyping platform 
with ~200,000 markers, of which the great 
majority map within the 183 loci associated 
to immune-related diseases11,12. This platform 
was specifically designed to fine-map currently 
known GWAS loci and results, on average, in a 
12-15x greater marker density than a standard 
GWAS chip. 
We applied two different strategies to assess 
the genetic architecture of coeliac disease 
in the north Indian population: (1) an ‘exact’ 
analysis, directly testing the index top-
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(2) a ‘transferability’ analysis7, testing the exact 
European SNP along with the variants in LD 
(r2 >0.05) which were present on the 
Immunochip. Our main objectives were to 
evaluate the known coeliac disease-associated 
loci in an ethnically distinct north Indian 
population, and to refine the association 
signals. Using this approach, we convincingly 
replicated 13 of the 26 loci (50%). Had we tested 
only the reported European variant using the 
‘exact’ approach, the replication success rate 
would have been 19%. We further performed 
the cross-ethnic fine-mapping by comparing 
LD structures between the north Indian and 
Dutch cohorts for all 12 transferable loci and 
assessed the signatures of selection pressure 
acting upon them.
RESULTS
We obtained high quality genotype data 
for 160,448 polymorphic variants that were 
common in 497 north Indian coeliac disease 
cases and 736 north Indian controls, and in 1150 
Dutch coeliac disease cases and 1173 Dutch 
controls. The first three components of multi-
dimensional scaling analysis (MDS) showed that 
the north Indian samples overlapped with the 
GIH samples from HapMap3 (Gujarati Indians 
in Houston, Texas) (Figure_S1). However, the 
analysis of GIH and our north Indian samples 
indicated subtle population substructures. The 
second component separated the north Indian 
samples from the GIH samples, while the third 
component identified further gradients in both 
these populations. The fact that the first and 
third components seemed to extract similar 
information from both the GIH and our cohort 
indicates that the bias is not due to our cohort 
sampling but is a genetic characteristic of this 
ethnic population. 
After stringent quality control (see Material and 
Methods), we obtained 17,979 SNPs mapping 
within the 26 non-HLA loci, 15,851 of which 
were polymorphic in at least the north Indian 
or the Dutch cohort and therefore informative 
for further analysis. Of the set of 15,851 SNPs, 
8,664 (54.7%) were variants with a low minor 
allele frequency (MAF<0.05) in the north 
Indians and 8,484 (53.5%) in the Dutch.
Replicating European signals in north Indian 
cohort
As expected, we observed strong association 
of the north Indian coeliac disease cases to 
the HLA region (rs2854275, p=2.634-49). We 
observed strong inflation in the test statistics 
among all Immunochip variants (λ=2.91), which 
is mainly driven by the HLA locus (Figure 1A) 
as exclusion of the HLA region SNPs reduced 
the λ to 1.04 (Figure 1B). As the Immunochip 
is preselected for “immune” SNPs, it is difficult 
to distinguish enrichment of true signals 
from population stratification. When we 
Figure 1 We observed strong inflation in the test statistics for all the Immunochip variants when including the HLA region 
(λ=2.91; panel A). This inflation decreased to λ=1.04 after excluding some 10,000 markers from the HLA locus, a well 
known, strong genetic risk factor for coeliac disease (panel B). The SNPs submitted for replication of the ‘reading and math 
skills’ were used as ‘null’ variants not confounded by the immune signal, to test for population stratification in our north 
Indian cohort (λ of 1.01; panel C). Variants in the 26 non-HLA, coeliac disease loci were strongly enriched for association 
signals (panel D).




Figure 2 Examples of cross-ethnic mapping results. A) Shifted and more localized association signal in the north Indian samples compared 
to the Dutch association. Note that the association signal in the smaller north Indian samples is stronger than in the Dutch samples, sug-
gesting that some loci may have stronger effects in one population than the  other. PLEK is also a locus for which we observed positive 
selection pressure. B) A cluster of correlated variants localizes in the intronic region of THEMIS gene, whereas the Dutch signal maps 124 
kb upstream, pointing towards the 3’UTR of the PTPRK gene. At this locus the index SNP was successfully replicated in north Indians 
(P<0.05). C) Overlapping signal between the Dutch and north Indians, with tighter SNP clustering over a 21 kb block in north Indians, 
compared to the dispersed association over a 103 kb block in the Dutch. D) The overlapping signal between the two populations is broadly 
spread across the region. However, in north Indians a cluster of correlated SNPs localizes in the small 21 kb LD block. Note the LD break-
age in north Indians due to the larger number of low frequency SNPs (MAF<0.1), which results in two smaller LD blocks. 
Dark blue represents the association signal in the north Indian samples and grey in the Dutch. Dark green depicts the most associated 
transferable SNP, and light green the SNPs strongly correlated with it (r2>0.08). Yellow depicts all the transferable SNPs and red indicates 
the index SNP. Colours may overlap. 
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Author summary
Most disease gene mapping approaches 
have been conducted in populations of 
European descent. It is unclear how many 
of these ﬁndings can be translated across 
diﬀerent racial/ethnic groups: are the risk 
alleles the same, are the eﬀects of 
associated alleles comparable, and how 
comparable are the localization signals? 
Fine-mapping is one approach to better 
localize the signals and thereby bring us 
closer to translational studies and a 
practical application of genetic ﬁndings. 
Cross-ethnic mapping in distinct 
populations has the potential to aid such 
ﬁne-mapping eﬀorts. We applied this 
mapping strategy to ﬁne-map 26 non-HLA 
loci associated to coeliac disease in 
Europeans. For the ﬁrst time, we used 
dense genotyping information from a 
custom-made platform to elucidate the 
best possible linkage disequilibrium 
resolution. We replicated 50% of these risk 
loci in a northern Indian cohort. For ﬁve of 
the regions, the signals from the north 
Indian population clustered separately 
from those in Europeans, which allowed us 
to reﬁne the association signal. In ﬁve 
other loci, we were able to narrow down 
the association to a smaller genetic 
interval, covering a cluster of correlated 
markers. This indicates that we may have 
identiﬁed regions which are likely to 
capture the causative variants.
used the 2,626 ‘null variants’ present on the 
Immunochip (see Materials and Methods), 
we noted that there was no inflation (λ=1.01), 
implying that the observed associations were 
not confounded by population substructure 
(Figure 1C). We observed a clear indication of 
association for the 15,851 SNPs residing in the 
26 non-HLA coeliac disease loci (λ=1.27, Figure 
1D).
The initial association of coeliac disease to 
the 26 non-HLA loci, all of which have modest 
effects on the genetic risk (OR of 0.74 -1.36), 
was performed in a sample size of over 5,000 
coeliac cases and 10,000 controls10. We realize 
that our north Indian cohort was underpowered 
to detect associations with small effects 
although we did reach 80% power for common 
SNPs (MAF>0.25) and OR>1.3 (Figure S2). 
‘Exact’ analysis
For the ‘exact’ analysis we aimed to test 
the same top-associated SNP reported for 
Europeans (‘index’ SNP), as described by Dubois 
et al.10, in our north Indian cohort. All of the 26 
European index SNPs were polymorphic and 
frequent (MAF>0.05) in north Indians, although 
the correlation of the minor allele frequencies 
for these 26 index SNPs between the north 
Indians and Dutch was much lower (r2=0.35) 
than the correlation between European cohorts 
(mean r2= 0.9) (Figure S3). Of the 26 index SNPs, 
five were directly replicated at p< 0.05, with the 
same direction as in Europeans (Table S1). The 
five SNPs tagged the following genes: IL12A 
(rs17810546, p = 0.02), ICOSLG (rs4819388, 
p = 0.035), ZMIZ1 (rs1250552, p =0.04), 
THEMIS/PTPRK (rs802734, p=0.047), and LPP 
(rs1464510, p=0.048) loci. Of the remaining 
21 variants that did not reach the replication 
significance threshold, 14 (66%) showed the 
same directionality as in Europeans, which is 
more than the 50% chance expected under the 
null hypothesis (p=0.05, binomial probability, 
we excluded two loci for which OR was 1) 
(Figure S4). 
‘Transferability’ analysis 
We next performed an analysis that accounts for 
the different LD patterns between Europeans 
and north Indians. In this we tested all the 
variants in each of the 26 non-HLA loci that 
were in LD with the top SNP (r2 > 0.05, based on 
CEU, 1000 Genomes Project). To claim a locus 
as ‘transferable’, at least one SNP per locus had 
to be associated at p<0.01 in our north Indian 
sample. Twelve of the 26 loci were transferable 
to Indians, which was significantly more than 
expected by chance (p
permuted
 = 0.031). These 
were: PLEK, IL18RAP, ITGA4/UBE2E3, CCR1/5, 
IL12A, IL/IL21, THEMIS/PTPRK, TNFAIP3, 
TAGAP, ZMIZ1, ETS1 and ICOSLG (Table 1, 
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and Table S2 for details on non-transferred 
loci); the IL12A, THEMIS/PTPRK, ZMIZ1 and 
ICOSLG loci were also identified by the ‘exact’ 
analysis. None of the transferable variants 
demonstrated significant cross-population 




Coverage and transferability rate
To investigate how much we gained by using 
a dense genotyping platform in contrast to 
a standard GWAS chip, we calculated the 
transferability success rate of the 1,284 SNPs 
that map within the 26 coeliac disease loci 
that are shared between the Illumina Hap550 
platform and Immunochip. We replicated 
nine loci at p<0.01, yielding a 35% success 
rate compared to the 50% when using the 
Immunochip (Table S3).
The transferability rate will be strongly 
influenced by the actual coverage of the genetic 
variation. We therefore assessed how well the 
Immunochip covers total variation at coeliac 
disease loci in the 1000 Genomes European 
samples. There are 26,863 polymorphic 
variants annotated within coeliac disease loci 
in CEU, TSI, FIN and GBR individuals, 12,497 
of which (46%) are shared with Immunochip 
SNPs (821 were non-polymorphic in either the 
Indians or Dutch). 648 SNPs were genotyped 
on Immunochip but were not present in the 
1000 Genomes data. 5,632 variants (39%) of 
the non-genotyped 1000 Genomes variants 
(14,366) contribute to the common variation in 
Europeans (MAF>0.1). The remaining variation 
is of low frequency (MAF<0.05, Figure S5), and 
it is likely that these are largely population-
specific or falsely called sequence variants.
Cross-population LD measure
To assess if the north Indian transferability 
signals reflect European associations, we 
estimated the degree of LD correlation 
(quantified by pair-wise SNP LD, r2) between 
the European index SNP and the north Indian 
top transferable SNP in CEU and north Indian 
data. We observed that the north Indian 
transferable signals reflected the European LD 
(correlation coefficient r2=0.83) (Figure S6A). 
However, the majority of the transferable 
signals accumulated in the lower tail of r2 
values, with a small shift towards less tight LD 
in north Indians than in the CEU population. 
We also evaluated the LD correlation between 
all transferable variants (all SNPs in r2> 0.05 
based on CEU, 1000 Genomes data, and present 
in north Indians) and the top SNP (Figure S6B). 
We observed similar results, although the LD 
correlation between CEU and Indians was lower 
(r2=0.55), most of the transferable variants 
were located in the lower tail of r2 values.
Contrasting association signals
As a consequence of longer LD blocks, 
associations in Europeans often map to regions 
containing multiple genes and because of 
the strong LD, it can be difficult to pinpoint 
the true risk gene. Using ethnically distinct 
populations offers the opportunity to fine-map 
signals because of population differences in LD 
structure.
From the 13 loci that were replicated in north 
Indians, we excluded the LPP locus because it 
was only replicated by the direct SNP test. We 
then compared the overlap of the association 
signal patterns between north Indians and 
the Dutch and evaluated the LD structure 
(Figure S7). For five loci (IL18RAP, CCR1/5, IL12A, 
IL2/IL21 and ETS1), the pattern of association 
in north Indians was consistent with that seen 
in the Dutch. Nonetheless, for some loci, the 
association signal could indeed be refined to a 
smaller region. Although in the 2q12.1 region 
(IL18RAP locus) the European and north Indian 
signals overlap, the LD is lower in the north 
Indians and the main LD block covering the 
association signals is 7 kb smaller than in the 
Dutch. This LD block covers IL18R1, IL18RAP 
and part of SLC9A4 but clearly excludes IL1RL2 
and IL1RL1 (Figure S7). The only transferable 
SNP mapped in the intron of IL18R1. Both 
Dutch and north Indian association signals 
show very high D’ with the European Index 
marker (Table 1). At the CCR1/5 locus, both 
populations show a similar LD background and 
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overlapping association signals, which narrows 
down the association signal to a smaller region 
of ~250 kb, including the CCR1, CCR2, CCR3, 
CCR5, CCRL2 and LTF genes. The north Indian 
top transferable SNP mapped in the exon 2 of 
CCR5. 
At the IL12A locus, association signals localized 
in the intergenic region between SCHIP1 
and IL12A with the top transferable north 
Indian SNP mapping in a small LD block of 
6 kb (161176264 bp – 161182066 bp) near the 
promoter of IL12A. The coeliac disease region 
at chromosome 4q27 harbours four genes, 
including two plausible candidates for coeliac 
disease, IL2 and IL21. Due to the strong LD 
across the locus, the signal cannot be further 
refined. However, in our north Indian cohort the 
LD was broken down due to the larger number 
of low frequency SNPs (MAF < 0.1) (Figure 2D, 
Figure S7), resulting in two smaller LD blocks in 
north Indians, compared with one large block 
in the Dutch (Figure S8D). The association 
signal was also spread along the whole region, 
although an outstanding cluster of most 
strongly associated SNPs was located in the 
small 21 kb LD block (123246379 bp - 123267309 
bp) adjacent to the large LD block that covers 
the KIAA1109 gene and top European SNP. 
At the ETS1 locus, the LD architecture is very 
similar between the Dutch and north Indians and 
the cross-population signals overlap (Figure 2C, 
Figure S7). However, the north Indian signal is 
much more tightly clustered around the top 
European SNP (21 kb block, from 127882690 bp 
to 127904148 bp), whereas the Dutch signal is 
widely spread (a 103 kb region from 127882690 
bp to 127985506 bp). 
At the TNFAIP3 and ZMIZ1 loci only a single 
SNP was transferable, hence it was not possible 
to deduce the association patterns. At ZMIZ1 
locus, the top transferable north Indian SNP 
is localized in proximity to the European index 
SNP in the intronic part of the ZMIZ1 gene 
(Figure S7). 
The remaining five loci showed a shift in the 
association pattern. At 2p14 the Dutch signal 
spreads over the middle LD block and covers 
the PLEK gene, whereas the north Indian 
signal locates at 69 kb from the European top 
SNP, downstream of this gene (Figure 2A, 
Figure S7). The north Indian signal is located 
in a block of low LD and is poorly correlated 
with the European index signal. At 2q31.3 the 
north Indian association signal is stronger than 
that in the Dutch population. In the Dutch, 
this region is covered by three LD blocks, with 
the association signal mapping in the second 
block, an intergenic region downstream of the 
UBE2E3 gene. In north Indians the LD is even 
more broken down and the association signal 
localizes in two clusters of SNPs: first, in a small 
block in close proximity to the top European 
SNP, and second, in a distal and stronger signal 
in the block partly corresponding to third 
LD region. (Figure S7). At the 6q22.33 locus 
we observed a cluster of correlated variants 
in the intronic region of the THEMIS gene. 
Interestingly, however, the Dutch signal at this 
locus maps 124 kb upstream, clearly pointing 
towards the 3’UTR of the PTPRK gene (Figure 
2, Figure S7). At the 6q25.3 locus, the European 
top SNP is located in the first exon of the 
TAGAP gene, whereas the north Indian signal 
is located in the promoter region, which partly 
also overlaps with the Dutch signal (Figure S7). 
At the ICOSLG locus, the signal overlapped 
with the European one to some degree, but we 
noticed a tight cluster of SNPs further upstream 
of the ICOSLG gene (Figure S7), suggesting that 
the causal variant could be captured within the 
17 kb LD block (from 44435321 bp to 44452009 
bp). 
 
Evaluation of the selection pressure
To understand evolutionary variability at the 26 
coeliac disease loci, we estimated a pair-wise 
fixation index (Fst) using the north Indian and 
Dutch cohorts. We tested Fst for all 12 reported 
index SNPs (Table S4). We found suggestive 
evidence for positive selection pressure for 
previously reported IL18RAP (rs7559479), 
CCR1/5 (rs13098911), PLEK (rs17035378) and 
SH2B3 (rs653178) loci (Fst>0.079) values. 
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DISCUSSION
Recent cross-ethnic studies indicate that a 
large proportion of disease- or trait-associated 
common variants established in populations of 
European descent also contribute to the risk 
in other ethnic groups3,4,13. Yet this observation 
cannot be generalized because only a limited 
number of the GWAS were conducted in non-
European populations14. In this study we sought 
to replicate and narrow down coeliac disease 
loci associated in Europeans in a north Indian 
cohort. To efficiently capture the differences 
in genetic background between two ethnically 
distinct populations we used the Immunochip, 
a genotyping platform that, at present, offers 
the highest coverage of regions associated to 
immune-related disorders. We directly tested 
for association of the top European SNP (exact 
test) and also performed association of the 
‘index’ SNP together with variants in LD with 
it (transferability test). When investigating 
the LD correlation between index SNPs and 
transferable markers we noticed a trend 
towards a lower range of r2 values in north 
Indians than in the Dutch (Figure S6). This 
indicates a lesser degree of tagging properties 
between the index SNP and transferable 
markers in north Indians, which could negatively 
influence our replication success rate. Of the 26 
coeliac disease loci established in Europeans, 
five were replicated by the exact index SNP 
association analysis and 12 were replicated 
by the transferability approach, yielding a 
total of 13 unique, replicated loci. Overall, our 
replication success rate was 50%, compared 
to the 19% that we would have obtained by 
testing only the European index SNP.
We observed an advantage of using the 
Immunochip over a standard GWAS platform, 
with a 50% vs. 35% successful transferability 
rate. Nonetheless, despite the high marker 
density, we estimate that the Immunochip 
only covers approximately 50% of the 
European genetic variants (based on the 1000 
Genomes data, release May 2011) and mainly 
misses the low frequency variants. Low and 
rare frequency variants are more likely to 
be population-specific14, therefore even if 
they were included on the Immunochip they 
might have been of limited value. At the 
moment there is no sequence data available 
for the north Indian populations and it is 
difficult to estimate how well the Immunochip 
performs in this population. Most likely our 
transferability success rate is underestimated, 
while differences in haplotype frequencies and 
linkage disequilibrium mean it is likely that the 
Immunochip covers the genetic variation in 
north Indians less well than in Europeans.
India has been underrepresented in genome-
wide associations and our study is the first 
to perform an association study on coeliac 
disease in north Indians and to establish the 
association of 13 loci in this population. The lack 
of replication of the remaining 13 European loci 
may be due to the limited power of our study, 
and/or poor tagging properties of the causal 
variant of the tested SNPs in north Indians, but 
it is also likely that some European loci will not 
confer risk for coeliac disease in north Indians. 
Interestingly, despite the fact that our north 
Indian cohort was half the size of the Dutch 
cohort, the association signals at the ITGA4/
UBE2E3, PLEK, TAGAP and ICOSLG loci were 
equal or stronger in the north Indians than 
those in the Dutch. This indicates that some 
regions may confer different risk burdens to 
different populations. 
North Indians, although genetically close 
to Europeans, differ markedly in their allele 
frequencies from Europeans, which is partly 
reflected by a lesser degree of LD structure 
compared to Europeans15. The different allele 
frequencies and lower extent of long-range 
LD in north Indians resulted in different 
association signal localization, or allowed finer-
scale mapping at some loci. For example,  the 
IL2/IL21 locus consists of a large LD block of 315 
kb that covers the majority of the 591 kb region 
with highly correlated markers. It contains 
four genes: two are interleukins, IL2 and IL21, 
one plays a role in spermatogenesis (ADAD1), 
and one is a transcript of unknown function 
(KIAA1109). Because of its very strong LD, this 
region has not been fine-mapped successfully 
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using European samples. Our study shows 
that north Indians have a higher proportion 
of low frequency markers (MAF<0.1) than the 
Dutch, which breaks down the LD structure. 
The association signal localizes in the small 21 
kb LD block (from 123246319 bp to 123267319 
bp) adjacent to the larger block covering 
the KIAA1109 gene and the top European 
associated SNP. Although we narrowed down 
the association signal to the 21 kb block, it 
does not include a gene, which could suggest 
that the causal variant plays a regulatory role, 
and although the associated LD block is in the 
immediate proximity of KIAA1109, the variant 
may also impact the more distal interleukin 
genes. This possibility, however, needs to 
be followed up, preferably by sequencing 
the region in the north Indians to identify all 
variants in LD with the top transferable SNP. 
Thus, although we were not able to point to the 
likely causal gene in this region, we did succeed 
in narrowing down the association to a small 
genetic interval. Another successful example is 
the ETS1 locus, where the north Indian signal is 
limited to tightly clustered variants, suggesting 
that the causative variant resides within a small 
21 kb genetic interval (from 127882690 bp to 
127904148 bp). 
Differently localized association signals could 
also indicate locus heterogeneity and different 
biological pathways underlying the disease 
aetiology. In our previous GWAS (10), in which 
we established the association at the 6q22.33 
locus, we suggested THEMIS as a plausible 
candidate gene. However, fine-mapping in 
the Europeans using Immunochip clearly 
points towards the neighbouring PTPRK gene, 
a protein tyrosine phosphatase, whereas the 
north Indian signal points towards THEMIS. 
Unless functional follow-up studies are 
conducted to confirm a gene’s causality, it 
is unclear which gene truly plays a role in 
the disease pathogenesis. Nevertheless, 
it is tempting to speculate that PTPRK, as 
a signalling molecule regulating a variety 
of cellular processes including cell growth 
or differentiation, is a less attractive gene 
candidate for an immune disease than the 
neighbouring THEMIS gene, which regulates 
positive and negative T-cell selection 
during thymocyte development. THEMIS is 
transcribed from the reverse strand and, in 
fact, both associations could still point to the 
same gene, for example in the Europeans by 
affecting the transcription regulation and in 
the north Indians by affecting a regulatory 
mechanism within the gene or by altering the 
gene structure. This requires follow-up studies 
for further elucidation.
We found suggestive evidence of positive 
selection pressure acting on four of the 26 
coeliac disease loci: IL18RAP (rs7559479), 
CCR1/5 (rs13098911), SH2B3 (rs653178) and 
PLEK (rs17035378) (Table S4)16-18. We found the 
strongest selection signal (Fst=0.251) at the 
SH2B3 locus, which was previously suggested 
to play a role in bacterial infection16. The SH2B3 
locus does not replicate in our north Indian 
cohort, possibly because of the selection 
pressure leading to a significant decrease in 
the risk allele frequency in north Indians (11% 
versus 47% in the Dutch). 
Here we have replicated coeliac disease 
associations in a north Indian population and 
also localized and fine-mapped the association 
signals. However, signatures of positive 
selection pressure acting on 15% of the loci 
and our partial replication success may indicate 
that there are different mechanisms of disease 
pathogenesis in the two populations. The 
modest size of our cohort requires our results 
to be followed-up in more extensive samples. 
We recommend that in any future replication 
studies in north Indians or other non-Caucasian 
populations, both the European index SNPs, as 
well as the top variants from this study, should 
be tested to better distinguish relevant signals. 
Furthermore, our studies will benefit greatly 
from the 1000 Genomes sequence information 
for north Indians. This data will allow us to 
collate information on all the variants that are 
in LD with the transferable markers identified 
in our study and to describe more precisely 
the LD structure and genetic boundaries of 
variants strongly correlated with associated 
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SNPs. The key to effective fine-mapping is to 
perform dense genotyping that includes all 
known markers present in the north Indians. 
The results could have an immediate impact 
by allowing us to refine the associated coeliac 
disease regions to precise genetic intervals 
which include the causal variants. 
MATERIALS AND METHODS
Ethical statement
Ethical approval for this study was granted 
by the respective institutional and university 
ethical committees. Informed written consent 
was acquired from all participants. 
Study populations
We analyzed two distinct populations: north 
Indians and a Dutch population. Indian patients 
were recruited from a regional hospital in 
Punjab, northern India. Indian controls included 
blood donors recruited from the same region as 
the cases and who tested negative for coeliac 
disease serology. Dutch cases were recruited 
from University Medical Centre Utrecht, Leiden 
University Medical Centre and VU Medical 
Centre, Amsterdam. A small proportion of 
samples was recruited via the Dutch patients’ 
society (‘Glutenonderzoek’). Coeliac patients 
were diagnosed according to standard clinical, 
serological and histopathological criteria, 
including small intestinal biopsy. The majority 
of samples included in the current study have 
been described in detail elsewhere12.
DNA extraction and genotyping
The great majority of DNA samples came 
from blood, while a small proportion of Dutch 
cases and controls were derived from saliva. 
Samples were hybridized on the Immunochip, 
a custom-made Infinium chip with 196,524 
markers. Genotyping was carried out according 
to Illumina’s protocol at the genotyping 
facility, University Medical Centre Groningen. 
NCBI assembly hg18 was used to map to the 
genome (Illumina manifest file Immuno_
BeadChip_11419691_B.bpm). 
Genotype data quality control
We required samples to have a 98% call rate 
based on the 172,242 high quality, manually 
clustered SNPs. Individuals showing high 
relatedness (PI_HAT > 0.2), or discordant 
sex were removed. Markers with significant 
deviation from Hardy-Weinberg equilibrium 
(p > 10-3) or a per-SNP call rate < 99% were 
removed from the final dataset. 
Population outliers were identified by multi-
dimensional scaling (MDS implemented in 
PLINK21) on 11,192 SNPs that were common 
(MAF>0.05), LD pruned (a window of 1000 
variants, sliding by 10 SNPs at a pair-wise 
SNP-SNP correlation r2=0.05) and shared 
between Immunochip and HapMap3 samples. 
MDS analysis was performed jointly with 
HapMap GIH (Gujarati Indians in Houston, 
Texas), CEU (Utah residents with Northern and 
Western European ancestry from the CEPH 
collection), YRI (Yoruba in Ibadan, Nigeria) and 
CHB (Han Chinese in Beijing, China) samples 
to identify major population outliers and also 
locally, separately for Dutch and Indians, to 
ensure the cases-controls were matching. 
All outlying samples were excluded from the 
analysis. 
Immunochip contains 3016 variants submitted 
for the replication of the ‘Reading and math 
skills’ GWAS. As these SNPs are unlikely to be 
confounded by the immunity signal (49 SNPs 
mapping within HLA were excluded), we used 
this SNP set as a null reference for calculating 
genomic inflation.
Statistical analysis
Logistic regression was performed using PLINK 
v1.0721. Because we observed population 
substructure in the north Indian cohort, the 
north Indian association test was corrected for 
this by including the first three components of 
the MDS analysis as covariates in the logistic 
regression. For both cohorts, gender was 
included as a covariate in the logistic regression. 
26 non-HLA loci, associated with coeliac 
disease at genome-wide significance level10, 
were the focus of this study. We employed two 
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strategies to test for replication of European 
signals in Indians.
Exact replication tested for association signals 
(p≤0.05) among the 26 index SNPs from Dubois 
et al.10 (Table S1). Two of the index SNPs were 
not present on Immunochip and were replaced 
with their best proxy; within the IL18RAP locus, 
rs917997 was replaced by rs7559479 (r2=1) and 
within the ITGA4/UBE2E3 locus, rs13010713 by 
rs1018326 (r2=0.9). 
Transferability of European signals in Indians 
was assessed by extracting all correlated 
markers, measured by r2>0.0522 between index 
SNP and all variants present within coeliac 
loci in CEU (from 1000 Genomes data). LD 
boundaries were defined by extending 0.1 cM 
to the left and right of the European focal SNP 
as defined by the HapMap3 recombination map 
(reported in Dubois et al.10). We then mapped 
the transferable variants to Immunochip 
and required at least one variant per locus at 
p<0.01 to replicate the European signal. The 
SNP tagging ICOSLG locus was not present in 
the 1000 Genomes data, so we used rs2838531 
from HapMap3, a perfect proxy (r2=1).
To assess the rate of transferability expected 
by chance, we permuted case-control labels 
and mapped the transferable SNPs into the 
permuted data. For 1000 permutations, 31 loci 
transferred at p<0.01.
Genotype clusters for all the significant markers 
identified by any of the three approaches were 
manually inspected in GenomeStudio.
GWAS and 1000 Genomes data
We used previously published coeliac disease 
GWAS10 (Illumina Human Hap550 platform) 
and extracted 1,284 SNPs mapping in the 26 
coeliac loci and shared with Immunochip. To 
assess the transferability rate we followed the 
same analysis flow as for the Immunochip data.
To estimate the coverage of the genetic 
variation within coeliac loci we used 1000 
Genomes23 data (May 2011, SNP calling) and 
extracted all annotated variants present in the 
sequenced samples of European descent: CEU 
(CEPH individuals), TSI (Tuscan individuals, 
Italy), FIN (HapMap Finnish individuals from 
Finland) and GBR (British individuals from 
England and Scotland). The May release of 
1000 Genomes did not include any samples of 
Indian origin.
Test of heterogeneity
The homogeneity of ORs between Dutch and 
Indian cohorts was assessed by the Breslow-
Day test. To estimate the accurate significance 
threshold for this test we permuted the disease 
status labels in both cohorts and calculated the 
5% quantile of the nominal p-value distribution 
of Breslow-Day test statistics for 15,851 
polymorphic variants in 26 coeliac loci among 
1000 permutations.
Comparative LD background evaluation
For 11 transferable loci we visualized the LD 
structure for the entire regions in Indian and 
Dutch controls using Haploview v4.224. No 
minor allele pruning was performed to get 
an accurate account of the cross-population 
LD differences. In all but three loci, we used 
all 736 north Indian controls and 1150 Dutch 
controls. Due to computational limitations 
for the CCR1/5, IL2-IL21 and ITGA4/UBE2E3 
loci, we used 400 random controls from each 
population.
Estimation of fixation index (Fst)
A pair-wise fixation index25 was calculated for 
all 12 European index SNPs. We used a control 
dataset from Indian, Netherlands, UK, Polish, 
Italian and Spanish populations. We calculated 
the significance level at Fst=0.079 based on the 
upper 5th percentile of Fst distribution for 8007 
‘neutral’ SNPs. We determined neutral SNPs 
as intronic and uncorrelated with the coding 
variants (pair-wise r2=0.05).
Software and resources
Raw genotype data was processed with 
GenomeStudio_v2010.3. Statistical analysis 
and quality control was performed with PLINK 
v1.07 (http://pngu.mgh.harvard.edu/~purcell/
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plink/). Plots were generated in R (http://
www.r-project.org/). Haploview v4.2 was used 
to visualize LD plots. 1000 Genomes data was 
retrieved from http://www.1000genomes.org/. 
World-wide allele frequency distribution data 
was taken from (http://hgdp.uchicago.edu/).
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Part 1. From genetics to disease biology
In 2007 the first genome-wide association study 
(GWAS) for coeliac disease pointed to association 
with variants in a locus harbouring IL2 and 
IL21 genes1. This GWAS used ~300,000 single 
nucleotide polymorphisms (SNPs) genotyped 
in a small British cohort of 778 coeliac cases 
and 1,422 controls. Soon afterwards, this locus 
was replicated in rheumatoid arthritis and 
type 1 diabetes, pointing to a general risk 
locus for autoimmune diseases2. The top 1,020 
most strongly associated variants from the 
coeliac disease GWAS were further taken for 
replication in an additional 1,643 cases and 
3,406 controls and seven additional risk loci 
were identified3. As the majority of these loci 
harboured immune system-related genes, this 
pointed to an impaired immune response in 
coeliac disease involving both the adaptive as 
well as the innate immune system. At the same 
time, more associations for immune-mediated 
diseases were emerging and indicated overlap 
across the disease loci. This suggested that 
cross-disease replications could yield further 
insight into the genetics of diseases. For 
example, coeliac disease and type 1 diabetes 
are two diseases with a strong inflammatory 
component which co-segregate in populations 
and families, suggesting a common genetic 
background. A replication across these 
two disorders identified seven shared 
regions, suggesting that common biological 
mechanisms may lead to the aetiological 
features of immune-related diseases4.
Three major conclusions have emerged from 
these studies: (1) SNPs scattered throughout 
the genome are a powerful gene-discovery tool 
when genotyped simultaneously in hundreds of 
case-control subjects, (2) the observed effects 
of associated variants are small and therefore 
large sample sizes (several thousands) are 
required to discover additional risk loci, and (3) 
immune-mediated diseases share a part of their 
genetic background. In this thesis, we aimed 
to further investigate the genetic background 
of coeliac disease by identifying additional 
genetic risk loci (Part 1) and dissecting the 
genetic architecture at established risk loci 
(Part 2). To identify more common disease-
alleles we took three approaches: (i) deep 
replication of the UK coeliac disease GWAS 
in multi-population cohorts from Europe, (ii) 
meta-analysis of GWAS conducted across four 
European populations, and (iii) cross-disease 
replication. To interpret the coeliac disease 
associations we performed: (i) fine-mapping at 
these loci using a dense genotyping platform, 
and (ii) cross-ethnic mapping.
Through the genetic studies outlined in part 1 of 
this thesis we established associations between 
coeliac disease and 26 non-HLA loci. These are 
highly enriched for immune-system genes. For 
instance, the deep replication of the UK GWAS 
(Chapter 2) identified two loci, harbouring REL 
and TNFAIP3 genes in proximity to associated 
SNPs, pointing towards the involvement of 
the nuclear factor kappa B (NF-κB) pathway. 
This was the first indication of the role of 
genetic variation in this immune pathway. 
Additional immune pathways emerged from 
the GWAS we conducted on 15,283 samples 
(Chapter 4), where we found association to loci 
harbouring the THEMIS, ETS1 or RUNX3 genes. 
These indicated the thymocyte selection in 
the thymus as an impaired pathway in coeliac 
disease. Some studies have suggested that 
high number of rotavirus infections may 
increase the risk of coeliac disease5. Our 
GWAS results point to the genetic basis for 
this increased susceptibility. The association of 
loci, including genes such as TLR7/TLR8, BACH2 
and IRF4, indicates an altered innate response 
to infection. Although the majority of coeliac 
disease SNPs map in the proximity of immune 
genes, there are loci which harbour genes with 
a more structural function, e.g. the LPP region. 
Very often we are biased when interpreting 
GWAS results and we tend to favour particular 
genes or pathways, hence neglecting genes 
with a less obvious function for the disease 
pathogenesis. Nonetheless, these “less 
obvious” coeliac disease genes could well 
implicate new venues of disease pathogenesis, 
e.g. the impaired barrier in the small intestine.
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As more GWAS across diseases with immune 
or inflammatory components were conducted, 
it became clear that these diseases share a 
substantial part of their genetic background 
outside the well-known HLA region6. There is 
a large overlap between coeliac disease loci 
and those for type 1 diabetes, rheumatoid 
arthritis, multiple sclerosis or inflammatory 
bowel disease. In addition, there is also 
genetic sharing between coeliac disease and 
haematological, metabolic traits, and several 
types of cancers (Chapter 5). A proportion of 
‘disease-specific’ genes could reflect distinctive 
disease biology, although this should be 
interpreted with caution. For example, the LPP 
region is the most associated non-HLA coeliac 
disease locus. Its association was established 
in 20083 and despite the large number of 
GWAS conducted in multiple immune- and 
other traits, it remained ‘specific’ for coeliac 
disease. Only two years later the LPP region 
was reported as a strong risk factor for vitiligo 
-immune disease not yet studied with GWAS7. 
This example shows that the genetic sharing 
will in fact be greater than currently observed, 
because of sample size limitations, platform 
coverage differences, and the stronger gene 
effect size in one disease than another. 
Therefore, cross-disease replication studies, 
where disease-alleles from one disorder 
are tested in the other, have emerged as an 
efficient approach to identify further risk genes 
at relatively low cost. In Chapter 3 we described 
such a study by cross-testing coeliac disease 
and rheumatoid arthritis variants. This pointed 
to six shared loci between the two diseases. 
Further genetic sharing can be identified via 
more comprehensive meta-analysis of GWAS 
results across diseases8, 9. The joint analysis of 
15,283 samples from the coeliac GWAS and 
22,770 samples from a rheumatoid arthritis 
study increased the genetic sharing from six to 
further fourteen regions8. In our Immunochip 
study (Chapter 6) we noted an excess of 
intermediate range p-values at the remaining 
147 non-coeliac disease autoimmune loci, thus 
confirming the large genetic overlap between 
immune-mediated diseases and indicating 
hundreds of genes potentially underlying 
coeliac disease susceptibility.
It is nonetheless challenging to interpret the 
locus sharing. On the one hand, a consistent 
direction of the same allele in two diseases 
may imply a shared causal mechanism and 
the same risk genes. On the other hand, we 
often see the same loci but different SNPs, or 
the same SNPs but with opposite effects, are 
associated, e.g. the IL18RAP region shares the 
same SNP but with opposing effects for coeliac 
disease and type 1 diabetes4. It is therefore 
likely that a gene will protect from one disease 
while predisposing to another. Until extensive 
functional follow-up studies can be conducted 
to characterize the molecular mechanisms 
of associations and direct causal genes are 
identified, the interpretation of shared loci will 
remain unclear.
One way to gain insight into the molecular 
basis of genetic associations is to correlate the 
genotypes of disease-alleles with expression of 
the genes in their proximity (cis-eQTL mapping; 
further discussed in section 2.2 “Disease 
relevant tissues and target genes”). Such an 
approach may be especially helpful in the 
regions of strong linkage disequilibrium (LD) 
with multiple, functionally plausible disease 
genes. For example, SNP rs917997 maps to a 
region of strong LD at 2q12.1, covering four 
immune-related, strong candidate genes 
for coeliac disease, IL18RAP, IL18R1, IL1RL1, 
IL1RL2, nevertheless there is a strong cis-eQTL 
only for IL18RAP. Although this does not prove 
the causality it does give an indication of which 
could be the best gene for functional follow-up 
studies. Over 50% of coeliac disease SNPs are 
significant cis-eQTLs, indicating that subtle 
changes in gene expression are likely to be 
the underlying causal mechanism (Chapter 4). 
At successfully fine-mapped coeliac disease 
loci (Chapter 6), we observed clustering 
of associated variants to regulatory gene 
regions, either 3’ or 5’. This further supports 
a deregulation of gene expression being the 
likely disease-driving mechanism (Figure 1).
Our Immunochip study10, apart from fine-
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mapping, also aimed at establishing new disease 
loci (Chapter 6). This platform includes ~200,000 
SNPs with a strong pre-selection for immune 
system genes. It was designed to densely cover 
183 loci associated with 12 immune-related 
diseases and included intermediate GWAS 
results for these diseases. This design made 
that Immunochip worked extremely well for 
coeliac disease, increasing the total number of 
risk loci from 26 to 39, covering 57 independent 
disease SNPs. However, despite establishing a 
large number of disease associated alleles, this 
study also indicated that a large proportion of 
heritability still needs to be explained. With 39 
non-HLA loci we can only explain 14% of the 
genetic risk and further 40% is accounted for 
by the HLA locus. Even with 24,000 samples 
we had limited power to detect additional 
common, small effect size variants. The more 
disease loci we discover, the smaller the effects 
they account for. Hence, in order to detect 
these slight effects, we need even larger 
studies or further replications in extended 
case-control cohorts of maybe hundreds of 
thousands of individuals. Further common 
variations, possibly hundreds of them, are likely 
to cumulatively account for a large proportion 
of the disease risk. 
Part 2. Future perspectives
Part 2.1. Identifying further genetic risk variants
The genetics of coeliac disease is now at an 
important crossroads. Tens of associations 
identified via GWAS are awaiting functional 
dissection in order to understand the 
mechanisms of causality, a step crucial for 
translating genetic findings into clinically 
relevant information. At the same time, 
hundreds of additional risk genes remain to 
be discovered. In this part, I discuss the future 
perspectives for coeliac disease in respect to 
further gene discovery. In most cases these 
approaches also apply to other complex traits, 
which are facing similar dilemma.
Heritability estimates
To carry on with gene mapping it is important to 
know how much of the genetic risk is explained 
by the established loci. We reported in Chapter 
6 that the non-HLA variants account for 14% 
of the genetic variance, however, these results 
should be treated as estimates. The genetic 
variance was calculated based on assumptions 
of 1% disease prevalence and 50% heritability. 
To make accurate estimates of the genetic risk 
that can be attributed to variants identified via 
GWAS, it is essential to have accurate estimates 
of the heritability and disease prevalence. 
First, coeliac disease has a broad spectrum of 
manifestation and therefore remains one of 
the most under-diagnosed diseases11. More 
accurate diagnosis will certainly influence 
prevalence estimates. Recent population-
based studies in the UK indicate that the 
prevalence of coeliac disease is higher than 
previously assumed and it is now estimated 
at 1.6%12. Another study, based on a cohort 
of Swedish children, estimates coeliac disease 
prevalence at 3%13. Different disease prevalence 
impact the estimates of explained genetic 
variance, e.g. using a prevalence of 1.6% the 
associated non-HLA loci account for 16% of the 
heritability, whereas with 3% prevalence it is 
19% (Figure 2).
Second, the heritability estimates may not 
be accurate. Italian twin studies calculated 
coeliac disease heritability at 89% assuming 
a population prevalence of 1/91 (1.1%). 
Figure 1 Some 4% of the variants map in the conserved 
regions, another 2% localizes in the regulatory regions in 3’ 
or 5’ UTRs, 3% map within the chromatin regions with high 
regulatory potential, and only 1% are exonic variants. Over half 
of coeliac disease-associated variants have an effect on gene 
expression (cis-eQTL). 
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However, this study used a small sample 
size, only 23 monozygotic and 50 dizygotic 
twin pairs, which resulted in a very broad 
range for the confidence interval, from 
49%-100%14. Depending on the heritability 
assumed, 50% or 89%, the explained genetic 
variance accounted for by non-HLA alleles 
is 14% or 8%, respectively. This again varies 
for different disease prevalence (Figure 2), 
which all indicates the importance of accurate 
heritability estimates. To accurately calculate 
disease heritability, large-scale twin studies 
are required, especially to narrow down the 
confidence intervals. Alternatively, a method 
that estimates heritability based on genome-
wide sharing between distantly related 
individuals could be used15. 
In summary, the explained variance should 
be treated as a rough estimate rather than a 
real measure. These calculations should be 
performed in a population-specific manner 
because: (i) the prevalence of the disease varies 
between populations, (ii) allele frequencies 
differ between populations, and (iii) heritability 
is expected to vary across environments. 
All these factors will affect the accuracy of 
estimates.
More common variants: large-scale GWAS and 
SNP prioritization for replication
A large number of identified coeliac disease-
alleles only accounts for a small proportion of 
the disease risk, indicating that many more 
genes still remain to be discovered16. The 
GWAS we conducted, as well as most of the 
GWAS performed on complex diseases were 
underpowered to detect common variants of 
small effect sizes. The polygenic models of 
immune, complex diseases, Crohn’s disease 
or type 1 diabetes15, show that a substantial 
proportion of genetic variance is associated 
with common SNPs. Although coeliac disease 
was not tested in this model, it is highly likely 
Figure 2 The genetic variance accounted for by the 57 non-HLA coeliac disease variants is strongly influenced by the 
heritability estimates (50% shown in blue and 89% in red) and by the different prevalence values. The extreme curves of 
the genetic variance differ by 11%, with 19% explained assuming 50% heritability and 3% disease prevalence but only 8% 
for 89% heritability and 1% prevalence.
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that hundreds of genes will eventually account 
for its genetic background. GWAS employ strict 
significance thresholds when testing individual 
SNPs. This ensures high true-positive rates at 
the cost of increased false-negatives. In order 
to find additional risk variants at the genome-
wide significance level, sample sizes of 
hundreds of thousands will be necessary. This 
is supported by observations from quantitative 
trait studies, such as for height and lipid levels17, 
which both used over 100,000 individuals to 
provide the power to detect the small effects of 
common trait-alleles.
However, genome-wide genotyping of 
hundreds of thousands of individuals is very 
costly, and an alternative approach can be to 
prioritize SNPs for replication, e.g. based on 
their function or enrichment of the genes from 
similar pathways located in proximity to the 
associated SNPs. For example, the majority of 
coeliac disease loci harbour immune-related 
genes and thus the emerging pathways point 
towards different levels of immune-system 
regulation, e.g. the cytokine-cytokine receptor 
interaction pathway (Chapter 5). Replication of 
selected SNPs based on over-representation of 
immune pathways, by enrichment of SNPs in 
proximity to immune-related genes has proven 
successful for coeliac disease. First, there was 
the replication of >1,500 moderately associated 
GWAS SNPs that were enriched for immune-
signal, which discovered ten new disease loci3 
(Chapter 2). Second, more broadly by using the 
Immunochip10, which is strongly enriched for 
SNPs tagging immune system genes (Chapter 
6), identified further thirteen loci. 
Additionally, the analysis can be supplemented 
by pathway-based tools, which use prior 
biological knowledge on gene function to help 
more powerful analysis of the GWAS18. The 
principle for these approaches is to test if a 
group of related genes, in the same functional 
pathway, is associated with the disease. 
Pathway analysis approaches are enabling 
powerful association testing and helping 
formulate new hypotheses on disease aetiology. 
A successful example is rheumatoid arthritis, 
where SNPs were selected for replication based 
on their score in the Gene Relationships Across 
Implicated Loci (GRAIL)19 method. This method 
performs statistical text mining of PubMed 
abstracts and scores the genes of interest for 
their functional relationships to the disease-
established loci. Prioritization of SNPs for 
replication with this approach has established 
association with three additional loci20.
Although pathway tools may aid in 
interpretation of GWAS results, or help 
generate hypothesis of disease pathogenesis 
and indicate additional gene candidates, they 
are not unbiased. When analysing a random 
selection of SNPs such tools especially favour 
the well-defined pathways21. Also, pathway 
tools may not consider those genes for which 
little is known about the function of their 
products. Association signals mapping to 
intergenic regions will also not be analysed. 
Although genes of poorly known function 
and intergenic regions are challenging to 
interpret and may not immediately fit into 
our understanding of disease pathogenesis, 
they should not be neglected as they may 
present new leads for the disease aetiology. 
And although pathway analysis can indicate 
the biological processes involved in the 
disease aetiology, the results should always be 
interpreted with caution; it is important that 
the results are followed-up by SNP replication 
to establish robust associations.
Another strategy may involve testing SNPs 
based on their function, e.g. a high percentage 
of coeliac disease alleles express an eQTL 
effect and one could then select for replication 
eQTL SNPs influencing expression of immune-
related genes with moderate association in the 
GWAS results. Similar approach successfully 
identified an association between Crohn’s 
disease and the UBE2L3 gene22. 
The value of diverse ethnic groups
The prevalence of coeliac disease varies 
worldwide. From less than 0.2% in Germany23 
up to 5% in the Western Sahara24. In general, 
there is a lower prevalence of the disease in 
the developing countries. This could be partly 
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explained by different eating habits and a 
more diverse gluten dietary intake, which to 
some extent correlates with the disease rate. 
This is also supported by the Swedish coeliac 
disease epidemic. Between 1984 and 1996 
Sweden experienced a marked epidemic of 
coeliac disease13, reaching a disease incidence 
rate of 3%. It is thought this high rate can be 
partly explained by a change made in the infant 
feeding guidelines. Before the coeliac disease 
epidemic, it was recommended to introduce 
gluten in the infant diet from 4-6 months of 
age, at the same time breast-feeding was 
being discontinued. Independently, this 
coincided with the commercial baby cereal 
milk products having higher gluten content. 
The end of the epidemic was preceded by a 
recommendation to introduce gluten gradually 
while the baby was still breast-feeding and this 
also overlapped with a reduction in the gluten 
content in commercial infant food.
Yet, it is not clear whether coeliac disease is 
rare in some populations because of a lack of 
predisposing genes or whether the genes are 
not expressed because food containing gluten 
is not traditionally consumed. Studies on 
second-generation immigrants and adoptees 
in Sweden show a decreased incidence 
of coeliac disease among children whose 
biological parents are from countries with a 
low disease prevalence and at the same time 
children of parents from Western, Eastern and 
Northern Europe have a similar incidence of 
coeliac disease as in Sweden25. This suggests 
that ethnic genetic heterogeneity contributes 
to the worldwide variation. 
Different ethnic backgrounds may emphasize 
different mechanisms of disease pathogenesis. 
Different environments may lead to different 
selection pressure, which impacts the allele 
frequencies. Four of coeliac disease loci (SH2B3, 
IL18RAP, PLEK and CCR1/5) have signatures of 
positive selection. At three loci the selection is 
acting on the protective allele. Interestingly, at 
the SH2B3 locus the favoured risk-allele is not 
present at all in South Asians or South Africans 
but in Europeans it reaches almost 50% 
frequency. This suggests that new, important 
associations between disease and genetic 
variants may be found easily in populations 
with locally common risk allele frequencies. 
GWAS has proved very successful in relatively 
small and homogeneous populations, such as 
in Iceland or Sardinia. Limited migration and 
large families are common for populations in 
Africa or Latin America, and some groups in 
these continents exhibit high coeliac disease 
rates. New genetic insights will emerge from 
studying such diverse ethnicities, for example 
groups from Mexico, Uruguay, Algeria and 
Syria (see Figure 2 of Preface). In all these 
populations the prevalence of coeliac disease 
is at increased levels (>1.6%). Of particular 
interest is the population of the Western 
Sahara, where the coeliac disease rate reaches 
an especially high level of 5%.
The study of blood lipid levels shows that most 
of the common disease-variants contribute 
to the risk in other ethnic groups17. Yet this 
observation cannot be generalized as only 
about 4% of the GWAS were conducted on non-
European populations26, and it is likely that 
findings from one population may not always 
translate to others. For example, rs9282541 
is strongly associated with type 2 diabetes, 
obesity and low high-density lipoprotein 
cholesterol (HDL-C), but is exclusive to Native 
Americans and not present in European, Asian 
or African individuals27.
When attempting to replicate associations 
established on Europeans in other ethnicities, 
it is important to account for cross-population 
differences in LD structure. GWAS identified 
variants are, with few exceptions, associated 
to, but not causing the disease. Depending on 
the LD block structure and frequencies of tag 
and causal genetic variants, associations from 
one population may not be generalized across 
another. Especially testing the index European 
SNP (reported SNP from a discovery study) 
may not be sufficient to replicate the signal in 
another ethnic group. It is then better to use 
the index SNPs jointly with variants in LD with 
it in replication studies28. Using this approach 
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we were able to replicate 13 of the 26 coeliac 
disease loci in a north Indian population. 
Had we tested the index SNP only, we would 
have missed signals for eight loci (Chapter 7). 
The choice of a north Indian population was 
beneficial because this population is ethnically 
different from Europeans, resulting in a lesser 
degree of long-range LD. This has proven 
advantageous for fine-mapping association 
signals (section 2.2, “Fine-mapping”). 
Finally, part of the “hidden heritability” is 
also attributed to low-frequency and rare 
variants, i.e. those present at MAF less than 
5%. However, rare variants are population-
specific29, even more opting for studies which 
include diverse genetic populations, or else our 
understanding of the disease genetics will be 
strongly biased. 
Rare variants
The genetic architecture of complex diseases 
comprises both common and rare variants. Part 
of the ongoing debate is whether the “hidden 
heritability” can to some extent be explained 
by the rare, large effect size variants. GWAS 
have been successful at finding associations 
to common variants, partly because GWAS 
platforms mainly consist of variants with MAF 
greater than 5%. Due to this and the fact that 
LD correlation between common and rare 
variants is limited, direct sequencing is required 
to uncover rare disease variants. Studies to 
identify rare variants in the proximity of the 
common variant signal have already shown 
success in e.g. type 1 diabetes30.
In our Immunochip study10 (Chapter 6) we did 
identified low frequency and rare variants 
(minor allele frequency MAF <5%) associated 
with coeliac disease but of moderate effect 
sizes; we did not observe any rare variant 
with very strong effect. The strongest effect 
had an odds ratio (OR) of 1.7 for a variant 
(imm_16_11281298) with a MAF of 0.004%. 
We also reasoned that if rare, large effect 
size variants underlie associations at coeliac 
disease loci, we would expect the MAF of most 
associated variants to decrease with increasing 
genotyping density. This was not the case, and 
compared to our GWAS we did not observe 
any such trend. However, our study had certain 
limitations.
Rare variants tend to be population-specific 
and require large sample sizes to reach a high 
significance level. Our Immunochip study is 
overrepresented by the UK population (16,000 
UK samples in a total of 24,000). Variants with 
less than 5% frequency should be analysed in 
a population-specific manner as in the pooled 
analysis population specific effects may be 
diluted by other cohorts. However, except for 
the UK cohort, the other six cohorts were not 
sufficiently powered for this type of analysis. 
Furthermore, rare variant detection requires 
case resequencing data, as has been included 
on the Immunochip, but the sequencing was 
performed only on UK cases and only for 
thee coeliac loci. Therefore, again, if rare, 
population-specific variants confer the risk at 
coeliac disease loci they should be analysed 
only in the UK samples. In addition, the 
Immunochip has a patchy coverage of rare 
variants. It was designed based on an early 
release of the 1000 Genomes Project, which 
should identify the vast majority of common 
(MAF>5%) variants, but it was underpowered 
to comprehensively detect rare frequency 
variants. Our Immunochip dataset captured 
47,602 variants with a MAF<5%. On the other 
hand, despite the uneven coverage of rare 
variants, we might have expected to capture at 
least one rare variant from the 39 loci if single 
rare variants explain the highest association 
signals, but we did not. It seems unlikely that 
a single rare variant explains most of the 
association signal. However, the statistical 
analysis we applied cannot robustly refuse that 
a combination of multiple rare variants jointly 
explains the association signal.
Part 2.2. From SNP association to function
Genome-wide association studies (GWAS), in 
conjunction with the most recent Immunochip 
study, have led to the identification of 39 
genomic regions being associated with the risk 
of coeliac disease1,3,8,10,31,32. These associations 
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have improved our understanding of the disease 
biology and pointed to new disease pathways. 
Despite the exciting progress made with 
mapping disease loci, it is disappointing that for 
the majority of loci it is still unclear how the risk 
alleles alter the function of neighbouring genes 
to disrupt critical molecular pathways leading 
to disease. Without knowing more about the 
biological functions of the risk alleles, it is very 
difficult to develop novel therapeutic strategies 
to treat or possibly cure autoimmune diseases.
There are at least three reasons why it has been 
difficult to understand the biological function of 
risk alleles. First, risk loci often contain multiple 
genes, many of which may be biologically 
strong candidate genes, e.g. the 3p21.31 
region, harbouring a cluster of chemokine 
receptors. And even more challenging, some 
risk loci map to intergenic regions where no 
genes are present. Second, multiple alleles 
may be in linkage disequilibrium (LD) with 
the disease-associated SNP. Unless a variant 
disrupts an obvious conserved sequence motif 
(e.g. by altering the protein-coding structure of 
a gene), it is not possible to determine which 
is the “causal variant”. And third, without 
knowing the causal gene or causal variant, it is 
difficult to collate information across risk loci to 
gain insight into critical biological pathways. 
Fine-mapping
Before understanding a function of the disease 
variant it is necessary to identify the most 
plausible causal variant(s) that can be further 
taken into functional follow-up studies. In 
majority GWAS establish associations between 
the disease trait and tag-SNPs. This is due to 
the design of the genotyping platforms used 
in GWAS, which try to capture most of the LD 
structure. Fine-mapping aims at narrowing the 
association signal down to the disease-causing 
variant, which is in LD with the associated, 
tag-SNP. It requires sequencing of cases and 
controls and can be supplemented by the 1000 
Genomes project, which catalogues common 
(>5%) and low (1-5%) frequency variants in 
individuals from diverse ethnic populations33. 
Currently, intensive whole-genome 
sequencing efforts in hundreds of samples 
are being conducted and aim at generating 
comprehensive and detailed catalogues of the 
genetic variants specific to the populations 
of interest, for example the “Genome of the 
Netherlands” project. The “Genome of the 
Netherlands” will characterize the genomes 
of 750 Dutch individuals (250 trios) from four 
major provinces in the Netherlands. Such a 
reference set will have a higher specificity to 
complement analyses focused on the samples 
of Dutch origin than the 1000 Genomes CEU 
panel.
One can choose to follow-up only a subset of 
“best” plausible causal variants or to genotype 
all the identified sequence variants. The latter 
is a more unbiased approach and omits the 
chance of missing the causal variant in the 
replication, due to prioritization of the follow-
up SNPs. A similar reasoning underlies the 
design of Immunochip, where all the variants, 
irrespective of the LD correlation or minor 
allele frequencies, were submitted for the 
design. This strategy provided a detailed, 
unbiased picture of the genetic architecture 
at the disease loci. Ideally one would like to 
perform a sequencing case-control association 
study to fully exclude the possibility of missing 
the causal variant.
Another fine-mapping approach involves using 
GWAS information from ethnically different 
populations, on the assumption that similar 
associations are generalized across these 
populations. One of the most genetically 
informative ethnic groups to study is the 
African population, which is much older than 
Europeans and therefore has a generally smaller 
LD block structure. This gives opportunities to 
localize association signals to a smaller genetic 
interval and narrow down the list of putative 
disease variants.
Evaluating functions of associated variants
HLA has long been studied in the context of 
coeliac disease pathogenesis and the molecular 
mechanism is well known. However, this is not 
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the case for the other loci, with the exception 
of the 12q24.12 region, where more than ten 
genes are present in the LD block but the 
strongest association maps to a coding SNP 
within the SH2B3 gene. Individuals carrying the 
risk allele show an increased pro-inflammatory 
immune response against bacterial infection34. 
This locus is also under positive selection 
pressure. It is a very rare example for complex 
diseases, where the most significant GWAS 
SNP is a coding variant. In the other loci, only 
a few carry the coding variant in LD with the 
most associated SNP. 
On the other hand we observe that most of 
the signals localize in the plausible regulatory 
regions in proximity to or within the 5’ and 3’ 
ends of transcription. This could indicate a 
disease mechanism via deregulation of gene 
expression. Consistent with that is the fact that 
for over 50% of coeliac disease variants in our 
GWAS study we observed correlation with gene 
expression (cis-eQTL). More broadly, genome-
wide studies of gene expression linked with 
GWAS data have shown that approximately 
40% of disease-associated SNPs affect 
expression levels of genes in cis35.
The emerging picture thus suggests that many 
of the causal variants will disrupt the gene 
expression of a neighbouring causal gene, either 
by (i) affecting pathways that control activity of 
transcription factors36, (ii) directly disrupting 
sequence motifs that bind transcription factors 
regulating the expression of neighbouring 
genes, or (iii) disrupting or creating miRNA 
binding motifs37. For example, NF-kB, 
one of the most important transcription 
factors modulating immune response, has 
been implicated in the pathogenesis of 
coeliac disease and multiple other immune-
mediated diseases. Associations with genes 
that regulate the activity of NF-kB have 
been described (e.g. TNFAIP3 in psoriasis38,39, 
rheumatoid arthritis40, 41, coeliac disease32 and 
systemic lupus erythematosus42, 43, as well 
as associations mapped to a subunit of NF-
kB itself, c-REL (ulcerative colitis44, Crohn’s 
disease45, psoriasis39, rheumatoid arthritis41, 
and coeliac disease32). 
It is relatively easy to assess the causality 
for the coding variants as they may alter 
protein sequences, but more challenging 
for the non-coding ones. Recently, a new 
method has become available to identify 
functional motifs in DNA sequence: 
chromatin immunoprecipitation followed 
by high-throughput sequencing (ChIP-seq) 
to generate genome-wide chromatin data 
sets. By mediating regulatory signals and 
controlling DNA accessibility, active chromatin 
elements steer gene expression in a tissue-
specific manner. The ENCODE Project46 
provides comprehensive genome annotation 
of the regulatory elements that emerge 
from chromatin profiling studies. Chromatin 
regulatory elements include enhancers, 
insulators, promoters, and silencers, and 
of these, enhancers are the most abundant 
and often cell-specific47. Associated, disease 
variants can therefore be annotated if they 
map within such chromatin functional 
elements. Additionally, associated variants 
can also be tested for their consequences on 
regulatory motifs (disruption or creation) for 
predicted transcription factors. Given the high 
rate of eQTL effects among disease-associated 
SNPs, the enrichment of these variants within 
regulatory elements is expected. This can 
pinpoint the specific disease mechanisms by 
which a disease-allele leads to the phenotype.
Characterizing the landscape of disease-
associated SNPs by integrating fine-mapping 
information with chromatin modification 
(e.g. chromatin regulatory elements, open 
chromatin), genome conservation and e-QTL 
data will provide an important step towards 
understanding how risk alleles affect function. 
With the emerging picture of noncoding 
variants contributing to the disease, it would 
be desirable to design a chip that combines 
sequencing variants with chromatin regulatory 
information to aid fine-mapping efforts.
Disease-relevant tissues and target genes
While many individual loci have emerged 
from GWAS, identification of the 
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exact causal gene and tissues in which 
they act has remained a challenge. In particular, 
autoimmune diseases are a major challenge, 
with a broad range of immune-cell types that 
may be impacted by genetic variation and 
lead to the disease. Thus it is essential that 
the function of genetic variants is studied in 
systems most representative for the disease. 
It is not straightforward to pinpoint the right 
disease tissues, however few approaches have 
recently been suggested, e.g. by scoring the 
enrichment of genes implicated by disease-
associated SNPs across different cell types. For 
instance, there is a significant enrichment of 
the gene expression of CD4+ effector memory 
T-cell genes among rheumatoid arthritis loci48.
Another approach could involve annotating 
the disease-associated variants. For example, 
chromatin enhancers have high tissue specificity 
and mapping associated variants for chromatin 
functional elements shows that disease SNPs 
are enriched within these enhancer elements49. 
Further, testing the enrichment of enhancers 
with disease-alleles across different cell types 
may explain the tissue- and disease-specific 
nature of the disease-variants. For example, 
systemic lupus erythematosus SNPs are 
enriched within strong enhancer states in 
B-lymphoblastoid cells, but not in eight other 
cell types tested49. This, however, requires a 
comprehensive catalogue for many different 
cell types. For coeliac disease-alleles, it would 
be important to test not only immune cells but 
also cells making up the small intestine.
After choosing the disease-relevant tissue, the 
next step is to identify the disease-causing gene. 
A considerable proportion of associated loci will 
harbour variants that influence the abundance 
of specific transcripts. Studying the correlation 
between genetic variants and the expression of 
neighbouring genes is a straightforward way 
to link risk-alleles with putative target genes. 
Importantly, not only messenger RNA (mRNA) 
but also microRNA (miRNA) and non-coding 
(ncRNA) transcripts can be regulated by genetic 
variation and should be taken into account in 
such an analysis. A complementary approach 
to define the local impact of genetic variation 
on gene expression is allele-specific gene 
expression in individuals heterozygous for risk 
alleles. Nonetheless, an identified transcript 
that strongly correlates with a disease-variant 
does not mean it is definitely involved in the 
disease and functional follow-up studies will be 
critical for proving the causality.
Environmental risk factors and genetic variation
Our understanding of the complex interplay 
between genetics and environment poses a 
particular challenge for post-GWAS follow-up. 
Determining the disease-triggering factors 
is crucial for future studies and only when we 
identify the environmental factors will we be 
able to link them with genetic information and 
gain a full picture of the disease pathogenesis. 
This picture will help us to understand 
the molecular mechanisms of the genetic 
associations. Coeliac disease is an excellent 
example of such a translation of information, 
the strongest genetic determinant is HLA, 
more specifically the HLA-DQ2 and HLA-DQ8 
molecules, which bind the gluten peptides, 
the environmental factor. This knowledge 
has immediate translation to the patients, as 
restricting the presence of gluten in the diet 
completely reverses the disease symptoms 
for 95% of coeliac patients. To gather detailed 
environmental information, prospective 
studies including large numbers of participants 
are required. Such efforts are ongoing, for 
example in the Netherlands there is “LifeLines”, 
a three-generation population-based project50. 
LifeLines is recruiting 165,000 participants from 
the northern provinces of the Netherlands, 
collecting extensive phenotype information 
and generating genotyping profiles to 
understand how the interplay between genetic 
and non-genetic factors modifies an individual’s 
susceptibility to multifactorial diseases. 
Of particular interest is how diet influences the 
composition and dynamics of the gut microbial 
communities (microbiota) and impacts the 
innate and adaptive immune system. The 
digestive tract is the major part of the immune 
system and highly exposed to environmental 
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factors. Our knowledge of the species and 
composition of the human gut microbiome 
has been greatly expanded in recent years. It 
now appears that, across the world, human 
populations share three robust clusters, 
composed of multiple microbial species, and 
there are a limited number of symbiotic, well-
balanced host-microbial states, which may 
have different responses to diet or drugs51. 
The microbial composition strongly correlates 
with human phenotypes, for instance there is a 
significant difference between the microbiomes 
of obese and lean people, indicating the 
diagnostic potential of microbial markers52. It 
could be of great diagnostic value to analyse, 
and if possible, create the microbial profile 
for coeliac disease. Further, the integration of 
microbiome profiles with genetic information 
could become an important pre-diagnostic tool 
for the diseases.
Part 2.3 Clinical translation
Despite many genes being identified for 
complex traits their use for clinical testing is still 
poor. First, the majority of identified variants 
are surrogates of the real disease-alleles and 
their effect-sizes are only proxies of the real 
effects. Second, the identified variants account 
for very modest effect sizes. Coeliac disease 
is one of the genetically best understood 
complex diseases, with its very strong risk 
effect of the HLA molecules. Due to this, 
prediction models for coeliac disease are some 
of the most successful to identify individuals 
at high disease risk. If individuals carry an 
intermediate HLA risk, the load of non-HLA 
risk alleles improves the prediction model53. 
This model will improve further, as we identify 
more common and rare variants, and will help 
to better calculate the risk for individual to 
develop the disease. With the genetic advances 
in coeliac and other immune-related disease, it 
will be possible to generate a general profile of 
the risk for immune-related diseases.
Although current GWAS results still lack high 
predictive value, identified loci can point 
towards novel pathways and therefore lead to 
identification of therapeutic targets. Genetic 
overlap between immune-mediated diseases 
indicates shared molecular pathways, which 
may provide new targets for clinical treatment, 
while similar compounds could be used for a 
broad spectrum of diseases with respect to 
an individual’s genetic profile. GWAS results 
can also point towards environmental factors 
contributing to the disease, enabling public-
health prevention measures to be taken.
GWAS results have the potential to facilitate 
personalized medicine and clinical care but 
there is still a long way to go. Until we identify 
the disease risk alleles, understand their 
molecular consequences on a single locus level 
as well as on the biological system level, we will 
not be able to effectively translate the genetics 
to clinical care. Ultimately, the combination of 
genetic markers and biomarkers of the disease, 
for example, antibodies or microbiome 
signatures, may lead to better pre-diagnosis 
and effective prevention.
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Genetics is one of the most dynamically evolving 
fields of science. The full sequencing of the 
human genome was completed only in 2003. It 
was an immense effort which took 13 years to 
perform, at a cost of $3,000,000,000. Currently 
the cost of sequencing a single genome is 
$10,000 and it takes less than a month. From 
the sequence of the human genome we learned 
that there are about 10,000,000 common, 
genetic variations, changes at a single position 
in the DNA, these are called single nucleotide 
polymorphisms (SNPs). The majority of SNPs 
are expected to be neutral, however, some 
of them are present with a higher frequency 
in patients suffering from a certain disease 
when compared to healthy individuals. Recent 
technological advances have led to platforms 
capable of simultaneously testing (genotyping) 
hundreds of thousands of SNPs (from 300,000 
up to 2,000,000) in hundreds of individuals. 
These platforms are used in case-control studies 
and allow us to infer the genotypes of each SNP 
and compare the frequencies between patients 
and healthy individuals. Statistically significant 
differences indicate the regions of the genome 
that are relevant for the disease development, 
disease loci. Such a study design is called a 
genome-wide association study (GWAS). 
However, one of its drawbacks is that it does not 
identify the causal gene or mutation directly, 
but rather points to a region harbouring the 
disease gene. Often such regions are large and 
they contain multiple genes which are strongly 
correlated with each other due to the linkage 
disequilibrium (LD) structure. It therefore 
becomes difficult to pinpoint the true disease-
causing gene and after identifying the disease 
regions with GWAS, we need to perform 
further fine-mapping studies to narrow down 
the signal and uncover the casual variant.
It is due to this technological development 
that the past few years have yielded such a 
tremendous advance in our understanding 
of the genetic background of many diseases. 
The success has been most pronounced for 
monogenic disorders, in which a change in a 
single gene leads to the development of the 
disease. About five years ago we also began to 
see successes for complex diseases. These are 
disorders that result from small, simultaneous 
dysfunctions of many, even hundreds, of genes. 
Yet, it is not simply the genetic component that 
leads to development of the disease, but also 
the interplay between disease genes and one 
or more environmental factors.
Coeliac disease is the most common food 
intolerance, affecting some 1-3% of Western 
populations. It results from an intolerance 
to gluten peptides in genetically susceptible 
individuals. Gluten is found in wheat, barley 
and rye, and is widely present in Western food 
products. The intake of gluten causes a strong 
immune response and leads to damage of 
the small intestine in such individuals. People 
with coeliac disease can suffer from a broad 
spectrum of symptoms, from classical ones 
such as diarrhoea, abdominal distension and 
abdominal pain, to atypical ones that include 
anaemia, osteoporosis and neurological 
symptoms.
Genetically, coeliac disease is well characterized 
by the strong effect of two particular HLA 
molecules, HLA-DQ2 and HLA-DQ8. These 
molecules account for 35-40% of the genetic 
risk, yet are present in 30% of the general 
population, indicating that other genetic risk 
factors must be involved. By 2008, eight non-
HLA regions had been identified by a GWAS in 
coeliac disease patients. The aim of this thesis 
was to further identify the genes predisposing 
to the disease development.
In Chapter 2, we describe the results of deep 
replication studies of the coeliac disease GWAS. 
We genotyped approximately 500 SNPs that 
had a moderate association signal in the GWAS 
in 1,682 cases and 3,258 controls and identified 
association of two additional genomic regions. 
Both regions harboured genes involved in 
modulating the activity of the NF-kB pathway, 
one of the essential transcription factors 
mediating the immune response. 
Immune-related diseases often co-occur in 
families or patients, for example, patients with 
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coeliac disease are also often affected by type 
1 diabetes. In Chapter 3 we analyse the extent 
of genetic sharing between two autoimmune 
conditions, coeliac disease and rheumatoid 
arthritis. We tested if the genes associated 
to one disease also confer risk for the other. 
This strategy enabled us to report a total of 
six shared regions, confirming two previously 
known loci and identifying four new ones.
Further coeliac disease genes were discovered 
via a large-scale GWAS (described in Chapter 4) 
in 15,000 individuals from four populations (UK, 
the Netherlands, Italy and Finland). The top 131 
SNPs that showed the strongest association 
in the analysis across these populations were 
replicated in an additional 10,000 individuals 
from USA, Hungary, Ireland, Poland, Spain, Italy 
and Finland. With this approach, we brought the 
total number of coeliac disease loci to 26. The 
majority of these regions harbour genes with 
an immune-related function. Apart from the 
genes involved in modulating the innate and 
adaptive immune responses, we also describe 
genes implicating the role of lymphocyte 
development on the thymus, as well as genes 
involved in the innate immune detection of 
viral infection. Importantly, we report that over 
50% of coeliac disease-associated SNPs have a 
strong effect on gene expression. This suggests 
that one of the main causal mechanisms for 
coeliac disease associations, and probably 
for other complex diseases, is the alteration 
caused in the levels of gene expression.
In Chapter 5, we give an overview of the progress 
made by genetic studies in coeliac disease and 
of the advance in our understanding of the 
molecular mechanisms underlying the disease.
Our Immunochip study (described in Chapter 
6) further confirmed that one of the major 
mechanisms driving the disease pathogenesis 
is the deregulation of gene expression. The 
Immunochip is a custom-made platform 
designed specifically for use in genetic studies 
of immune-related diseases. Its SNP content 
has been enriched for regions harbouring 
‘immune genes’ and SNPs previously associated 
to any of the immune-related diseases. In 
particular, the Immunochip was designed to 
aid fine-mapping, to more precisely localize the 
association signal, in 183 regions associated to 
immune-related disorders. For this work, these 
regions have been enriched with markers at a 
much greater density than in GWAS platforms 
(10-20x). The greater SNP density provides a 
better resolution of the linkage disequilibrium 
and permits a more precise localization of 
the association signal. The application of the 
Immunochip in 12,000 coeliac disease patients 
and 12,000 controls from six different countries 
successfully allowed the signal to be localized 
to a single gene at more than half of the 
coeliac disease loci. Furthermore, at 20% of the 
coeliac loci, the signal was localized in a gene 
regulatory region, again pointing towards the 
deregulation of gene expression as a molecular 
mechanism underlying the association signals. 
In addition to fine-mapping, the Immunochip 
study identified 13 additional coeliac disease 
loci, making a total of 39 non-HLA regions 
carrying a coeliac disease risk. 
To further understand the genetic architecture 
of coeliac disease, we performed a cross-ethnic 
analysis, between the Dutch and northern 
Indians. We successfully replicated 13 of 26 
tested loci. We observed a difference in long-
range linkage disequilibrium between these 
populations, which resulted in finer signal 
localization in the northern Indians at five 
loci and a signal shift at the remaining ones. 
For a number of loci, we were able to report 
signatures of positive selection pressure acting 
upon them. 
The main conclusions from this thesis are:
- 39 non-HLA loci have been associated with 
coeliac disease so far and, together with HLA, 
they explain 53% of the genetic risk.
- Coeliac disease and other immune-related 
diseases share substantial parts of their genetic 
background.
- Loci associated to coeliac disease are greatly 
enriched for immune-system genes.
- Over half of the associated variants affect the 
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expression of neighbouring genes.
- Coeliac disease-associated variants are mostly 
non-coding and localize in the gene regulatory 
regions, indicating that gene deregulation can 
be one of  the major molecular mechanism 
driving the disease pathogenesis.
- 13 coeliac disease loci mapped in European 
populations also confer coeliac disease risk in a 
north Indian population. 
Glossary 
DNA: the molecule that stores the genetic 
information. The basic unit building up the 
DNA is a nucleotide.
Genome: the hereditary information describing 
the development and functioning of living 
organisms. It consists of genes and non-coding 
parts of the genome. 
GWAS: genome-wide association study, the 
genotyping of hundreds of thousands of SNPs 
(from 300,000-2 million) in the DNA obtained 
from large cohorts of cases and controls 
(usually comprising hundreds to thousands of 
individuals).
Heritability: the proportion of the phenotypic 
variation in the population, e.g. a disease, eye 
colour or baldness, that is attributed to genetic 
variation between individuals.
LD: linkage disequilibrium, the correlation 
between SNPs. The higher the LD, the stronger 
the correlation is between SNPs. 
Locus (plural loci): a region on the DNA. 
Sequencing: reading the DNA code.
SNP: a single nucleotide polymorphism, a 








Genetica is een van het meest dynamische 
ontwikkelde onderzoeksvelden. Het menselijk 
genoom is namelijk pas in 2003 volledig 
gesequenced. Dit was een immense klus die 13 
jaar geduurd heeft en $3.000.000.000 gekost 
heeft. Op dit moment kost het $10,000 om een 
enkel genoom te sequencen en duurt het korter 
dan een maand. Door het sequencen van het 
menselijk genoom weten we dat er ongeveer 
10.000.000 veel voorkomende genetische 
variaties, single nucleotide polymorphisms 
(SNPs), verandering op een enkele positie in 
het DNA, bestaan. Het grootste gedeelte van 
de SNPs zullen een neutraal effect hebben, 
maar sommige SNPs komen voor met 
een hogere frequentie in patiënten, dan in 
gezonde controles. Recente technologische 
ontwikkelingen hebben geleidt tot platforms 
die in staat zijn om honderdduizend SNPs in 
een keer tegelijkertijd te testen (genotyping). 
Deze platforms worden gebruikt in patiënt-
controle (case-control) studies en geven de 
mogelijkheid om het genotype van iedere 
SNP te bepalen en om de frequenties tussen 
patiënten en controles te meten. Statistisch 
significante verschillen duiden regio’s aan in het 
genoom (disease loci) die belangrijk zijn voor 
ziekte ontwikkeling. Dit studieontwerp wordt 
een genoom-wijde associatie studie (GWAS) 
genoemd. Desondanks, een nadeel van deze 
aanpak is dat het niet direct het ziekte gen of 
de mutatie detecteert, maar slechts de regio 
aanwijst waar het ziekte gen zich bevindt. Deze 
regio’s zijn vaak groot en bevatten vele genen 
die sterk gecorreleerd met elkaar zijn door 
de onderliggende linkage disequilibrium (LD) 
structuur. Mede hierdoor wordt het erg moeilijk 
om het ziekte gen te detecteren, en moeten we 
nadat de disease loci geïdentificeerd zijn met 
GWAS, verdere verfijndere studies uitvoeren 
om de locatie van het associatie signaal beter 
te bepalen en de ziekteveroorzakende variant 
te identificeren. 
Door deze technologische ontwikkeling, is er 
de laatste jaren erg veel inzicht verkregen in de 
genetische achtergrond van menige ziekten. 
Dit succes was vooral duidelijk voor monogene 
aandoeningen, waarbij een verandering in 
een enkel gen al tot ziekte lijdt. Ongeveer vijf 
jaar geleden, werd het succes ook merkbaar 
voor compexe ziekten. Deze aandoeningen 
ontstaan door kleine, gelijktijdige malfuncties 
van vele en soms wel honderden genen. Toch 
is het hier niet alleen maar de genetische 
component die tot ziekte lijdt, het gaat om het 
samenspel tussen deze ziekte genen en een of 
meerdere omgevingsfactoren, 
Coeliakie is de meest voorkomende voedsel 
intolerantie, die bij 1-3% van de westerse 
populatie voorkomt, en ontstaat door een 
gluten peptiden intolerantie in genetisch 
gevoelige personen. Gluten zit in tarwe, 
rogge, gerst of haver wat veel zit in westerse 
voedsel producten. Het innemen van gluten 
veroorzaakt een sterke immuunreactie en 
veroorzaakt schade aan de dunne darmen. 
Mensen met coeliakie kunnen leiden aan een 
heel spectrum van symptomen zoals klassieke 
klachten diaree, een opgezwollen buik en 
buikpijn maar ook atypische klachten zoals 
bloedarmoede en neurologische symptomen. 
Genetisch is coeliakie goed gekarakteriseerd 
door het sterke effect van twee specifieke 
HLA moleculen, HLA-DQ2 and HLA-DQ8. 
Deze moleculen verklaren 35-40% van het 
genetische risico, maar komen ook in 30% van 
de algemene populatie voor. Dit duidt erop dat 
andere genetische factoren dus ook betrokken 
moeten zijn. Sinds 2008, waren er acht niet-
HLA loci geïdentificeerd door GWAS in coeliakie 
patiënten. Het doel van dit proefschrift was het 
identificeren van andere genen die bijdragen 
aan de ziekte ontwikkeling. 
In hoofdstuk 2, beschrijven we de resultaten 
van serieuze herhalingsstudies van de coeliakie 
GWAS. We genotypeerden ongeveer 500 SNPs 
die gebruikt waren tijdens de GWAS en die een 
gemiddeld associatie signaal hadden, in 1682 
en 3258 controles en vonden 2 extra regio’s in 
het genoom die geassocieerd bleken te zijn. 
Beide loci bevatten genen die betrokken zijn 
bij het aansturen van de NF-KB route, een 




Immuun- gerelateerde ziekten komen 
vaak samen voor in families of patiënten, 
bijvoorbeeld coeliakie patiënten lijden ook 
vaak aan type 1 diabetes. In hoofdstuk 3 
analyseerden wij de genetische overlap van 
twee auto-immuun ziekten, coeliakie en reuma. 
We testten of de genen die geassocieerd waren 
met een van deze ziekten ook bijdragen aan 
het genetische risico voor de andere. Deze 
strategie maakte het mogelijk om 6 gedeelde 
regio’s te rapporteren, waarvan 2 loci al 
eerder gevonden waren en 4 nog niet eerder 
geïdentificeerd.
Meer coeliakie genen werden ontdekt door een 
grootschalig GWAS (beschreven in hoofdstuk 
4) in 15000 individuen uit vier populaties (UK, 
Nederland, Italië en Finland). De top 131 SNPs 
met de sterkste associatie tijdens de analyse in 
deze populaties werden herhaald in 10000 extra 
individuen uit de USA, Hongarije, Ierland, Polen, 
Spanje, Italië en Finland. Met deze aanpak, 
brachten wij het totale aantal coeliake ziekte 
loci op 26. Het overgrote deel van deze regio’s 
bevatten genen met een immuun-gerelateerde 
functie. Behalve genen die betrokken zijn bij het 
moduleren van de innate en adaptieve immuun 
respons, vonden we naast genen met een rol in 
lymfocyt ontwikkeling in de thymus, ook genen 
betrokken bij de innate immuun detectie van 
virale infecties. Wat erg belangrijk was dat 
50% van de coeliakie geassocieerde genen 
een sterk effect hadden op gen expressie. Dit 
suggereert dat veranderingen in gen expressie 
een van de belangrijkste ziekte veroorzakende 
mechanismen kan zijn die coeliakie associaties 
en waarschijnlijk ook andere complexe ziekten 
onderliggen.
In hoofdstuk 5 geven we een overzicht van de 
vooruitgang die plaats gevonden heeft door 
het uitvoeren van genetische studies naar 
coeliakie en hoe dit er toe bijgedragen heeft in 
het vergroten van ons inzicht in de moleculaire 
mechanismen die deze ziekte onderliggen. 
Onze Immunochip studie (beschreven in 
hoofdstuk 6), bevestigde dat disregulatie 
van gen expressie een van de grootste 
onderliggende mechanismen is in de ziekte 
pathogenese. De Immunochip is een op de maat 
gemaakt platform speciaal ontworpen voor het 
gebruik in genetische studies naar immuun 
gerelateerde ziekten. De SNP inhoud is verrijkt 
voor loci die “immuun  genen”bevatten en SNPs 
die eerder geassocieerd waren met een van de 
immuun gerelateerde ziekten. De Immunochip 
was vooral ontworpen om de locatie van het 
associatie signaal te verfijnen (fine-mappen) 
in 183 regio’s geassocieerd met immuun-
gerelateerde ziekten. Voor dit werk, werden 
deze loci veel verder verrijkt met een hele hoge 
dichtheid van de zogenoemde genetische 
markers (SNPs) dan gebruikelijk is in GWAS 
platforms (10-20x). Een hogere dichtheid 
van SNPs leidt tot een betere resolutie van 
het linkage disequilibrium en zorgt voor een 
betere, preciezere lokalisatie van  het associatie 
signaal. De applicatie van de Immunochip in 
12000 coeliakie patiënten en 12000 controles 
uit zes verschillende landen, zorgde ervoor 
dat het associatie signaal herleidt kon worden 
naar een enkel gen in meer dan de helft van 
de coeliakie loci. Daarnaast, in 20% van de 
coeliakie loci, was het signaal gelokaliseerd 
in de regulatoire regio van het gen, wat weer 
bevestigde dat disregulatie van gen expressie 
het moleculaire mechanisme kan zijn dat het 
associatie signaal veroorzaakt. Naast fine-
mapping, identificeerde de Immunochip studie 
13 andere coeliakie loci, wat het totaal op 
39 niet-HLA regio’ bracht die coeliakie risico 
dragen. 
Om de genetische architectuur van 
coeliakie beter te begrijpen, hebben we een 
zogenoemde cross-etnische analyse gedaan 
tussen Nederlanders en noord Italianen. We 
bevestigden en herhaalden 13 van de 26 geteste 
loci succesvol. We observeerden een verschil in 
het lange-afstand linkage disequilbrium tussen 
deze populaties, wat leidde tot een verfijning 
van de signaal lokalisatie in vijf loci in de noord 
Italianen en een signaal verschuiving in de 
andere. Voor een aantal van de loci waren we 
in staat om kenmerken van positieve selectie 
druk tegen deze gebieden te rapporteren.
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De belangrijkste conclusies van dit proefschrift 
zijn:
- Tot nu toe zijn 39 niet-HLA loci zijn 
geassocieerd met coeliakie en samen met HLA 
verklaren zij 53% van het genetische risico.
- Coeliakie en andere immuun-gerelateerde 
ziekten delen een groot deel van hun genetische 
achtergrond.
- Geassocieerde coeliakie loci zijn grotendeels 
verrijkt met immuun systeem genen.
- Meer dan de helft van de geassocieerde 
varianten veranderen de expressie van 
naastgelegen genen. 
- Coeliakie geassocieerde varianten zijn meestal 
niet-coderend en bevinden zich in regulatoire 
regio’s, wat er opduidt dat gen disregulatie een 
van de belangrijkste moleculaire mechanismen 
kan zijn voor de pathogenese van de ziekte. 
- Dertien coeliakie loci die gelokaliseerd zijn in 
Europese populaties bevatten ook risico voor 
coeliakie in een noord Italiaanse populatie.
Vakwoordenlijst
DNA: het molecuul dat alle genetische 
informatie bevat. De basis eenheid van DNA is 
een nucleotide. 
Genoom: de erfelijke informatie die de 
ontwikkeling en het functioneren van een 
levend organisme beschrijft. Het genoom 
bestaat uit genen en niet-coderende delen 
(alles wat geen gen is).
GWAS: Genoom-wijde associatie studie, het 
genotyperen van honderd duizenden SNPs 
(300.000-2 miljoen) in het DNA verkregen 
van grote verzamelingen van patiënten en 
controles (bestaande uit meestal honderden of 
duizenden personen).
Erfelijkheid: het gedeelte van de fenotypische 
variatie in een populatie, dus zoals een ziekte, 
oogkleur of kaalheid, dat toegekend is aan de 
genetische variatie tussen individuen. 
Linkage disequilibruim (LD): de correlatie 
tussen SNPs. Hoe hoger het LD, hoe sterker de 
correlatie tussen de SNPs.
Loci (meervoud van locus): een regio op het 
DNA.
Sequencen: het lezen van de DNA code.
SNP: single nucleotide polymorphism, 








Genetyka jest jedną z najszybciej rozwijających 
się dziedzin naukowych. Sekwencjonowanie 
całego ludzkiego genomu zakończone zostało 
zaledwie w 2003 roku. Ten przełomowy projekt 
trwał 13 lat i kosztował trzy miliardy dolarów. 
Obecnie koszt sekwencjonowania genomu 
jednej osoby wynosi jedynie 10 tysięcy dolarów 
i trwa krócej niż miesiąc. Nasz genom zawiera 
około 10 milionów powszechnie występujących 
polimorfizmów, zmian w pojedynczym miejscu 
w DNA (nukleotydzie), (ang. SNP – single 
nucleotide polymorphism). Większość z tych 
polimorfizmów jest neutralna i tym samym nie 
wpływa na rozwój choroby, jednakże niektóre 
polimorfizmy obserwowane są z większą 
częstotliwością u chorych w porównaniu do 
osób zdrowych. W ostatnich latach zaistniał 
w genetyce ogromny postęp technologiczny, 
który pozwolił na stworzenie mikromacierzy 
umożliwiających równoczesne badanie 
(genotypowanie) setek tysięcy polimorfizmów 
pojedynczych nukleotydów - SNP (od 300 
tysięcy do 2 milionów) u setek, a nawet u tysięcy 
osób. Mikromacierze te używane są w tzw. 
badaniach kliniczno-kontrolnych, składających 
sie z próbek pochodzących od osób chorych 
i zdrowych, i pozwalają określić genotyp dla 
każdego polimorfizmu oraz porównać jego 
częstość występowania pomiędzy chorymi a 
zdrowymi osobami. SNP, dla których częstość 
występowania jest statystycznie różna 
pomiędzy chorymi a zdrowymi wskazują na 
regiony genomu istotne dla rozwoju choroby. 
Tego typu test nosi nazwę genomowego 
badania asocjacyjnego (ang. GWAS – genome-
wide association study). Jednakże jedną z 
wad takich badań jest fakt, że pozwalają one 
jedynie na identifikację szerokich regionów 
genomowych, a nie wskazują bezpośrednio 
na geny lub mutacje prowadzące do rozwoju 
choroby. Zidentyfikowane regiony często 
zawierają wiele genów, które są od siebie 
zależne, zjawisko znane jest jako nierównowaga 
sprzężeń (ang. linkage disequilibrium – LD). 
Genomowe badania asocjacyjne rzadko 
bezpośrednio wskazują na gen odpowiedzialny 
za wystąpienie choroby, dlatego też po 
zidentyfikowaniu zasocjowanych regionów 
chorobowych niezbędne są dalsze badania 
mające na celu zawężenie obszaru i wskazanie 
genu lub mutacji prowadzącej do rozwoju 
choroby (ang. fine-mapping).
To właśnie rozwojowi technologii 
zawdzięczamy ogromny postęp w rozumieniu 
podłoża genetycznego wielu chorób. 
Sukces jest najlepiej widoczny w grupie 
chorób monogenowych, w których zmiana 
w pojedynczym genie zawsze prowadzi do 
rozwoju choroby. Około pięć lat temu sukces 
zaczął również być widoczny dla chorób o 
wieloczynnikowej etiologii. Zaburzenia te 
są rezultatem niewielkich i jednoczesnych 
dysfunkcji w wielu (nawet kilkuset) genów. 
Jednak sam komponent genetyczny nie jest 
wystarczający do wywołania choroby i wiele 
czynników środowiskowych oddziaływujących 
z genami w ostateczności prowadzi do jej 
rozwoju.
Celiakia jest najpowszechniejszą trwałą 
nietolerancją pokarmową dotykającą 
około 1-3% zachodnich populacji. Jest 
wynikiem nietolerancji glutenu u osób 
predysponowanych genetycznie. Gluten jest 
białkiem obecnym w pszenicy, jęczmieniu, 
życie i powszechnie występuje w produktach 
żywnościowych. Spożycie glutenu powoduje 
silną, autoimmunologiczną reakcję zapalną 
i prowadzi do uszkodzenia jelita cienkiego. 
Chorzy na celiakię mogą prezentować 
szerokie spektrum objawów, począwszy 
od klasycznych, jak na przykład biegunka, 
wzdęcia, niedożywienie oraz bóle brzucha, a 
skończywszy na atypowych, takich jak anemia, 
osteoporoza czy objawy neurologiczne.
Celiakia jest dobrze scharakteryzowana 
genetycznie, od ponad trzydziestu lat 
wiadomo, że obecność specyficznych 
genotypów w regionie HLA, dokładnie genów 
kodujących cząsteczki HLA-DQ2 i HLA-DQ8 
jest wysoce skorelowana z chorobą. Genotypy 
te są odpowiedzialne za 35-40% genetycznego 
ryzyka wystąpienia choroby, jednakże są one 
również obecne u ok. 30% osób zdrowych w 
ogólnej populacji. Fakt ten wskazuje, że do 
rozwoju choroby niezbędne jest zaangażowanie 
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innych czynników genetycznych. Do 2008 roku, 
za pomocą genomowych badań asocjacyjnych, 
zidentyfikowano osiem obszarów poza 
regionem HLA, które mogą predysponować 
do rozwoju celiakii. Celem tej pracy doktorskiej 
było zidentyfikowanie dodatkowych genów 
predysponujących do wystąpienia choroby.
W rozdziale drugim przedstawiamy wyniki 
badań, które opisują genotypowanie około 
500 SNP posiadających umiarkowany sygnał 
asocjacji we wcześniej przeprowadzonym 
genomowym badaniu asocjacyjnym w celiakii. 
Polimorfimzy te zostały przetestowane na 
grupie 1 682 pacjentów z celiakią oraz 3 
258 zdrowych osób. To podejście pozwoliło 
na zidentyfikowanie dwóch dodatkowych 
regionów w genomie, zawierających geny 
związane z regulacją aktywności szlaku NF-κB, 
jednego z kluczowych czynników regulujących 
odpowiedź immunologiczną.
Choroby immunologiczne często 
współwystępują z innymi chorobami wśród 
rodzin lub pacjentów, na przykład chorzy na 
celiakię często również chorują na cukrzycę 
typu pierwszego. Rozdział trzeci miał na 
celu analizę stopnia w jakim celiakia oraz 
reumatoidalne zapalenie stawów, dzielą między 
sobą te same czynniki genetyczne. Obydwie 
choroby mają podłoże autoimmunologiczne. 
Przetestowaliśmy czy geny predysponujące 
do jednej choroby stanowią o ryzyku 
zachorowania na drugą. Ta strategia umożliwiła 
odkrycie sześciu regionów wspólnych dla tych 
chorób, potwierdzając dwa poprzednio znane  i 
identfikując cztery nowe.
Kolejne regiony zasocjowane z celiakią 
zostały zidentyfikowane za pomocą drugiego 
genomowego badania asocjacyjnego 
(opisanego w rozdziale czwartym), który 
został przprowadzony na grupie 15 000 osób 
pochodzących z czterech różnych europejskich 
populacji (Brytyjczyków, Holendrów, Włochów 
i Finów). Aby potwierdzić wyniki z owej analizy, 
131 polirmofizmów z najsilniejszym sygnałem 
asocjacji zostało dodatkowo zgenotypowanych 
w niezależnej grupie 10 000 osób ze Stanów 
Zjednoczonych, Węgier, Irlandii, Polski, 
Hiszpanii, Włoch oraz Finlandii. Ostatecznie 
liczba regionów zasocjowanych z celiakią 
wzrosła do 26, z czego wiekszość zawiera 
geny związane z układem immunologicznym. 
Poza genami związanymi z regulacją 
szlaków wrodzonej i nabytej odpowiedzi 
immunologicznej opisaliśmy również geny 
zaangażowane w dojrzewanie limfoctów 
w grasicy oraz geny związane z wykryciem 
infekcji wirusowych poprzez wrodzoną 
odpowiedź immunologiczną. Ponadto, 
wykazaliśmy,  że ponad 50% polimorfizmów 
zasocjowanych z celiakią ma wpływ na 
ekspresję genów. Sugeruje to, że jednym z 
głównych mechanizmów prowadzących do 
rozwoju celiakii, oraz prawdopodobnie innych 
chorób wieloczynnikowych, będzie zmiana w 
stopniu ekspresji genów.
W rozdziale piątym omawiamy postęp w 
badaniach genetycznych nad celiakią oraz 
zrozumieniu mechanizmów molekularnych 
będących podłożem choroby.
Badanie z użyciem mikromacierzy 
„Immunochip” (opisane w rozdziale szóstym) 
dodatkowo potwierdziło, że głównym 
mechanizmem powodującym chorobę jest 
rozlegulowana ekspresja genów. Immunochip 
został zaprojektowany specyficznie do badań 
podłoża genetycznego chorób związanych z 
układem immunologicznym. Polimorfizmy 
zawarte na tej mikromacierzy reprezentują 
regiony bogate w geny o funkcji związanej 
z układem immunologicznym oraz te 
poprzednio zasocjowane z chorobami 
immunologicznymi. W szczególności 
Immunochip został zaprojektowany w celu 
precyzyjnego zlokalizowania sygnałów 
asocjacji w 183 regionach związanych z 
chorobami o podłożu immunologicznym. W 
tym celu regiony te zostały wzbogacone w 
dodatkowe markery w rezultacie zwiększając 
gęstość polimorfizmów od 10 do 20 razy w 
porównaniu z mikromacierzami używanymi 
w standardowych genomowych badaniach 
associacyjnych. Większa gęstość markerów 
genetycznych zapewnia dokładniejszą analizę 
korelacji pomiedzy polimorfizmami i pozwala na 
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bardziej precyzyjne określenie sygnału asocjacji. 
Zgenotypowanie przy użyciu Immunochip ok. 
12 000 pacjentów z celiakią oraz 12 000 osób 
kontrolnych pochodzących z sześciu różnych 
krajów pozwoliło na zlokalizowanie sygnału 
do poziomu pojedynczego genu dla ponad 
połowy regionów zasocjowanych z celiakią. 
Dodatkowo, dla 20% z identyfikowanych 
regionów, sygnał zlokalizowany był w części 
regulatorowej genu, ponownie wskazując 
na rozlegulowanie ekspresji genów jako 
przyczynę molekularnego mechanizmu 
leżącego u podstaw choroby. Badanie z 
użyciem Immunochip również zidentyfikowało 
13 kolejnych regionów zasocjowanych z 
celiakią, co daje w sumie 39 regionów, poza 
HLA, związanych ze zwiększonym ryzykiem 
zachorowania na celiakię.
Aby dalej zrozumieć genetyczne podłoże 
celiakii przeprowadziliśmy analizę pomiędzy 
dwoma etnicznie oddalonymi populacjami. 
Porównując Holendrów i Hindusów z północy 
Indii wykazaliśmy, że 13 z 26 poprzednio 
zasocjowanych regionów również zwiększa 
ryzyko choroby w populacji północno Indyjskiej. 
Jednocześnie zaobserwowaliśmy różnicę w 
korelacji polimorfizmów, w szczególności w 
długodystansowej nierównowadze sprzężeń, 
pomiędzy tymi populacjiami. Doprowadziło to 
do dokładniejszej lokalizacji sygnału asocjacji 
wśród Hindusów dla pięciu regionów oraz 
przesunięcia sygnału w pozostałych regionach. 
Dla kilku regionów również zaobserwowaliśmy 
działanie pozytywnej selekcji.
Główne wnioski z tej pracy doktorskiej to:
- Poza obszarem HLA do tej pory zostało 
zidentyfikowanych 39 regionów zwiększających 
ryzyko zachorowania na celiakię. Wspólnie 
te 40 regionów wyjaśnia 53%  dziedziczności 
celiakii.
- Celiakia oraz inne choroby związane z układem 
odpornościowym współdzielą znaczną część 
podłoża genetycznego.
- Regiony zasocjowane z celiakią w dużej 
mierze zawierają w geny powiązane z układem 
odpornościowym.
- Ponad połowa zasocjowanych wariantów 
wpływa na ekspresję genów.
- Warianty zasocjowane z celiakią są w 
większości niekodujące oraz zlokalizowane w 
regulatorowych częściach genomu. Wskazuje 
to, że rozlegulowana ekspresjia genów może 
stanowić jeden z głównych, molekularnych 
mechanizmów prowadzących do rozwoju 
choroby.
- Spośród regionów zidentyfikowanych w 
populacjach Europejskich, 13 również stanowi 
genetyczne ryzyko wystąpienia celiakii w 
populacji Hindusów z północnych Indii.
Słownik:
DNA: cząsteczka przechowująca informację 
genetyczną. Podstawową jednostką budującą 
DNA jest nukleotyd.
Genom: dziedziczna informacja dotycząca 
rozwoju i funkcjonowania żywych organizmów. 
Składa się z genów oraz części niekodujących.
GWAS (ang. genome-wide association study): 
genomowe badanie asocjacyjne polegające 
na testowaniu setek tysięcy (od 300 tysięcy 
do 2 milionów) markerów genetycznych, tzw. 
polimorfizmów (patrz SNP poniżej). Do badań 
tych wykożystywane jest DNA uzyskane z 
grup kliniczno-kontrolnych, od osób chorych 
i zdrowych (zwykle składających się z kilkuset 
lub tysięcy osób).
Dziedziczność: część zmienności fenotypowej 
w populacji, np. choroba, kolor oczu lub 
łysienie, która przypisywana jest zróżnicowaniu 
genetycznemu pomiędzy osobami z tej samej 
populacji.
Nierównowaga sprzężeń (ang. linkage 
disequilibrium): korelacja pomiędzy 
polimorfizmami. Im większa nierównowaga 
sprzężeń, tym większa zależność pomiędzy 
tymi markerami i prawdopodobieństwo 
dziedziczenia ich razem.
Locus (l.mn loci): region w cząsteczce DNA.
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Sekwencjonowanie: odczytywanie kodu DNA.
SNP (ang. single nucleotide polymorphism) – 
polimorfizm pojedynczego nukleotydu, zmiana 





This ‘PhD journey’ was way more than just lab 
work and data analysis. It involved many people 
who shared the joy, frustration, motivation, ups 
and downs, and the fun of conducting science. 
It is inevitable that my journey would never 
have been so much fun if some of these people 
had not joined me on this boat. There are way 
too many of you to thank you all individually 
here, but I will try to list those who played an 
essential role in my PhD adventure. 
It is clear that my PhD would never have taken 
shape without the great mentorship from 
my supervisor. Dear Cisca, thank you for your 
unbelievable trust in me, I still remember the 
moment when you told me I would be the one 
to analyze the GWAS data and I thought that 
you had completely lost your mind to hand me 
the responsibility of leading such a massive 
project (and I mean both the amount of data 
as well as the amount of money that went 
through my hands as chips and reagents). 
Surprisingly (to me but I guess not to you), 
I managed to get on with this project and it 
turned out to be a tremendous lesson for me. 
Not only scientifically, but more importantly it 
was a lesson that taught me to believe in myself 
a bit more. I am very grateful to you for all the 
support I have always received from you, I have 
learned so much from you. Thank you!
Further, the great support from all my 
colleagues in the coeliac mafia was essential 
during these four years. 
My SNP adventure started with a person I value 
very much. Sasha, I admire your optimism, lack 
of stress (even in the most extreme situations), 
your scientific criticism and ability to generate 
great ideas, and most of all I admire you as a 
person. The way you combine science with 
your family life is a skill I wish to pursue myself. 
You are one of the best scientists I have met 
during these four years. It has always been 
a great pleasure to brainstorm with you, as 
well as simply to chat about books or food 
or go shopping for shoes with a crazy Italian 
salesman in Montreal. Please don’t worry that 
I will not be in Groningen anymore, the world of 
science is small and I am sure we will continue 
to work on some joint projects, simply because 
it is a lot of fun together!
Dear Jihane, I am extremely happy that we had 
a chance to be in this PhD boat together! I very 
much enjoyed our scientific and non-scientific 
chats! I am not sure how it would all have ended 
up if not for the support I’ve had from you in the 
last years of our PhDs, especially during these 
last few months of wrapping up our theses. You 
have the great ability to bring me down to earth, 
tell me to breath and calm down! Thank you for 
being a friend and thank you for bringing some 
fashion into the coeliac group! I wish you lots 
of success in your new career steps, it will work 
out great, I am certain about that.
Agata, thank you very much for all the silly 
jokes and all the laughter we had together in 
the lab, in the Irish pub and at home. These 
moments were often a crucial escape from the 
lab frustrations. It would have been boring if 
you had not been around. Thank you also for 
the ‘Summary Translation Service’, invaluable! 
Zawsze będę miło wspominać nasze głupkowate 
rozmowy. Dziękuję Ci bardzo za wszystko! 
Trzymam za Ciebie kciuki!...i ryjek do góry ;)
Lude (although you are not truely the coeliac 
mafia), thank you for all the great chats we had 
about science and for all your nasty comments, 
it was really COOL to work with you! Like Cisca, 
you also shared the madness in believing in my 
abilities to lead the GWAS. I know you have 
your opinion on population-specific variants, 
but I think Cisca and you carry a rare, Dutch-
specific haplotype, maybe worth investigating 
in the future! I look forward to reading your 
next paper in Science ;)
Isis, Javier, Rodrigo, Juha, Harm-Jan, you guys 
are like the musketeers to me! I will miss all 
the chats, parties and BBQs with food and 
drinks from all over the world, … I wish you all 
the best! And you’d better stay in touch or I’ll 
come back for your PhD defenses to ask nasty 
questions! From now on, attending the  ASHG 




Most of my projects could not have been 
performed at the efficiency and speed that they 
were carried out without two people, Mathieu 
and Elvira. You were the greatest companion 
in the lab! Hybridizinging the GWAS and 
Immunochip slides together was fantastic fun! 
I will feel a bit nostalgic when remembering 
the good, loud, rock music in the Illumina 
lab, the “whoosh-tips” weapon, silly jokes 
and comments! My greatest THANK YOU for 
turning work into great fun!
Asia, thanks for bringing craziness into the 
group, especially when it comes in bright 
colours or red trousers! ;) I think it is greatly 
needed to balance the grey weather outside! 
Thank you very much for joining forces with 
Agata in the ‘Summary Translation Service’! 
Powodzenia ze wszystkim, nie daj się!
My dear coeliac companions, Astrid, Barbara, 
Cleo, Jingyuan, Marcel B., Martin W., Ron, 
Rutger, Sebo, Soesma and Vinod, thank you 
for sharing your energy and creating positive 
atmosphere in the group … even at the 
crazily early hour of Monday morning work 
discussions. It was a great pleasure to work with 
you all. I will miss you! Dear Sabyasachi, thank 
you for joining us in the group and performing 
the cross-ethnic study with me. Dasha, I wish 
you lots of success in your PhD.
Without two other people this thesis would 
probably never have ended up in time and 
with all the papers arranged. Dear Jackie, you 
are the one who always helps, even when it 
is sent to you at the last minute (which, in my 
case, unfortunately was most of the time, my 
apology, one day it will change … one day). 
Your input in this thesis is immeasurable! Thank 
you for all our chats about Britain, Holland, 
PhD, books … possibly everything. Thank you 
for helping me find a place to stay in London. 
I very much admire you personally with all the 
positive vibes that you spread around. Dear 
Hélène, thank you for all your help with all my 
PhD documents and actually many other issues 
I had. I don’t know how you do it, managing to 
organize everything, but I am greatly thankful 
for this magic of yours. 
Dear IBD people, Rinse - it was always a big 
pleasure to see you around. Thank you for our 
discussions and your very valuable criticism. 
Noortje, Karin and Suzanne, thank you for 
your collaboration and support. It was great 
fun to work with you. I wish you all lots of great 
publications and success in the IBD genetics.
Genetics brings together biology and 
bioinformatics, and without the latter it would 
be very difficult for a biologist to pursue the 
analysis of genetic data. Therefore a great big 
thank you to Patrick, Mark-Jan, Roan, Alex, 
Freerk, Laurent and Morris. Thank you for your 
help in running all the different analyses I was 
struggling with. Martijn, thank you for your 
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